Document:

EX-10.11

 Exhibit 10.11 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to
Rule 406 of the Securities Act of 1933, as amended. 
  

			
	 Confidential
	  	 EXECUTION VERSION

  
 DISCOVERY COLLABORATION AND LICENSE
AGREEMENT 
 between 

HARPOON THERAPEUTICS, INC. 

and 
 ABBVIE
BIOTECHNOLOGY LTD. 
 Dated as of October 10, 2017 

 EXECUTION VERSION 

 
  

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1     DEFINITIONS
	  	 	1	 
		
	 ARTICLE 2     TARGET NOMINATION AND [***]
	  	 	18	 
			
	2.1	  	 Target Nomination.
	  	 	18	 
	2.2	  	[***]	  	 	19	 
	2.3	  	[***]	  	 	19	 
	2.4	  	 Effect of [***] or [***]
	  	 	19	 
		
	 ARTICLE 3     COLLABORATION MANAGEMENT
	  	 	19	 
			
	3.1	  	 Joint Research Committee
	  	 	19	 
	3.2	  	 General Provisions Applicable to the JRC
	  	 	20	 
	3.3	  	 Interactions Between a Committee and Internal Teams
	  	 	21	 
	3.4	  	 Working Groups
	  	 	22	 
	3.5	  	 Expenses
	  	 	22	 
		
	 ARTICLE 4     DEVELOPMENT AND REGULATORY
	  	 	22	 
			
	4.1	  	 T-Cell Receptor Sequence Delivery
	  	 	22	 
	4.2	  	 Creation of Discovery T-Cell Receptor
Constructs
	  	 	22	 
	4.3	  	 Development of Discovery T-Cell Receptor Constructs and
Licensed Products
	  	 	23	 
	4.4	  	 Supply of Technology for Development Purposes
	  	 	23	 
	4.5	  	 Expenses and Invoicing
	  	 	24	 
	4.6	  	 Subcontracting
	  	 	24	 
	4.7	  	 Regulatory Matters
	  	 	24	 
		
	 ARTICLE 5     COMMERCIALIZATION
	  	 	26	 
			
	5.1	  	 In General
	  	 	26	 
	5.2	  	 Commercialization Diligence
	  	 	26	 
	5.3	  	 Booking of Sales; Distribution
	  	 	26	 
	5.4	  	 Product Trademarks
	  	 	27	 
	5.5	  	 Commercial Supply of Discovery T-Cell Receptor
Constructs or Licensed Products
	  	 	27	 
		
	 ARTICLE 6     GRANT OF RIGHTS
	  	 	27	 
			
	6.1	  	 Grants to AbbVie
	  	 	27	 
	6.2	  	 Grants to Licensor
	  	 	28	 
	6.3	  	 Sublicenses
	  	 	28	 
	6.4	  	 Distributorships
	  	 	28	 
	6.5	  	 Co-Promotion Rights
	  	 	28	 
	6.6	  	 Retention of Rights
	  	 	29	 
	6.7	  	 Confirmatory Patent License
	  	 	29	 
	6.8	  	 Exclusivity with Respect to the Territory
	  	 	29	 
	6.9	  	 In-License Agreements
	  	 	29	 
		
	 ARTICLE 7     PAYMENTS AND RECORDS
	  	 	30	 
			
	7.1	  	 Upfront Payment
	  	 	30	 
	7.2	  	 Development Milestones
	  	 	30	 
	7.3	  	 Regulatory Milestones
	  	 	31	 
	7.4	  	 Commercialization Milestones
	  	 	31	 
	7.5	  	 Sales-Based Milestones
	  	 	32	 
	7.6	  	 Royalties
	  	 	33	 
	7.7	  	 Royalty Payments and Reports
	  	 	34	 
	7.8	  	 Mode of Payment; Offsets
	  	 	34	 
	7.9	  	 Withholding Taxes
	  	 	34	 
	7.10	  	 Indirect Taxes
	  	 	35	 

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

							
	7.11	  	 Interest on Late Payments
	  	 	36	 
	7.12	  	 Audit
	  	 	36	 
	7.13	  	 Audit Dispute
	  	 	36	 
	7.14	  	 Confidentiality
	  	 	36	 
	7.15	  	 [***]
	  	 	37	 
	7.16	  	 No Other Compensation
	  	 	37	 
		
	 ARTICLE 8     INTELLECTUAL PROPERTY
	  	 	37	 
			
	8.1	  	 Ownership of Intellectual Property
	  	 	37	 
	8.2	  	 Maintenance and Prosecution of Patents
	  	 	38	 
	8.3	  	 Enforcement of Patents
	  	 	42	 
	8.4	  	 Infringement Claims by Third Parties
	  	 	44	 
	8.5	  	 Invalidity or Unenforceability Defenses or Actions
	  	 	45	 
	8.6	  	 Third Party Licenses
	  	 	46	 
	8.7	  	 Product Trademarks
	  	 	46	 
	8.8	  	 Inventor’s Remuneration
	  	 	46	 
	8.9	  	 Common Interest
	  	 	46	 
		
	 ARTICLE 9     PHARMACOVIGILANCE AND SAFETY
	  	 	47	 
			
	9.1	  	 Pharmacovigilance
	  	 	47	 
	9.2	  	 Global Safety Database
	  	 	47	 
		
	 ARTICLE 10   CONFIDENTIALITY AND
NON-DISCLOSURE
	  	 	47	 
			
	10.1	  	 Product Information
	  	 	47	 
	10.2	  	 Confidentiality Obligations
	  	 	48	 
	10.3	  	 Permitted Disclosures
	  	 	49	 
	10.4	  	 Use of Name
	  	 	50	 
	10.5	  	 Public Announcements
	  	 	51	 
	10.6	  	 Publications
	  	 	51	 
	10.7	  	 Return of Confidential Information
	  	 	51	 
	10.8	  	 Survival
	  	 	52	 
		
	 ARTICLE 11   REPRESENTATIONS AND WARRANTIES
	  	 	52	 
			
	11.1	  	 Mutual Representations and Warranties
	  	 	52	 
	11.2	  	 Additional Representations and Warranties of Licensor
	  	 	53	 
	11.3	  	 Additional Representations and Warranties of AbbVie
	  	 	56	 
	11.4	  	 Covenants of Licensor
	  	 	57	 
	11.5	  	 Covenants of AbbVie
	  	 	58	 
	11.6	  	 DISCLAIMER OF WARRANTIES
	  	 	58	 
		
	 ARTICLE 12   INDEMNITY
	  	 	58	 
			
	12.1	  	 Indemnification of Licensor
	  	 	58	 
	12.2	  	 Indemnification of AbbVie
	  	 	58	 
	12.3	  	 Notice of Claim
	  	 	58	 
	12.4	  	 Control of Defense
	  	 	59	 
	12.5	  	 Special, Indirect, and Other Losses
	  	 	60	 
	12.6	  	 Insurance
	  	 	61	 
		
	 ARTICLE 13   TERM AND TERMINATION
	  	 	61	 
			
	13.1	  	 Term
	  	 	61	 
	13.2	  	 Termination for Material Breach
	  	 	62	 
	13.3	  	 Additional Termination Rights by AbbVie
	  	 	63	 
	13.4	  	 Termination for Insolvency
	  	 	63	 

  
 - ii - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

							
	13.5	  	 Rights in Bankruptcy
	  	 	63	 
	13.6	  	 Termination in Entirety
	  	 	64	 
	13.7	  	 Termination of Terminated Territory
	  	 	65	 
	13.8	  	 Termination of Accepted Target
	  	 	65	 
	13.9	  	 Remedies
	  	 	66	 
	13.10	  	 Accrued Rights; Surviving Obligations
	  	 	66	 
		
	 ARTICLE 14   MISCELLANEOUS
	  	 	67	 
			
	14.1	  	 Force Majeure
	  	 	67	 
	14.2	  	 Change in Control of Licensor
	  	 	67	 
	14.3	  	 Export Control
	  	 	68	 
	14.4	  	 Assignment
	  	 	68	 
	14.5	  	 Severability
	  	 	68	 
	14.6	  	 Governing Law, Jurisdiction and Service
	  	 	69	 
	14.7	  	 Dispute Resolution
	  	 	69	 
	14.8	  	 Notices
	  	 	70	 
	14.9	  	 Entire Agreement; Amendments
	  	 	71	 
	14.10	  	 English Language
	  	 	71	 
	14.11	  	 Equitable Relief
	  	 	71	 
	14.12	  	 Waiver and Non-Exclusion of Remedies
	  	 	72	 
	14.13	  	 No Benefit to Third Parties
	  	 	72	 
	14.14	  	 Further Assurance
	  	 	72	 
	14.15	  	 Relationship of the Parties
	  	 	72	 
	14.16	  	 Performance by Affiliates
	  	 	73	 
	14.17	  	 Counterparts; Facsimile Execution
	  	 	73	 
	14.18	  	 References
	  	 	73	 
	14.19	  	 Schedules
	  	 	73	 
	14.20	  	 Construction
	  	 	73	 

 SCHEDULES 
  

			
	Schedule 1.45	  	Discovery Research Plan
	Schedule 1.50	  	Discovery T-Cell Receptor Construct Success Criteria
	Schedule 2.1.2	  	Unavailable Targets as of the Effective Date
	Schedule 4.6	  	Pre-Approved Third Party Providers
	Schedule 11.2.1	  	Existing Patents
	Schedule 14.7.3	  	ADR Procedures

  
 - iii - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 DISCOVERY COLLABORATION AND LICENSE AGREEMENT 

This Discovery Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of
October 10, 2017 (the “Effective Date”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Licensor”), and AbbVie Biotechnology Ltd., a Bermuda corporation (“AbbVie”). Licensor
and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 
 WHEREAS,
Licensor Controls (as defined herein) certain intellectual property rights with respect to the development of T-Cell Receptor Constructs (as defined herein); and 

WHEREAS, Licensor wishes to grant a license to AbbVie, and AbbVie wishes to receive, a license under such intellectual property rights
to develop and commercialize Licensed Products (as defined herein) in the Territory, in each case in accordance with the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Unless otherwise specifically provided herein, the following terms shall have the following meanings: 

1.1 “AbbVie” has the meaning set forth in the preamble hereto. 

1.2 “AbbVie Background Know-How” means all Information that is
(a) Controlled by AbbVie or any of its Affiliates on the Effective Date or during the Term, (b) not generally known, (c) developed or invented as a result of performing activities outside the scope of this Agreement, and
(d) reasonably necessary or useful for the Development, Manufacture, or Commercialization of a Discovery T-Cell Receptor, Discovery T-Cell Receptor Construct or a
Licensed Product. For clarity, AbbVie Background Know-How includes such Information Controlled by AbbVie that is related to a Discovery T-Cell Receptor existing prior to
the Effective Date or developed or invented thereafter as a result of performing activities outside the scope of the activities contemplated by this Agreement and excludes TriTAC Constructs. 

1.3 “AbbVie Background Patents” means all Patents that (a) are Controlled by AbbVie or any
of its Affiliates on the Effective Date or during the Term and (b) claim or cover AbbVie Background Know-How. 
  

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.4 “AbbVie In-License
Agreement” means any agreement entered into during the Term between AbbVie and a Third Party under which payments by AbbVie or its Affiliates are required to Exploit any Discovery T-Cell
Receptor Construct or Licensed Product, including any agreement entered into pursuant to Section 8.6, as such agreements may be amended from time-to-time, but excluding any agreement
granting or assigning any rights with respect to [***] or any [***] AbbVie or its Affiliates or Sublicensees. 
 1.5
“AbbVie Indemnitees” has the meaning set forth in Section 12.2. 

1.6 “AbbVie Program Know-How” means all Program Know-How to the extent (a) specifically related to (i) a Discovery T-Cell Receptor or (ii) an Accepted Target (including [***]), or (b) conceived,
discovered, developed or otherwise made solely by or on behalf of AbbVie or its Affiliates except to the extent included in Sections 1.92(a) or 1.117. 

1.7 “AbbVie Program Patents” means Program Patents that claim or cover AbbVie Program Know-How. 
 1.8 “Acceptance” means, with respect to a Drug
Approval Application, receipt of written notice from the applicable Regulatory Authority indicating that such Drug Approval Application has been accepted for filing and further review. 

1.9 “Accepted Target” has the meaning set forth in Section 2.1.3.

 1.10 “Accepted Target Deliverables” has the meaning set forth in
Section 4.2. 
 1.11 “Accounting Standards” means, with respect to
a Party, that such Party shall maintain records and books of accounts in accordance with United States Generally Accepted Accounting Principles. 

1.12 “Acquisition” means, with respect to a Party, a merger, acquisition (whether of all of the
stock or all or substantially all of the assets of a Person or any operating or business division of a Person) or similar transaction by or with the Party, other than a Change in Control of the Party. 

1.13 “ADR” has the meaning set forth in Section 14.7.1. 

1.14 “Adverse Ruling” has the meaning set forth in Section 13.2.1.

 1.15 “Affiliate” means, with respect to a Party, any Person that, directly or indirectly,
through one (1) or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and
“under common control with” means (a) the possession, directly or indirectly, of the power to direct the management or policies of a Person, whether through the ownership of voting securities, by contract relating to voting rights or
corporate governance, or otherwise; or (b) the ownership, 

  
 - 2 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of a Person (or, with respect to a limited partnership or other similar entity, its
general partner or controlling entity). The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor
may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management or policies of such entity. 

1.16 “Agreement” has the meaning set forth in the preamble hereto. 

1.17 “Alliance Manager” has the meaning set forth in Section 3.2.5.

 1.18 “Applicable Law” means federal, state, local, national and supra-national laws,
statutes, rules, and regulations, including any rules, regulations, guidelines, or other requirements of the Regulatory Authorities, major national securities exchanges or major securities listing organizations, that may be in effect from time to
time during the Term and applicable to a particular activity or country or other jurisdiction hereunder. 
 1.19
“Audit Arbitrator” has the meaning set forth in Section 7.13. 

1.20 “Bankruptcy Code” has the meaning set forth in Section 13.5.1.

 1.21 “Binds” means, with respect to a first moiety that binds to a second moiety, having a
binding affinity between the first moiety and second moiety that is [***]. 
 1.22 “Biosimilar
Application” has the meaning set forth in Section 8.3.3. 
 1.23
“Biosimilar Competition” has the meaning set forth in Section 7.6.3. 

1.24 “Biosimilar Product” means, with respect to a particular Discovery T-Cell Receptor Construct or Licensed Product in a particular country, a biologic product that is substantially similar to or interchangeable with such Discovery T-Cell
Receptor Construct or Licensed Product and any related formulations thereof, so as to permit the biosimilar applicant to rely for approval by the applicable Regulatory Authority on such Discovery T-Cell
Receptor Construct or Licensed Product as the reference product, or otherwise reference such Discovery T-Cell Receptor or Licensed Product for approval by the applicable Regulatory Authority. A Licensed
Product licensed, marketed, sold, manufactured or produced by AbbVie or its Affiliates or Sublicensees will not constitute a Biosimilar Product. 

1.25 “BLA” has the meaning set forth in the definition of “Drug Approval
Application.” 

  
 - 3 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.26 “Board of Directors” has the meaning set
forth in the definition of “Change in Control.” 
 1.27 “Breaching Party” has the
meaning set forth in Section 13.2.1. 
 1.28 “Business Day” means a
day other than a Saturday or Sunday on which banking institutions in New York, New York are open for business. 

1.29 “Calendar Quarter” means each successive period of three (3) calendar months
commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1,
April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term. 

1.30 “Calendar Year” means each successive period of twelve (12) calendar months
commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year
of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term. 

1.31 “Change in Control” with respect to a Party, shall be deemed to have occurred if any of
the following occurs after the Effective Date: 
 1.31.1 any “person” or “group” (as such terms are defined
below) (a) is or becomes the “beneficial owner” (as defined below), directly or indirectly, of shares of capital stock or other interests (including partnership interests) of such Party then outstanding and normally entitled (without
regard to the occurrence of any contingency) to vote in the election of the directors, managers or similar supervisory positions (“Voting Stock”) of such Party representing fifty percent (50%) or more of the total voting power of
all outstanding classes of Voting Stock of such Party or (b) has the power, directly or indirectly, to elect a majority of the members of the Party’s board of directors, or similar governing body (“Board of Directors”),
excluding in each case (clauses (a) and (b)) [***]; or 
 1.31.2 such Party enters into a merger, consolidation or similar
transaction with another Person (whether or not such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction (a) the members of the Board of Directors of such Party immediately prior to such
transaction constitute less than a majority of the members of the Board of Directors of such Party or such surviving Person immediately following such transaction or (b) the Persons that beneficially owned, directly or indirectly, the shares of
Voting Stock of such Party immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of such Party representing at least a majority of the total voting power of all outstanding classes of Voting
Stock of the surviving Person in substantially the same proportions as their ownership of Voting Stock of such Party immediately prior to such transaction; or 

  
 - 4 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.31.3 such Party sells or transfers to any Third Party, in one (1) or more
related transactions, properties or assets representing all or substantially all of such Party’s assets to which this Agreement relates; or 

1.31.4 the holders of capital stock of such Party approve a plan or proposal for the liquidation or dissolution of such Party. 

For the purpose of this definition of Change in Control, (a) “person” and “group” have the meanings given such terms under
Section 13(d) and 14(d) of the United States Securities Exchange Act of 1934 and the term “group” includes any group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the said Act; (b) a “beneficial owner” shall be determined in accordance with Rule 13d-3 under the aforesaid Act; and (c) the terms
“beneficially owned” and “beneficially own” shall have meanings correlative to that of “beneficial owner.” 

1.32 “Clinical Data” means all Information with respect to any Discovery T-Cell Receptor Construct or Licensed Product and made, collected, or otherwise generated under or in connection with Clinical Studies, including any data (including raw data), reports, and results with respect
thereto. 
 1.33 “Clinical Studies” means a First-in-Human Clinical Trial, Non-Pivotal Human Clinical Trial, Pivotal Human Clinical Trial, and such other tests and studies in human subjects that are required by
Applicable Law, or otherwise recommended by the Regulatory Authorities, to obtain or maintain Regulatory Approvals for a Licensed Product for one (1) or more indications, including tests or studies that are intended to expand the Product
Labeling for such Licensed Product with respect to such indication. 
 1.34 “Combination Product”
means a Licensed Product that is: (a) sold in the form of a combination product containing both a Discovery T-Cell Receptor Construct and one (1) or more independently therapeutically active
pharmaceutical or biologic products; or (b) sold in a form that contains (or is sold bundled with) any (i) diagnostic product, process, service or therapy or (ii) product, process, service or therapy that is administered separately
from the Licensed Product, in both cases (clauses (a) and (b)) sold as a unit at a single price and excluding any Delivery System. 

1.35 “Commercialization” means any and all activities directed to the preparation for sale of,
offering for sale of, or sale of a Discovery T-Cell Receptor Construct or LicensedProduct, including activities related to marketing, promoting, distributing, importing and exporting such Discovery T-Cell Receptor Construct or Licensed Product, and interacting with Regulatory Authorities regarding any of the foregoing. When used as a verb, “to Commercialize” and
“Commercializing” means to engage in Commercialization, and “Commercialized” has a corresponding meaning. 

1.36 “Commercially Reasonable Efforts” means, with respect to the [***] 

  
 - 5 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.37 “Competing Product” means any
pharmaceutical or biologic product, process, service or therapy that Binds to any Accepted Target for any Indication. 

1.38 “Competitor” means (a) any Person that [***]; and (b) any Person that [***] with
respect to any Competing Product. 
 1.39 “Confidential Information” means any Information
provided orally, visually, in writing or other form by or on behalf of one (1) Party (or an Affiliate or representative of such Party) to the other Party (or to an Affiliate or representative of such other Party) in connection with this
Agreement, whether prior to, on, or after the Effective Date, including Information relating to the terms of this Agreement, the Discovery T-Cell Receptor Construct or any Licensed Product (including the
Regulatory Documentation and regulatory data), any Exploitation of the Discovery T-Cell Receptor Construct or any Licensed Product, any Novel Target, any know-how with
respect thereto developed by or on behalf of the disclosing Party or its Affiliates, or the scientific, regulatory or business affairs or other activities of either Party. Notwithstanding the foregoing, (a) Joint Program Know-How shall be deemed to be the Confidential Information of both Parties, and both Parties shall be deemed to be the receiving Party and the disclosing Party with respect thereto, and (b) all Regulatory
Documentation owned by AbbVie pursuant to Section 4.7.1 shall be deemed to be the Confidential Information of AbbVie, and AbbVie shall be deemed to be the disclosing Party and Licensor shall be deemed to be the receiving
Party with respect thereto. In addition, all information disclosed by Licensor to AbbVie under the Mutual Non-Disclosure Agreement between Licensor and AbbVie Inc., an Affiliate of AbbVie, dated July 7,
2016, (the “Prior NDA”) shall be deemed to be Licensor’s Confidential Information disclosed hereunder, and all information disclosed by AbbVie Inc. to Licensor under the Prior NDA shall be deemed to be AbbVie’s
Confidential Information disclosed hereunder. 
 1.40 “Control” means, with respect to any
item of Information, Regulatory Documentation, material, Patent, or other property right, the possession of the right, whether directly or indirectly, and whether by ownership, license, covenant not to sue or otherwise (other than by operation of
the license and other grants in Sections 6.1 or 6.2), to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation, material, Patent, or other
property right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party. 

1.41 “Default Notice” has the meaning set forth in Section 13.2.1.

 1.42 “Delivery System” has the meaning set forth in the definition of “Net
Sales.” 

  
 - 6 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.43 “Development” means all activities
related to research, pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development,
manufacturing scale-up, qualification and validation, quality assurance/quality control, Clinical Studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation
and submission of Drug Approval Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of
obtaining or maintaining a Regulatory Approval. When used as a verb, “Develop” means to engage in Development. For purposes of clarity, Development shall include any submissions and activities required in support thereof, required
by Applicable Laws or a Regulatory Authority as a condition or in support of obtaining a pricing or reimbursement approval for an approved Licensed Product. 

1.44 “Discovery Research Activities” means the Development activities set forth in the
Discovery Research Plan to be performed by Licensor (or, by or on behalf of AbbVie pursuant to Section 4.2). 

1.45 “Discovery Research Plan” means the research plan setting forth the activities (and estimated
timelines) for [***], such plan attached as Schedule 1.45, as the same may be amended from time to time in accordance with the terms hereof. 

1.46 “Discovery T-Cell Receptor” has the meaning set forth in
Section 4.1. 
 1.47 “Discovery T-Cell
Receptor Construct” means a T-Cell Receptor Construct comprising or incorporating a Discovery T-Cell Receptor. 

1.48 “Discovery T-Cell Receptor Construct Delivery Deadline”
means, on an Accepted Target-by-Accepted Target basis, the date that is [***] after the date on which AbbVie delivers to Licensor the TCR Sequence Information pursuant
to Section 4.1. 
 1.49 “Discovery T-Cell
Receptor Construct Failure” means, with respect to a Licensed Product, that, due to [***] after the Effective Date, [***] that it is unlikely that [***] will be able to, [***] it is unlikely that [***] will be able to maintain [***] in each
case without including [***]. 
 1.50 “Discovery T-Cell Receptor
Construct Success Criteria” means the success criteria with respect to a Discovery T-Cell Receptor Construct set forth on Schedule 1.50. 

1.51 “Dispute” has the meaning set forth in Section 14.7. 

1.52 “Distributor” has the meaning set forth in Section 6.4. 

1.53 “Divestiture” means, with respect to a Party, (a) the divestiture [***] through [***] or
[***] with respect to such [***] with respect to such [***] (for clarity, the [***] in connection with a [***] of such [***] for any such divestiture) or (b) [***]. When used as a verb, “Divest” and “Divested” means
to cause a Divestiture. 

  
 - 7 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.54 “Dollars” or “$”
means United States Dollars. 
 1.55 “Drug Approval Application” means a Biologics License
Application (a “BLA”) as defined in the FFDCA, or any corresponding foreign application in the Territory, including, with respect to the European Union, a Marketing Authorization Application (a “MAA”) filed with the
EMA or with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other national approval procedure. 

1.56 “Effective Date” means the effective date of this Agreement as set forth in the preamble hereto.

 1.57 “EMA” means the European Medicines Agency and any successor agency(ies) or authority having
substantially the same function. 
 1.58 “European Major Market” means each of the [***]. 

1.59 “Existing AbbVie TCR Patents” has the meaning set forth in
Section 11.3.2. 
 1.60 “Existing Patents” has the meaning set forth in
Section 11.2.1. 
 1.61 “Exploit” or “Exploitation” means
to make, have made, import, export, use, have used, sell, have sold, or offer for sale, including to Develop, Commercialize, register, modify, enhance, improve, Manufacture, have Manufactured, hold, or keep (whether for disposal or otherwise), or
otherwise dispose of. 
 1.62 “FDA” means the United States Food and Drug Administration and any
successor agency(ies) or authority having substantially the same function. 
 1.63 “FFDCA” means the
United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and
modifications thereto). 
 1.64 “Field” means all human and
non-human diagnostic, prophylactic, and therapeutic uses. 
 1.65
“First Commercial Sale” means, with respect to a Licensed Product and a country, the first sale for monetary value for use or consumption by the end user of such Licensed Product in such country after Regulatory Approval for such
Licensed Product has been obtained in such country. [***] shall not be construed as a First Commercial Sale. 

  
 - 8 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.66 “First-in-Human Clinical Trial” means the first-ever human clinical trial in any country conducted in accordance with good clinical practices (as defined under Applicable Law) that is intended to
initially evaluate a Licensed Product with respect to safety, tolerability, pharmacological effects and determination of maximum tolerated dose or recommended dose of such Licensed Product for subsequent human clinical trials as the primary
endpoint, or that would otherwise satisfy requirements of 21 CFR 312.21(a), or its foreign equivalent. Such trials may include but are not limited to dose range exploration, pharmacokinetics studies, mechanistic and pharmacodynamics studies,
drug-drug-interaction and food effect studies, assessment of pharmacokinetics in renal or hepatic impairment patients, and initial evaluation of combinations of a Licensed Product with other drugs or drug candidates. 

1.67 “IMS” has the meaning set forth in Section 7.6.3(a). 

1.68 “Immune Effector Target” means a Target that is [***]. 

1.69 “In-Licensed Patents” has the meaning set forth in
Section 11.2.3. 
 1.70 “IND” means an application filed with a Regulatory
Authority for authorization to commence Clinical Studies, including (a) an Investigational New Drug Application as defined in the FFDCA or any successor application or procedure filed with the FDA, (b) any equivalent thereof in other
countries or regulatory jurisdictions, (e.g., a Clinical Trial Application (CTA) in the European Union) and (c) all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect to the foregoing. 

1.71 “Indemnification Claim Notice” has the meaning set forth in
Section 12.3. 
 1.72 “Indemnified Party” has the meaning set forth in
Section 12.3. 
 1.73 “Indication” means each separate and distinct
disease, disorder, illness, health condition, or interruption, cessation or disruption of a bodily function, system, tissue type or organ, for which Regulatory Approval is required. 

1.74 “Indirect Taxes” has the meaning set forth in Section 7.10. 

1.75 “Information” means all knowledge of a technical, scientific, business and other nature,
including know-how, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures,
computer programs, apparatuses, specifications, data, results and other material, regulatory data, and other biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical,
pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and protocols, reagents (e.g., plasmids, proteins, cell lines, assays and compounds) and
biological methodology, in each case (whether or not confidential, proprietary, patented or patentable, of commercial advantage or not) in written, electronic or any other form now known or hereafter developed. 

  
 - 9 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.76 “Initiation” or “Initiate”
means, with respect to a Clinical Study, the first dosing of the first human subject in such Clinical Study. 
 1.77
“Intellectual Property” has the meaning set forth in Section 13.5.1. 

1.78 “Internal Reserved Program” means [***] internal program of [***] of such program and has [***]
of such program [***]. 
 1.79 “Joint Intellectual Property Rights” means the Joint Program Know-How and Joint Program Patents. 
 1.80 “Joint Program Know-How” means all Program Know-How that is conceived, discovered, developed, or otherwise made jointly by or on behalf of AbbVie, or its Affiliates or Sublicensees,
on the one hand, and Licensor, or its Affiliates or licensees, on the other hand, but expressly excluding any AbbVie Program Know-How, Licensor Program Know-How, and
Product-Specific Know-How. 
 1.81 “Joint Program Patents”
means all Program Patents that claim or cover Joint Program Know-How, but expressly excluding any AbbVie Program Patents, Licensor Program Patents, and Product-Specific Patents. 

1.82 “Joint Research Committee” or “JRC” has the meaning set forth in
Section 3.1.1. 
 1.83 “Knowledge” means [***] of the [***] of a Party, or
any personnel holding positions equivalent to such job titles (but only to the extent such positions exist at such Party). 

1.84 [***] 

1.85 “Licensed Product” means any product comprising or containing a Discovery T-Cell Receptor Construct, alone or in combination with one (1) or more other active ingredients, in any and all forms, presentations, delivery systems, dosage forms and strengths, and formulations. 

1.86 “Licensor” has the meaning set forth in the preamble hereto. 

1.87 “Licensor Background Know-How” means all Information that
is (a) Controlled by Licensor or any of its Affiliates on the Effective Date or during the Term, (b) not generally known, (c) developed or invented as a result of performing activities outside the scope of this Agreement, and
(d) reasonably necessary or useful for [***]. For the purposes of clarity, Licensor Background Know-How shall exclude the Discovery T-Cell Receptors. 

  
 - 10 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.88 “Licensor Background Patents” means all Patents
that (a) are Controlled by Licensor or any of its Affiliates on the Effective Date or during the Term and (b) claim or cover Licensor Background Know-How. 

1.89 “Licensor In-License Agreement” has the meaning set forth
in Section 11.2.3. 
 1.90 “Licensor Indemnitees” has the meaning set
forth in Section 12.1. 
 1.91 “Licensor Platform” means Information,
Patents and other intellectual property rights that are (a) Controlled by Licensor or any of its Affiliates on the Effective Date or during the Term and (b) claim or cover [***] including (i) [***] and (ii) [***] to the extent applicable
to [***]. For the purposes of clarity, Licensor Platform or any component of the Licensor Platform does not include Information, Patents and other intellectual property rights that [***]. 

1.92 “Licensor Program Know-How” means all Program Know-How to the extent (a) specifically related to the Licensor Platform or any component of the Licensor Platform, [***], or (b) conceived, discovered, developed or otherwise made solely by or on behalf
of Licensor or its Affiliates except to the extent included in Sections 1.6(a) or 1.117. 
 1.93
“Licensor Program Patents” means all Program Patents that claim or cover Licensor Program Know-How. 

1.94 “Losses” has the meaning set forth in Section 12.1. 

1.95 “MAA” has the meaning set forth in the definition of Drug Approval Application. 

1.96 “Major Market” means each of the [***]. 

1.97 “Major Regulatory Filing” means major regulatory filings and documents (including INDs, Drug
Approval Applications, material labeling supplements, Regulatory Authority meeting requests, and core data sheets). 

1.98 “Manufacture” and “Manufacturing” means all activities related to the synthesis,
making, production, processing, purifying, formulating, filling, finishing, packaging, labeling, shipping, and holding of the Discovery T-Cell Receptor Construct, any Licensed Product, or any intermediate
thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial production and analytic development,
product characterization, stability testing, quality assurance, and quality control. 
 1.99 “Net
Sales” means[***] 

  
 - 11 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.99.1 [***] 

1.99.2 [***] 

1.99.3 [***] 

1.99.4 [***] 

1.99.5 [***] 

1.99.6 [***] of such Licensed Product and to the extent [***], where for purposes of this Net Sales definition, [***] such Licensed
Product; 
 1.99.7 [***], provided that [***]; 

1.99.8 [***] 

1.99.9 [***] 

1.99.10 [***], but which [***]. 

[***] 
 1.99.11 In the
event that a Licensed Product is sold in any country or other jurisdiction [***] 
 (a) [***] 

(b) [***] 
 (c) [***] 

(d) [***] 

1.100 “Neutral” has the meaning set forth in Schedule 14.7.3. 

1.101 “New Target” has the meaning set forth in Section 2.3. 

1.102 “Nominated Target” has the meaning set forth in Section 2.1.3. 

1.103 “Non-Breaching Party” has the meaning set forth in
Section 13.2.1. 
 1.104 “Non-Pivotal Human
Clinical Trial” means an exploratory trial that has clinical efficacy, safety, pharmacodynamics or biological activity as primary endpoint which is prospectively designed to generate sufficient data that may permit commencement of Pivotal
Human Clinical Trials or a similar clinical study or that otherwise satisfies the requirements of 21 CFR 312.21(b) or its foreign equivalent. 

  
 - 12 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.105 “Novel Target” means a Therapeutic Target
which, as of the time of the initial nomination by AbbVie of the corresponding TCR Target as a potential Accepted Target, [***]. 

1.106 “Other Product” means, with respect to a Combination Product, such independently therapeutically
active pharmaceutical or biologic products referenced in Section 1.34(a) or such diagnostic or other product, process, service or therapy referenced in Section 1.34(b), in each case other than the
Discovery T-Cell Receptor Construct. 
 1.107 “Owned
Patents” has the meaning set forth in Section 11.2.3. 
 1.108
“Party” and “Parties” has the meaning set forth in the preamble hereto. 
 1.109
“Patents” means (a) all national, regional and international patents and patent applications, including provisional patent applications, (b) all patent applications filed either from such patents, patent applications or
provisional applications or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals,
converted provisionals and continued prosecution applications, (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design patents and
certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions
(including any pediatric exclusivity and other such exclusivities that are attached to patents, supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b), and (c)), and (e) any similar rights,
including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and
patents. 
 1.110 “Person” means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political
subdivision, department or agency of a government. 
 1.111 “PHSA” means the United States Public
Health Service Act, as amended from time to time. 
 1.112 “Pivotal Human Clinical Trial” means a
trial in any country conducted in accordance with GCP that is designed to establish statistically significant evidence of efficacy and safety of a Licensed Product as a basis for a BLA or that would otherwise satisfy requirements of 21 CFR
312.21(c), or its foreign equivalent. 

  
 - 13 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.113 “PMDA” means Japan’s Pharmaceuticals and
Medical Devices Agency and any successor agency(ies) or authority having substantially the same function. 
 1.114
“Product Information” has the meaning set forth in Section 10.1. 
 1.115
“Product Infringement” has the meaning set forth in Section 8.3.1. 

1.116 “Product Labeling” means, with respect to a Licensed Product in a country or other jurisdiction
in the Territory, (a) the Regulatory Authority-approved full prescribing information for such Licensed Product for such country or other jurisdiction, including any required patient information, and (b) all labels and other written,
printed, or graphic matter upon a container, wrapper, or any package insert utilized with or for such Licensed Product in such country or other jurisdiction. 

1.117 “Product-Specific Know-How” means all Program Know-How to the extent specifically related to a Discovery T-Cell Receptor Construct and/or a Licensed Product, but excluding, for clarity, Program Know-How that is conceived, discovered, developed, or otherwise made by or on behalf of AbbVie and is specifically related to formulations, methods of manufacturing, or methods of use, provided that such
formulations, methods of manufacturing, or methods of use are not specific to a Discovery T-Cell Receptor Construct and/or a Licensed Product. 

1.118 “Product-Specific Patents” means Program Patents that claim or cover Product-Specific Know-How. 
 1.119 “Product Trademarks” means the Trademark(s) to
be used by AbbVie or its Affiliates or its or their respective Sublicensees for the Development or Commercialization of Licensed Products in the Territory and any registrations thereof or any pending applications relating thereto in the Territory
(excluding, in any event, any trademarks, service marks, names or logos that include any corporate name or logo of the Parties or their Affiliates or the term “TriTAC”). 

1.120 “Program Know-How” means all Information and inventions
that are conceived, discovered, developed, or otherwise made by or on behalf of either Party or its Affiliates or licensees, solely or jointly with the other Party or its Affiliates or licensees, under this Agreement. 

1.121 “Program Patents” mean all Patents that claim or cover Program
Know-How. 
 1.122 “Proposed Future
In-Licensed Rights” has the meaning set forth in Section 6.9. 

1.123 “Regulatory Approval” means, with respect to a country or other jurisdiction in the Territory,
all approvals (including Drug Approval Applications), licenses, registrations, or authorizations of any Regulatory Authority necessary to Commercialize a Discovery T-Cell Receptor Construct or Licensed Product
in such country or other jurisdiction, including, where applicable, pricing or reimbursement approval in such country or other jurisdiction. 

  
 - 14 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.124 “Regulatory Authority” means any applicable
supra-national, federal, national, regional, state, provincial, or local governmental or regulatory authority, agency, department, bureau, commission, council, or other entities (e.g., the FDA, EMA and PMDA) regulating or otherwise exercising
authority with respect to activities contemplated in this Agreement, including the Exploitation of the Discovery T-Cell Receptor Constructs or Licensed Products in the Territory. 

1.125 “Regulatory Documentation” means all (a) applications (including all INDs and Drug Approval
Applications and other Major Regulatory Filings), registrations, licenses, authorizations, and approvals (including Regulatory Approvals), (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and
official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, adverse event files, and complaint
files, and (c) Clinical Data and data contained or relied upon in any of the foregoing, in each case ((a), (b), and (c)) to the extent relating to a Discovery T-Cell Receptor Construct or Licensed
Product. 
 1.126 “Regulatory Exclusivity” means, with respect to any country or other jurisdiction
in the Territory, an additional market protection, other than Patent protection, granted by a Regulatory Authority in such country or other jurisdiction which confers an exclusive Commercialization period during which AbbVie or its Affiliates or
Sublicensees have the exclusive right to market and sell a Discovery T-Cell Receptor Construct or Licensed Product in such country or other jurisdiction through a regulatory exclusivity right (e.g., new
chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug exclusivity, or any applicable data exclusivity). 

1.127 “Royalty Term” means, with respect to each Licensed Product and each country or other
jurisdiction in the Territory, the period beginning on the date of the First Commercial Sale of such Licensed Product in such country or other jurisdiction, and ending on the latest to occur of (a) the expiration, invalidation or abandonment
date of the last Valid Claim of any Joint Program Patent, Licensor Background Patent, Licensor Program Patent, or Product-Specific Patent that covers [***] in such country or other jurisdiction [***] in such country or other jurisdiction (provided
that (A) [***], (b) the expiration of applicable Regulatory Exclusivity in such country or other jurisdiction for such Licensed Product or (c) the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product in such country or
other jurisdiction. 
 1.128 [***]” has the meaning set forth in [***]. 

  
 - 15 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.129 “Segregate” means, with respect to a [***]
relating to such [***] under this Agreement, including using [***] relating to the [***] or any other [***]; and (b) [***] relating to the [***]; provided, that, in [***] in connection with [***]. 

1.130 “Senior Officer” means, with respect to Licensor, its [***], and with respect to AbbVie, its
[***]. 
 1.131 “Sublicensee” means a Person, other than an Affiliate or a Distributor, that is
granted a sublicense by AbbVie under the grants in Section 6.1 as provided in Section 6.3. 

1.132 [***] 

1.133 “T-Cell Receptor” means (i) a protein naturally
expressed by a T-cell on the cell surface of a T-cell that Binds to a particular TCR Target, or any modification or derivative thereof, such as a single chain version of
such protein, that Binds to such TCR Target, or (ii) such protein referenced in clause (i) expressed non-naturally by genetically engineered cells. 

1.134 “T-Cell Receptor Construct” means a TriTAC Construct
comprising or incorporating a T-Cell Receptor as the domain that binds to a TCR Target. 

1.135 “Target” means a protein identified by a unique NCBI Entrez Gene Symbol and NCBI RefSeq
accession number or similar information, such as its amino acid or nucleic acid sequence. Such Target shall be deemed to include (a) any mutant or allelic variant of such protein referenced in the first sentence of this definition, including
transcriptional and post-transcriptional isoforms (e.g., alternative splice variants), and post-translational modification variants (e.g., protein processing, maturation and glycosylation variants); and (b) truncated forms (including fragments
thereof) of such protein or variant, in each case (clauses (a) and (b)) [***]. 
 1.136 “Target
Acceptance Date” has the meaning set forth in Section 2.1.3. 
 1.137
“Target Availability Notice” has the meaning set forth in Section 2.1.3. 

1.138 [***] 

1.139 “Target Nomination Notice” has the meaning set forth in Section 2.1.3.

 1.140 “TCR Sequence Information” has the meaning set forth in
Section 4.1. 
 1.141 “TCR Target” means [***]. Such [***] shall be
referred to in this Agreement as [***]. 
 For the purposes of clarity, a given TCR Target refers to [***]. For illustrative purposes only, in the case of a
[***]. 

  
 - 16 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.142 “Term” has the meaning set forth in
Section 13.1.1. 
 1.143 “Terminated Target” has the meaning set forth in
Section 13.8. 
 1.144 “Terminated Territory” means each Major Market with
respect to which this Agreement is terminated by Licensor pursuant to Section 13.2.2, each country with respect to which this Agreement is terminated by AbbVie pursuant to Section 13.3.2, or, if
this Agreement is terminated in its entirety, the entire Territory. 
 1.145 “Territory” means the
entire world. 
 1.146 “Therapeutic Target” means a Target that is [***]. 

1.147 “Third Party” means any Person other than Licensor, AbbVie and their respective Affiliates. 

1.148 “Third Party Claims” has the meaning set forth in Section 12.1. 

1.149 “Third Party Provider” has the meaning set forth in Section 4.6. 

1.150 “Trademark” means any word, name, symbol, color, designation or device or any combination
thereof that functions as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo, business symbol or domain name, whether or not registered. 

1.151 “TriTAC Construct” means a tri-specific antigen-binding
molecule that contains (a) one anti-CD3 binding domain, including a [***], (b) one domain that binds to a Therapeutic Target or a TCR Target and [***] 

1.152 “Unavailable Target(s)” has the meaning set forth in Section 2.1.2.

 1.153 “Unblocking License” means a [***] license under [***] for the sole purpose of and solely
to the extent necessary to [***], as applicable, but expressly excluding (a) any rights to any [***]. 
 1.154
“United States” or “U.S.” means the United States of America and its territories and possessions (including the District of Columbia and Puerto Rico). 

1.155 “Valid Claim” means a claim of any [***] whose validity, enforceability, or patentability has
not been rendered invalid by any of the following: (a) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer; or (b) a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, governmental agency, national or regional patent office, or other appropriate body that has competent jurisdiction, such holding, finding, or decision being final and unappealable or
unappealed within the time allowed for appeal. 

  
 - 17 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 1.156 “Voting Stock” has the meaning set forth in the
definition of “Change in Control.” 
 1.157 “Withholding Amount” has the meaning set forth
in Section 7.9. 
 1.158 “Withholding Party” has the meaning set forth in
Section 7.9. 
 1.159 “Working Group” has the meaning set forth in
Section 3.4. 
 ARTICLE 2 

TARGET NOMINATION AND [***] 

2.1 Target Nomination. 

2.1.1 Subject to this ARTICLE 2, AbbVie has the right to select a total of up to two (2) TCR Targets as Accepted Targets
under this Agreement for purposes of Development and Commercialization of Discovery T-Cell Receptor Constructs and Licensed Products. The first such TCR Target must be initially nominated by AbbVie no later
than [***] following the Effective Date and the second such TCR Target must initially be nominated by AbbVie no later than [***] following the Effective Date. [***]. 

2.1.2 Licensor shall maintain an up-to-date list of
unavailable Therapeutic Targets (collectively, “Unavailable Targets”). As of the Effective Date, such Unavailable Targets include those Therapeutic Targets in Schedule 2.1.2. The list of Unavailable Targets shall be limited
to (a) Therapeutic Targets [***] with respect to [***], (b) Therapeutic Targets covered by [***] or (c) Therapeutic Targets that are the [***] such Therapeutic Target, provided, however, that such Therapeutic Target may [***], not to
exceed: (i) [***], if Licensor and such [***] or (ii) [***] if Licensor and [***], provided, that, such [***]. In addition, if Licensor [***], in each such case (clauses (A) through (C)) with respect to a [***], then the Therapeutic Target
[***] shall be deemed to be an Unavailable Target. The identity of the Unavailable Targets is deemed to be the Confidential Information of Licensor. 

2.1.3 To nominate a TCR Target as an Accepted Target, AbbVie shall provide Licensor with a confidential written description of the
Therapeutic Target (the “Nominated Target”) corresponding to such TCR Target, including, to the extent available, the NCBI Entrez Gene Symbol and NCBI RefSeq accession number and the amino acid sequence for such Therapeutic Target
(the “Target Nomination Notice”). Within [***] following the Licensor’s receipt of the Target Nomination Notice with respect to a Nominated Target, Licensor shall verify whether such Nominated Target is on the list of
Unavailable Targets and notify AbbVie in writing (“Target Availability Notice”) whether such proposed Nominated Target is or is not on the Unavailable Target list. If the Target Availability Notice indicates that the Nominated
Target is not on the Unavailable Target list, then the TCR Target corresponding to such Nominated Target shall automatically be designated as an “Accepted Target” on the date of AbbVie’s receipt of the Target Availability
Notice (the “Target Acceptance Date”), and the Parties will have all rights and obligations hereunder in connection with such Accepted Target (including exclusivity in accordance with Section 6.8) as of the
Target Acceptance Date. If the 

  
 - 18 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
Target Availability Notice indicates that the Nominated Target is on the Unavailable Target list, then (a) [***] and (b) AbbVie shall have the right to nominate an alternative Nominated
Target (or the same Nominated Target, if it becomes available) in accordance with this Section 2.1.3 on or prior to the later of (i) the deadline set forth in Section 2.1.1 or (ii) the
date that is [***] after AbbVie’s receipt of such Target Availability Notice notwithstanding the deadline set forth in Section 2.1.1. In the event that [***] Licensor will [***] such Nominated Target [***]. In all
cases, Licensor acknowledges and agrees that if AbbVie is the first Person to submit a Target Nomination Notice for a Nominated Target, then the TCR Target corresponding to such Nominated Target will, subject to the terms of this Agreement, be
deemed an Accepted Target, unless such Nominated Target is subject to an Internal Reserved Program. 
 2.2 [***] 

2.3 [***] 

2.4 Effect of [***] or [***]. In the event of a [***] 

ARTICLE 3 
 COLLABORATION
MANAGEMENT 
 3.1 Joint Research Committee. 

3.1.1 Formation. Within [***] after the Effective Date, the Parties shall establish a joint research committee (the
“Joint Research Committee” or “JRC”). The JRC shall consist of [***] representatives from each of the Parties, each with the requisite experience and seniority to enable such person to make decisions on behalf of
the Parties with respect to the issues falling within the jurisdiction of the JRC. From time to time, each Party may substitute one (1) or more of its representatives to the JRC on written notice to the other Party. [***] shall select from its
representatives the chairperson for the JRC. From time to time, [***]. 
 3.1.2 Specific Responsibilities. The JRC shall
develop the strategies for and oversee the research and discovery related activities relating to the conversion of Discovery T-Cell Receptors into Discovery T-Cell
Receptor Constructs in accordance with the Discovery Research Plan, and shall serve as a forum for the coordination of such activities. In particular, the JRC shall: 

(a) periodically (no less often than quarterly) review and serve as a forum for discussing the Discovery Research Plan for each Accepted
Target, and review and approve amendments thereto; 
 (b) serve as a forum for discussion of results from the conduct of the Discovery
Research Activities; 
 (c) [***] 

  
 - 19 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 (d) establish secure access methods (such as secure databases) for each Party to access
research and discovery and other JRC related Information as contemplated under this Agreement; and 
 (e) perform such other functions as
are set forth herein or as the Parties may mutually agree in writing, except where in conflict with any provision of this Agreement. 

3.2 General Provisions Applicable to the JRC. 

3.2.1 Meetings and Minutes. The JRC shall meet quarterly, or in each case as otherwise agreed to by the Parties, with
the location of such meetings alternating between locations designated by Licensor and locations designated by AbbVie. The Alliance Manager shall be permitted to attend any such JRC meetings. The chairperson of the JRC shall be responsible for
calling meetings on no less than [***] notice. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items at least [***] in advance of the applicable meeting; provided, that
under exigent circumstances requiring input by the JRC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting,
so long as the other Party consents to such later addition of such agenda items or the absence of a specific agenda for such meeting. The chairperson of the JRC shall prepare and circulate for review and approval of the Parties minutes of each
meeting within [***] after the meeting. The Parties shall agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JRC. 

3.2.2 Procedural Rules. The JRC shall have the right to adopt such standing rules as shall be necessary for its work, to the
extent that such rules are not inconsistent with this Agreement. A quorum of the JRC shall exist whenever there is present at a meeting [***] appointed by each Party. Representatives of the Parties on the JRC may attend a meeting either in person or
by telephone, video conference or similar means in which each participant can hear what is said by, and be heard by, the other participants. Representation by proxy shall be allowed. The JRC shall take action by consensus of the representatives
present at a meeting at which a quorum exists, with each Party having a single vote irrespective of the number of representatives of such Party in attendance, or by a written resolution signed by [***] appointed by each Party. Employees or
consultants of either Party that are not representatives of the Parties on the JRC may attend meetings of the JRC; provided, that such attendees (i) shall not vote or otherwise participate in the decision-making process of the JRC, and
(ii) are bound by obligations of confidentiality and non-disclosure equivalent to those set forth in ARTICLE 10. 

3.2.3 Dispute Resolution. If the JRC cannot, or does not, reach consensus on an issue, then the dispute shall first be referred
to the Senior Officers of the Parties, who shall confer in good faith on the resolution of the issue. Any final decision mutually agreed to by the Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are not able to
agree on the resolution of any such issue within [***] after such issue was first referred to them, then, such dispute shall be finally and definitively resolved by [***] provided, 

  
 - 20 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
however, that [***] provided, further, that [***] for the purposes of this Section. Disputes arising between the Parties in connection with or relating to this Agreement or any document or
instrument delivered in connection herewith, and that are outside of the jurisdiction of the JRC, shall be resolved pursuant to Section 14.7. 

3.2.4 Limitations on Authority. Each Party shall retain the rights, powers, and discretion granted to it under this Agreement
and no such rights, powers, or discretion shall be delegated to or vested in the JRC unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. The JRC shall not have the
power to amend, modify, or waive compliance with this Agreement, which may only be amended or modified as provided in Section 14.9 or compliance with which may only be waived as provided in
Section 14.12. 
 3.2.5 Alliance Manager. Each Party shall appoint a person(s) who shall oversee
contact between the Parties for all matters between meetings of the JRC and shall have such other responsibilities as the Parties may agree in writing after the Effective Date (each, an “Alliance Manager”). Each Party may replace
its Alliance Manager at any time by notice in writing to the other Party. 
 3.2.6 Discontinuation of the JRC. Upon
completion of the Discovery Research Plan for a given Accepted Target, the JRC shall have no further responsibilities or authority under this Agreement with respect to that Accepted Target and the associated Discovery
T-Cell Receptor Constructs and Licensed Products. Once the Discovery Research Plan has been completed for the [***] Accepted Target (or, if a [***] TCR Target is not nominated prior to the deadline set forth
in Section 2.1.1, the [***] Accepted Target), the JRC shall have no further responsibilities or authority under this Agreement with respect to that [***] Accepted Target and the associated Discovery T-Cell Receptor Constructs and Licensed Products. Once the Discovery Research Plan has been completed for [***], the JRC will be considered fully dissolved by the Parties. Additionally, in the event of a Change in
Control of Licensor involving a Competitor, AbbVie shall have the right at any time and for any reason, effective upon written notice, to disband the JRC pursuant to Section 14.2. In the event that the JRC is disbanded
pursuant to Section 14.2, (a) any information, documents or reports that a Party is otherwise required to provide to the JRC pursuant to this Agreement shall be provided directly to the other Party and (b) any matters
delegated to the JRC shall be made by mutual agreement of the Parties, subject to the dispute resolution provisions of Section 3.2.3. 

3.3 Interactions Between a Committee and Internal Teams. The Parties recognize that each Party possesses
an internal structure (including various committees, teams and review boards) that will be involved in administering such Party’s activities under this Agreement. Nothing contained in this Article shall prevent a Party from making routine day-to-day decisions relating to the conduct of those activities for which it has a performance or other obligations hereunder, in each case in a manner consistent with the
then-current Discovery Research Plan and the terms and conditions of this Agreement. 

  
 - 21 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 3.4 Working Groups. From time to time, the JRC may
establish and delegate duties to sub-committees or directed teams (each, a “Working Group”) on an “as-needed” basis to oversee particular
projects or activities (for example, joint project team, joint finance group, and/or joint intellectual property group). Each such Working Group shall be constituted and shall operate as the JRC determines; provided that each Working Group shall
have equal representation from each Party, unless otherwise mutually agreed. Working Groups may be established on an ad hoc basis for purposes of a specific project or on such other basis as the JRC may determine. Each Working Group and its
activities shall be subject to the oversight, review and approval of, and shall report to, the JRC. In no event shall the authority of the Working Group exceed that specified for the JRC. All decisions of a Working Group shall be by consensus. Any
disagreement between the designees of AbbVie and Licensor on a Working Group shall be referred to the JRC for resolution. 

3.5 Expenses. Each Party shall be responsible for all travel and related costs and expenses for its
members and other representatives to attend meetings of, and otherwise participate on, the JRC or any Working Group. 
 ARTICLE 4 

DEVELOPMENT AND REGULATORY 

4.1 T-Cell Receptor Sequence Delivery. For each Accepted Target,
AbbVie will deliver to Licensor the [***] Controlled by AbbVie that Bind to such Accepted Target (each, a “Discovery T-Cell Receptor”), together with related materials and data as set forth in
the Discovery Research Plan (collectively, with respect to the applicable Accepted Target, the “TCR Sequence Information”), within [***] following the applicable Target Acceptance Date. 

4.2 Creation of Discovery T-Cell Receptor Constructs. For each
Accepted Target (including any [***] or New Target), Harpoon shall carry out the Discovery Research Activities. Following delivery by AbbVie of the TCR Sequence Information with respect to an Accepted Target, Licensor will create and evaluate
against the Discovery T-Cell Receptor Construct Success Criteria [***] Discovery T-Cell Receptor Constructs per Discovery T-Cell
Receptor per Accepted Target in accordance with the Discovery Research Plan and timeline set forth therein. The Discovery Research Plan shall be conducted over a period of up to four (4) years from receipt of the TCR Sequence Information for each
Accepted Target. Following the completion of such Discovery Research Activities for an Accepted Target, Licensor shall deliver to AbbVie, by the applicable Discovery T-Cell Receptor Construct Delivery
Deadline, [***] (collectively, the “Accepted Target Deliverables”). Upon delivery of the Accepted Target Deliverables with respect to an Accepted Target, Licensor shall have completed all of its obligations under the Discovery
Research Plan with respect to such Accepted Target, and thereafter AbbVie shall evaluate whether the Discovery T-Cell Receptor Construct Success Criteria have been met. If Licensor is in material breach of its
obligation to perform any Discovery Research Activities and fails to remedy such 

  
 - 22 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
breach within [***] after written notice thereof from AbbVie, [***]. In the event of such [***]. The Parties acknowledge and agree that in the event [***]. If AbbVie so [***], to the extent
reasonably requested by AbbVie and permitted under the terms and conditions of [***] to the extent [***]. Following AbbVie’s receipt of the Accepted Target Deliverables, AbbVie will evaluate whether the Discovery
T-Cell Receptor Construct Success Criteria have been met. If AbbVie determines in good faith that the Discovery T-Cell Receptor Construct Success Criteria have not been
met by any of the Discovery T-Cell Receptor Constructs for an Accepted Target, [***] of AbbVie’s receipt of the Accepted Target Deliverables for such Accepted Target, provide written notice to Licensor
identifying the deficiencies and Licensor will [***] to AbbVie in accordance with this Section 4.2. 

4.3 Development of Discovery T-Cell Receptor Constructs and Licensed
Products. For each Accepted Target, following the applicable Target Acceptance Date, except for Licensor’s responsibilities in the conduct of the Discovery Research Plan, AbbVie shall have the sole right to Develop and Manufacture
(and shall control all aspects of Development and Manufacturing), including seeking Regulatory Approvals for, Discovery T-Cell Receptor Constructs and Licensed Products in the Field and in the Territory and,
for clarity, Licensor and its Affiliates shall have no right to do so. For each Accepted Target, following the creation of the applicable Discovery T-Cell Receptor Constructs, AbbVie shall use Commercially
Reasonable Efforts to Develop and obtain Regulatory Approval for a Licensed Product for at least one Indication for use in [***] Major Market. For the purposes of clarity, AbbVie’s obligation to Develop and obtain Regulatory Approval for a
Licensed Product as set forth in this Section 4.3 shall be satisfied by AbbVie’s Commercially Reasonable Efforts to Develop a Licensed Product directed to [***]. AbbVie shall have the right to satisfy its diligence
obligations under this Section 4.3 through its Affiliates or Sublicensees. Except as set forth in this Section 4.3, AbbVie shall have no other diligence obligations, express or implied, with
respect to the Development of the Discovery T-Cell Receptor Constructs or Licensed Products with respect to such Accepted Target in the Territory. For each Accepted Target, following the applicable Target
Acceptance Date and until submission of a BLA for a Licensed Product directed to such Accepted Target in a Major Market, AbbVie will provide to Licensor annual reports within [***] after the end of each Calendar Year summarizing the key Development
activities undertaken and summarizing the results achieved with respect to the applicable Discovery T-Cell Receptor Constructs and Licensed Products during such Calendar Year, and Licensor shall provide the
JRC with interim updates on such activities and results at its regularly scheduled meetings. 
 4.4 Supply of
Technology for Development Purposes. On an Accepted Target-by-Accepted Target basis: 

(a) Licensor shall, and shall cause its Affiliates to, [***] disclose and make available to AbbVie (which obligation may be satisfied by
granting personnel designated by AbbVie controlled access to an electronic data room), in such form as maintained by Licensor in the ordinary course of business, [***] for AbbVie’s Development of the Discovery
T-Cell Receptor Constructs (including sequence information), [***] of the Discovery T-Cell Receptor Constructs pursuant to Section 4.2 and
[***] of the development, making, conception, or reduction to practice of such [***]. 

  
 - 23 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 (b) Licensor shall provide AbbVie with all reasonable assistance required in order to
transfer to AbbVie the [***] required to be produced pursuant to clause (a) above, in each case in a timely manner, and shall assist AbbVie with respect to the [***]. Without prejudice to the generality of the foregoing, if visits of
Licensor’s representatives to AbbVie’s facilities are reasonably requested by AbbVie for purposes of transferring [***] to AbbVie or for purposes of providing AbbVie the assistance referenced in the preceding sentence, Licensor shall send
appropriate representatives to AbbVie’s facilities. For each Accepted Target, Licensor shall provide [***] pursuant to this Section 4.4 [***] and AbbVie shall reimburse Licensor for all
out-of-pocket travel and related expenses incurred pursuant to this Section 4.4; any additional consulting time shall be performed and
compensated as mutually agreed by the Parties in writing. 
 (c) The Parties may, each in their sole discretion, elect to collaboratively
develop [***], subject to the negotiation of a mutually agreed upon separate agreement. 
 4.5 Expenses and
Invoicing. Except as expressly set forth in this Agreement, each Party shall bear all costs and expenses associated with the Development activities for which such Party is responsible under this Agreement and the Discovery Research Plan;
provided, that [***] pursuant to (including the limitations set forth in) Section 4.2. If AbbVie [***] in accordance with Section 4.2, then [***] associated with [***], and, Licensor shall [***].

 4.6 Subcontracting. Each Party shall have the right to subcontract any of its Development activities
to a Third Party (a “Third Party Provider”); provided, that [***] to such Third Party Provider and the activities to be subcontracted [***] sufficient for Licensor to comply with the applicable terms and conditions of this
Agreement, including the confidentiality provisions of ARTICLE 10]. 
 4.7 Regulatory Matters. 

4.7.1 Regulatory Activities. 

(a) As between the Parties, AbbVie, at its sole expense, shall have the sole right to prepare, obtain, and maintain the Drug Approval
Applications (including the setting of the overall regulatory strategy therefor), other Regulatory Approvals and other regulatory submissions, and to conduct communications with the Regulatory Authorities, for Discovery T-Cell Receptor Constructs or Licensed Products in the Territory (which shall include filings of or with respect to INDs and other filings or communications with the Regulatory Authorities). Licensor shall support
AbbVie, as may be reasonably necessary, in obtaining Regulatory Approvals for the Licensed Products, and in the activities in support thereof, including providing necessary documents or other materials required by Applicable Law to obtain Regulatory
Approvals, in each case in accordance with the terms and conditions of this Agreement and the Discovery Research Plan. 

  
 - 24 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 (b) All Regulatory Documentation (including all Regulatory Approvals and Product Labeling)
specifically relating to the Discovery T-Cell Receptor Constructs or Licensed Products with respect to the Territory shall be owned by, and shall be the sole property and held in the name of, AbbVie or its
designated Affiliate, Sublicensee or designee. Licensor shall duly execute and deliver, or cause to be duly executed and delivered, such instruments and shall do and cause to be done such acts and things, including the filing of such assignments,
agreements, documents, and instruments, as may be necessary under, or as AbbVie may reasonably request in connection with, or to carry out more effectively the purpose of, or to better assure and confirm unto AbbVie its rights under, this Section.

 4.7.2 Recalls. AbbVie shall make every reasonable effort to notify Licensor promptly following its determination that any
event, incident, or circumstance has occurred that may result in the need for a recall, market suspension, or market withdrawal of a Licensed Product in the Territory, and shall include in such notice the reasoning behind such determination, and any
supporting facts. AbbVie (or its Sublicensee) shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension, or market withdrawal in the Territory. If a recall, market suspension, or market
withdrawal is mandated by a Regulatory Authority in the Territory, AbbVie (or its Sublicensee) shall initiate such a recall, market suspension, or market withdrawal in compliance with Applicable Law. For all recalls, market suspensions or market
withdrawals undertaken pursuant to this Section 4.7.2, AbbVie (or its Sublicensee) shall be solely responsible for the execution thereof, and Licensor shall reasonably cooperate in all such recall efforts, at AbbVie’s
expense. 
 4.7.3 Compliance. Each Party shall perform or cause to be performed, any and all of its Discovery Research
Activities in good scientific manner and in compliance with all Applicable Law. 
 4.7.4 Records. 

(a) Each of Licensor and AbbVie shall, and shall ensure that its Third Party Providers, maintain records in sufficient detail and in good
scientific manner appropriate for patent and regulatory purposes, and in compliance with Applicable Law, which shall be complete and accurate and shall properly reflect all work done and results achieved in the performance of its designated
Discovery Research Activities which shall record only such activities and shall not include or be commingled with records of activities outside the scope of this Agreement. Such records shall be retained by Licensor or AbbVie, as the case may be,
[***], or for such longer period as may be required by Applicable Law. Upon request, Licensor shall provide copies of the records it has maintained pursuant to this Section 4.7.4 to AbbVie. AbbVie shall maintain such
records and the information disclosed therein in confidence in accordance with ARTICLE 10. 
 (b) AbbVie shall have the right,
[***], to inspect and copy all records of Licensor maintained pursuant to Section 4.7.4. AbbVie shall maintain such records and the information disclosed therein in confidence in accordance with ARTICLE 10. 

  
 - 25 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 ARTICLE 5 

COMMERCIALIZATION 

5.1 In General. AbbVie (itself or through its Affiliates or Sublicensees) shall have the sole right to
Commercialize Discovery T-Cell Receptor Constructs and Licensed Products in the Territory at its own cost and expense. 

5.2 Commercialization Diligence. For each Accepted Target, AbbVie shall use Commercially Reasonable
Efforts to Commercialize one Licensed Product in [***] Major Market following receipt of Regulatory Approval therefor in such Major Market; provided, that (a) such obligation is expressly conditioned upon (i) Licensor’s and its
Affiliates’ performing their respective obligations hereunder, (ii) [***], and (iii) the [***] For the purposes of clarity, AbbVie’s obligation to Commercialize a Licensed Product as set forth in this
Section 5.2 shall be satisfied by AbbVie’s Commercially Reasonable Efforts to Commercialize a Licensed Product directed to [***]. Licensor acknowledges and agrees that, in addition to the foregoing, (A) the
Commercialization of Licensed Product may, subject to Section 14.1, be delayed, suspended or otherwise modified by AbbVie in response to circumstances outside the reasonable control of AbbVie, including force majeure
events, (B) AbbVie shall have the right to satisfy its diligence obligations under this Section through its Affiliates or Sublicensees, and [***]. With respect to a particular Accepted Target, in the event that AbbVie decides to discontinue the
development or commercialization of a Discovery T-Cell Receptor Construct or Licensed Product in favor of another Discovery T-Cell Receptor Construct or Licensed
Product, its obligations under this Section shall cease with respect to such initial Discovery T-Cell Receptor Construct or Licensed Product in favor of such other Discovery
T-Cell Receptor Construct or Licensed Product. Licensor further acknowledges that AbbVie is in the business of Exploiting products and nothing in this Agreement shall be construed as restricting such business
or imposing on AbbVie the duty to Exploit any Licensed Product for which royalties are payable hereunder to the exclusion of, or in preference to, any other product, or in any way other than in accordance with its normal commercial practices. If at
any time Licensor has a reasonable basis to believe that AbbVie is in material breach of its material obligations under this Section, then Licensor may so notify AbbVie, specifying the basis for its belief, and the Parties shall meet within [***]
after such notice to discuss in good faith Licensor’s concerns. 
 5.3 Booking of Sales;
Distribution. AbbVie shall have the sole right to invoice and book sales, establish all terms of sale (including pricing and discounts) and warehousing, and distribute the Licensed Products in the Territory and to perform or cause to be
performed all related services. AbbVie shall handle all returns, recalls, or withdrawals, order processing, invoicing, collection, distribution, and inventory management with respect to the Licensed Products in the Territory. 

  
 - 26 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 5.4 Product Trademarks. AbbVie shall have the sole right to
determine and own the Product Trademarks to be used with respect to the Exploitation of the Licensed Products on a worldwide basis. Licensor shall not, and shall not permit its Affiliates to, attack, dispute, or contest the validity of or ownership
of such Product Trademark anywhere in the Territory or any registrations issued or issuing with respect thereto or use in their respective businesses, any Trademark that is confusingly similar to, misleading or deceptive with respect to or that
dilutes any (or any part) of the Product Trademarks. Notwithstanding the foregoing, to the extent required by Applicable Law in a country or other jurisdiction in the Territory, the promotional materials, packaging, and Product Labeling for the
Licensed Products used by AbbVie and its Affiliates in connection with the Licensed Products in such country or other jurisdiction shall contain (a) the corporate name of Licensor (and to the extent required, Licensor grants AbbVie a license,
with the right to sublicense, to use the same for such purpose), and (b) the logo and corporate name of the manufacturer (if other than AbbVie or an Affiliate). 

5.5 Commercial Supply of Discovery T-Cell Receptor Constructs or Licensed
Products. As between the Parties, AbbVie shall have the sole right, at its expense, to Manufacture (or have Manufactured) and supply Discovery T-Cell Receptor Constructs and Licensed Products for
commercial sale in the Territory by AbbVie and its Affiliates and Sublicensees. 
 ARTICLE 6 

GRANT OF RIGHTS 

6.1 Grants to AbbVie. 

6.1.1 Upon the Effective Date, Licensor (on behalf of itself and its Affiliates) hereby grants to AbbVie, on an Accepted Target-by-Accepted Target basis: 
 (a) an exclusive (including
with regard to Licensor and its Affiliates, except as provided in Section 6.6) license (or sublicense), with the right to grant sublicenses in accordance with Section 6.3, under the Licensor
Background Patents, the Licensor Program Patents, the Licensor Background Know-How, the Licensor Program Know-How and Licensor’s interests in the Joint Program
Patents and the Joint Program Know-How, to Exploit the Discovery T-Cell Receptor Constructs and Licensed Products in the Field in the Territory; 

(b) an exclusive (including with regard to Licensor and its Affiliates, except as provided in Section 6.6) license
and right of reference, with the right to grant sublicenses and further rights of reference in accordance with Section 6.3, under the Regulatory Approvals and any other Regulatory Documentation that Licensor or its
Affiliates may Control with respect to the Discovery T-Cell Receptor Constructs or Licensed Products as necessary for purposes of Exploiting the Discovery T-Cell
Receptor Constructs and Licensed Products in the Field in the Territory; and 
 (c) a
non-exclusive, royalty-free license, with the right to grant sublicenses in accordance with Section 6.3, under the Licensor Background Patents, the Licensor Program Patents, the
Licensor Background Know-How, the Licensor Program Know-How and Licensor’s interests in the Joint Program Patents and the Joint Program Know-How, to conduct Discovery Research Activities assumed by AbbVie in accordance with Sections 4.2 (if any). 

  
 - 27 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 6.1.2 The grants set forth in Section 6.1.1 will
automatically come into full force and effect on the Target Acceptance Date for such Accepted Target without any further action required by either Party under this Agreement. 

6.2 Grants to Licensor. 

6.2.1 Upon the Effective Date, AbbVie hereby grants to Licensor, on an Accepted Target-by-Accepted Target basis, a non-exclusive, royalty-free license, without the right to grant sublicenses (other than to permitted subcontractors of Licensor in
accordance with Section 4.6), under the AbbVie Background Patents, AbbVie Background Know-How, AbbVie Program Patents, AbbVie Program Know-How,
and AbbVie’s interests in the Joint Program Patents and the Joint Program Know-How to Develop and Manufacture the Discovery T-Cell Receptor Constructs in the
Territory solely for purposes of performing its obligations as set forth in, and subject to, the Discovery Research Plan. 
 6.2.2
The grant set forth in Section 6.2.1 will automatically come into full force and effect on the Target Acceptance Date for such Accepted Target without any further action required by either Party under this Agreement. 

6.3 Sublicenses. AbbVie shall have the right to grant sublicenses (or further rights of reference),
through multiple tiers of sublicensees, under the licenses and rights of reference granted in Section 6.1, to its Affiliates and other Persons; provided that any such sublicenses shall be consistent with the terms and
conditions of this Agreement and AbbVie shall remain liable for its obligations under this Agreement and for the performance of all sublicensees. AbbVie shall provide Licensor with a copy of any such sublicense agreement within [***] after the
execution thereof, which copy may be redacted with respect to information not pertinent to compliance with this Agreement. 

6.4 Distributorships. AbbVie shall have the right, in its sole discretion, to appoint its Affiliates, and
AbbVie and its Affiliates shall have the right, in their sole discretion, to appoint any other Persons, in the Territory or in any country or other jurisdiction of the Territory, to distribute, market, and sell the Licensed Products. Where AbbVie or
its Affiliates appoints such a Person and such Person is not an Affiliate of AbbVie and does not have rights to, and does not, Manufacture any Licensed Product (except solely to package or label such Licensed Product purchased in bulk form from
AbbVie or its Affiliates), that Person shall be a “Distributor” for purposes of this Agreement. 

6.5 Co-Promotion Rights. For purposes of clarity, AbbVie and its
Affiliates shall have the right, in their sole discretion, to co-promote the Licensed Products with any other Person(s), or to appoint one (1) or more Third Parties to promote the Licensed Products
without AbbVie in all or any part of the Territory. 

  
 - 28 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 6.6 Retention of Rights. 

6.6.1 Notwithstanding the exclusive licenses granted to AbbVie pursuant to Section 6.1, Licensor retains the
right to practice under the Licensor Background Patents, the Licensor Program Patents, the Licensor Background Know-How, the Licensors Program Know-How, Licensor’s
interests in the Joint Program Patents and the Joint Program Know-How, Regulatory Approvals and any other Regulatory Documentation (a) to perform (and to sublicense Third Parties to perform as permitted
hereunder) its obligations under this Agreement and (b) for any purpose outside the scope of the licenses and rights granted pursuant to Section 6.1, including to Exploit any products or services other than Discovery T-Cell Receptor Constructs and Licensed Products subject to Section 6.8.1. Except as expressly provided herein, Licensor grants no other right or license, including any rights or licenses
to the Licensor Background Patents, the Licensor Program Patents, the Licensor Background Know-How, the Licensor Program Know-How, Licensor’s interests in the Joint
Program Patents and the Joint Program Know-How, the Regulatory Documentation or any other Patent or intellectual property rights not otherwise expressly granted herein. 

6.6.2 Except as expressly provided herein, AbbVie grants no other right or license, including any rights or licenses to the AbbVie
Background Patents, the AbbVie Program Patents, the AbbVie Background Know-How, the AbbVie Program Know-How, the Regulatory Documentation, or any other Patent or
intellectual property rights not otherwise expressly granted herein. 
 6.7 Confirmatory Patent
License. Licensor shall if requested to do so by AbbVie immediately enter into confirmatory license agreements consistent with this Agreement in the form or substantially the form reasonably requested by AbbVie for purposes of recording
the licenses granted under this Agreement with such patent offices in the Territory as AbbVie considers appropriate. Until the execution of any such confirmatory licenses, so far as may be legally possible, Licensor and AbbVie shall have the same
rights in respect of the Licensor Background Patents, Licensor Program Patents and Joint Program Patents and be under the same obligations to each other in all respects as if the said confirmatory licenses had been executed. 

6.8 Exclusivity with Respect to the Territory. 

6.8.1 Licensor shall not, and shall cause its Affiliates not to, on an Accepted Target-by-Accepted Target basis, beginning on the
applicable Target Acceptance Date until the termination or expiration of this Agreement with respect to the applicable Accepted Target (including by [***] or [***]), (a) directly or indirectly, whether alone or together with a Third Party, [***] for
any purpose except [***], (b) directly or indirectly, develop, commercialize or manufacture any Competing Product in any country or other jurisdiction in the Territory, or (c) license, authorize, appoint, or otherwise enable any Third Party to
directly or indirectly, develop, commercialize or manufacture any Competing Product in any country or other jurisdiction in the Territory. 

6.8.2 Notwithstanding the provisions of Section 6.8.1, if, during the Term, [***] 

6.9 In-License Agreements. During the Term, neither Licensor nor
any of its Affiliates shall, [***] enter into any agreement with a Third Party related to Information, Regulatory Documentation, materials, Patents, or other intellectual other property rights [***], provided that, for clarity, the foregoing shall
not restrict Licensor or its Affiliates from entering into any agreement with a Third Party related to Information, Regulatory Documentation, materials, Patents, or other intellectual other 

  
 - 29 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
property rights directed [***]. Subject to Section 8.6, if Licensor or any of its Affiliates, after the Effective Date, become a party to a license, sublicense or other
agreement for additional intellectual property rights, with the right to sublicense, that are [***] pursuant to the preceding sentence, then Licensor shall inform AbbVie and shall [***] (“Proposed Future
In-Licensed Rights”). If AbbVie notifies Licensor in writing within [***] after receipt of such copy that AbbVie wishes to receive a license or sublicense (as applicable) under, and be subject to the
rights and obligations of, the Proposed Future In-Licensed Rights as they apply to AbbVie and this Agreement, then the Proposed Future In-Licensed Rights shall
automatically be included in the Licensor Background Patents and/or Licensor Background Know-How (as applicable) hereunder and AbbVie agrees to abide by all applicable terms and conditions of such license,
sublicense or other agreement, as it relates to AbbVie and this Agreement, including payment of any financial obligations based upon AbbVie’s practice of such intellectual property rights. Except as provided in the preceding sentence, Licensor
shall be solely responsible for and shall bear any and all payments under any Licensor In-License Agreements. 

ARTICLE 7 
 PAYMENTS AND
RECORDS 
 7.1 Upfront Payment. [***] following the Effective Date, AbbVie shall pay Licensor an
upfront, non-refundable, non-creditable amount equal to Seventeen Million Dollars ($17,000,000). 

7.2 Development Milestones. In partial consideration of the rights granted by Licensor to AbbVie
hereunder and subject to the terms and conditions set forth in this Agreement, AbbVie shall pay to Licensor a non-refundable milestone payment within [***] after the achievement of each of the following
milestones for the first Licensed Product for each Accepted Target (irrespective of whether such Accepted Target is an initially nominated Accepted Target, [***] or New Target), calculated as follows: 

7.2.1 upon [***] for the first Licensed Product for an Accepted Target, [***]; and 

7.2.2 upon [***] for the first Licensed Product that [***] for an Accepted Target [***], [***]; provided, however, that if [***] for
such Licensed Product [***] 
 (a) in the amount of [***] upon the first achievement of such [***], if such [***]; or 

(b) in the amount of (i) [***] upon the first achievement of [***] of the [***], [***] upon the subsequent achievement of [***]. 

  
 - 30 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 On an Accepted
Target-by-Accepted Target basis, if a development milestone payment set forth in this Section 7.2 for a Licensed Product becomes due before an
earlier listed development milestone payment for such Licensed Product, then the earlier listed development milestone payment shall become payable upon the achievement of the later listed development milestone. Each milestone payment in this
Section 7.2 shall be payable only upon the first achievement of such milestone for an Accepted Target and no amounts shall be due for subsequent or repeated achievements of such milestone, whether for the same or a
different Licensed Product targeting such Accepted Target. The maximum aggregate amount payable by AbbVie pursuant to this Section 7.2 for each Accepted Target is [***] and for all Accepted Targets is [***]. 

7.3 Regulatory Milestones. In partial consideration of the rights granted by Licensor to AbbVie hereunder
and subject to the terms and conditions set forth in this Agreement, AbbVie shall pay to Licensor a non-refundable milestone payment within [***] after the achievement of each of the following milestones for
each Accepted Target (irrespective of whether such Accepted Target is an initially nominated Accepted Target, [***] or New Target), calculated as follows: 

7.3.1 upon the [***] for a Licensed Product for an Accepted Target, [***]; 

7.3.2 upon the [***] for a Licensed Product for an Accepted Target, [***]; 

7.3.3 upon the [***] for a Licensed Product for an Accepted Target, [***]; and 

7.3.4 upon the [***] for a Licensed Product for an Accepted Target, [***]. 

Each milestone payment in this Section 7.3 shall be payable only upon the first achievement of such milestone for an Accepted Target
and no amounts shall be due for subsequent or repeated achievements of such milestone, whether for the same or a different Licensed Product targeting such Accepted Target. The maximum aggregate amount payable by AbbVie pursuant to this
Section 7.3 for each Accepted Target is [***] and for all Accepted Targets is [***]. 
 7.4
Commercialization Milestones. In partial consideration of the rights granted by Licensor to AbbVie hereunder and subject to the terms and conditions set forth in this Agreement, AbbVie shall pay to Licensor the following non-refundable milestone payments due within [***] after the achievement of each of the following milestones for each Accepted Target (irrespective of whether such Accepted Target is an initially nominated Accepted
Target, [***] or New Target), calculated as follows: 
 7.4.1 upon the First Commercial Sale in [***] for an Accepted Target, [***];

 7.4.2 upon the First Commercial Sale in [***] for an Accepted Target, [***]; 

  
 - 31 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 7.4.3 upon the First Commercial Sale in [***] for an Accepted Target, [***]; and 

7.4.4 upon the First Commercial Sale in [***] for an Accepted Target, [***]. 

Each milestone payment in this Section 7.4 shall be payable only upon the first achievement of such milestone for each Accepted
Target and no amounts shall be due for subsequent or repeated achievements of such milestone, whether for the same or a different Licensed Product targeting such Accepted Target. The maximum aggregate amount payable by AbbVie pursuant to this
Section 7.4 for each Accepted Target is [***] and for all Accepted Targets is [***]. 
 7.5 Sales-Based
Milestones. In partial consideration of the rights granted by Licensor to AbbVie hereunder and subject to the terms and conditions set forth in this Agreement, AbbVie shall pay to Licensor the following
non-refundable milestone payments due within [***] in which such milestone was achieved for the first Licensed Product for each Accepted Target (irrespective of whether such Accepted Target is an initially
nominated Accepted Target, [***] or New Target), calculated as follows: 
 7.5.1 upon the Net Sales in the Territory of a particular
Licensed Product made by AbbVie or any of its Affiliates or Sublicensees a given Calendar Year equaling or exceeding [***]; 
 7.5.2
upon the Net Sales in the Territory of a particular Licensed Product made by AbbVie or any of its Affiliates or Sublicensees a given Calendar Year equaling or exceeding [***]; 

7.5.3 upon the Net Sales in the Territory of a particular Licensed Product made by AbbVie or any of its Affiliates or Sublicensees in
a given Calendar Year equaling or exceeding [***]; and 
 7.5.4 upon the Net Sales in the Territory of a particular Licensed Product
made by AbbVie or any of its Affiliates or Sublicensees a given Calendar Year equaling or exceeding [***]. 
 Each milestone payment in this
Section 7.5 shall be payable only upon the first achievement of such milestone for each Accepted Target and no amounts shall be due for subsequent or repeated achievements of such milestone, whether for the same or a
different Licensed Product targeting such Accepted Target. The maximum aggregate amount payable by AbbVie pursuant to this Section 7.5 for each Accepted Target is [***] and for all Accepted Targets is [***]. As used herein
a particular Licensed Product includes any Licensed Product that contains the same Discovery T-Cell Receptor Construct. 

  
 - 32 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 7.6 Royalties. 

7.6.1 Royalty Rates. As further consideration for the rights granted to AbbVie hereunder, subject to
Section 7.6.3, commencing upon the First Commercial Sale of a Licensed Product in the Territory, on a Licensed Product-by-Licensed Product
basis, AbbVie shall pay to Licensor a non-refundable royalty on Net Sales of each Licensed Product in the Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the
Territory for which the Royalty Term for such Licensed Product in such country or other jurisdiction has expired) during [***] at the following rates: 
  

			
	 Net Sales in the Territory of each Licensed Product [***] in
[***]
	  	Royalty Rate
		
	For that portion of aggregate Net Sales of each Licensed Product [***] in the Territory during [***]	  	[***]
		
	For that portion of aggregate Net Sales of each Licensed Product [***] in the Territory during [***] but [***]	  	[***]
		
	For that portion of aggregate Net Sales of each Licensed Product [***] in the Territory during [***]	  	[***]

 For the purposes of clarity, (a) all Licensed Products [***] shall be deemed to be the same Licensed Product for purposes
of the royalty tiers set forth in the table above, and (b) the royalty tiers set forth in the table above shall apply separately to Licensed Products that [***]. For example, if Net Sales for a particular Licensed Product [***] during [***],
and Net Sales for a Licensed [***], then the Net Sales for such respective Licensed Products during [***] for purposes of the royalty tiers set forth in the table above. 

With respect to each Licensed Product in each country or other jurisdiction in the Territory, from and after the expiration of the Royalty Term for such
Licensed Product in such country or other jurisdiction, Net Sales of such Licensed Product in such country or other jurisdiction shall be excluded for purposes of calculating the aggregate Net Sales amounts and applicable royalty rates set forth in
this Section 7.6.1. 
 7.6.2 Royalty Term. AbbVie shall have no obligation to pay any royalty with
respect to Net Sales of any Licensed Product in any country or other jurisdiction after the Royalty Term for such Licensed Product in such country or other jurisdiction has expired. 

7.6.3 Reductions. Notwithstanding the foregoing: 

(a) in the event that in any country or other jurisdiction in the Territory during the Royalty Term for a Licensed Product there is
Biosimilar Competition in such country or other jurisdiction, then for each such country or other jurisdiction, the royalties payable to Licensor for the Net Sales of such Licensed Product in such country or other jurisdiction shall be reduced by
[***] of the applicable royalty rate(s) set forth in Section 7.6.1. For purposes herein, “Biosimilar Competition” means, on a country or other jurisdiction and Licensed Product basis, [***] of such Licensed
Product sold in that country or other jurisdiction by AbbVie, its Affiliates and Sublicensees. Unless otherwise agreed by the Parties, the [***] shall be as [***] or any other [***] by the Parties; 

  
 - 33 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 (b) AbbVie shall be entitled to deduct from [***] payable hereunder with respect to a
Licensed Product for a particular country or other jurisdiction [***] of all [***] paid under AbbVie In-License Agreements with respect to such Licensed Product for such country or other jurisdiction; provided
that in no case shall such deduction reduce such [***] set forth in Section [***], as applicable, [***]; 
 (c) [***] in a country
or other jurisdiction in the Territory, then, for the purposes of calculating the royalties payable with respect to such Licensed Product under Section 7.6.1 [***]; and 

(d) in the event that, and in such case from and after the date on which, a Licensed Product is Exploited in a country or other jurisdiction
and is not covered by a Valid Claim of [***] Patent that covers (i) [***] in such country or other jurisdiction or (ii) [***] such Licensed Product [***] in such country or other jurisdiction (provided that (A) [***], or (B) [***], when [***]), the
royalty rate set forth in Section 7.6.1 with respect to such country or other jurisdiction (for purposes of calculations under Section 7.6.1), shall be reduced by [***]. 

7.7 Royalty Payments and Reports. AbbVie shall calculate all amounts payable to Licensor pursuant to
Section 7.6 at the end of each Calendar Quarter, which amounts shall be converted to Dollars, in accordance with Section 7.8. AbbVie shall pay to Licensor the royalty amounts due with respect to a
given Calendar Quarter within [***] after the end of such Calendar Quarter. Each payment of royalties due to Licensor shall be accompanied by a statement of the amount of Net Sales of each Licensed Product in each country or other jurisdiction the
Territory during the applicable Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars) and a calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter. 

7.8 Mode of Payment; Offsets. All payments to either Party under this Agreement shall be made by deposit of
Dollars in the requisite amount to such bank account as the receiving Party may from time to time designate by notice to the paying Party. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement
(including the calculation of Net Sales expressed in currencies other than Dollars), a Party shall convert any amount expressed in a foreign currency into Dollar equivalents using its, its Affiliate’s or Sublicensee’s standard conversion
methodology consistent with Accounting Standards. [***]. 
 7.9 Withholding Taxes. 

7.9.1 Withholding Amounts. Where any sum due to be paid to either Party hereunder is subject to any withholding or similar tax,
the Parties shall use their commercially reasonable efforts to do all such acts and things and to sign all such documents as will enable them to take advantage of any applicable double taxation agreement or treaty. In the

  
 - 34 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
event there is no applicable double taxation agreement or treaty, or if an applicable double taxation agreement or treaty reduces but does not eliminate such withholding or similar tax, the payor
shall remit such withholding or similar tax to the appropriate government authority, deduct the amount paid from the amount due to payee and secure and send to payee the best available evidence of the payment of such withholding or similar tax. Any
such amounts deducted by the payor in respect of such withholding or similar tax shall be treated as having been paid by the payor for purposes of this Agreement. In the event that a government authority retroactively determines that a payment made
by a Party to the other pursuant to this Agreement should have been subject to withholding or similar (or to additional withholding or similar) taxes, and such Party (the “Withholding Party”) remits such withholding or similar taxes
to the government authority, including any interest and penalties that may be imposed thereon (together with the tax paid, the “Withholding Amount”), the Withholding Party will have the right (a) to offset the Withholding
Amount against future payment obligations of the Withholding Party under this Agreement or (b) to invoice the other Party for the Withholding Amount (which shall be payable by the other Party within [***] of its receipt of such invoice). 

7.9.2 Withholding in Case of Assignment. Notwithstanding the foregoing, if AbbVie redomiciles, or if its assignee pursuant to
Section 14.4 is domiciled at the time of such assignment, or subsequently redomiciles to a jurisdiction outside Bermuda, and if as a result of such action, AbbVie (or its assignee pursuant to
Section 14.4) is required by Applicable Law to withhold taxes in respect of any amount payable under this Agreement, and such withholding taxes exceed the amount of withholding taxes that would have been applicable if such
action had not occurred, then any such amount payable shall be increased to take into account such increased withholding taxes as may be necessary so that, after making all required withholdings Licensor (or its assignee pursuant to
Section 14.4) receives an amount equal to the sum it would have received had no such increase in withholding been made; provided, however, that AbbVie will have no obligation to pay any additional amount under the
immediately preceding clause (a) to the extent [***], (b) if Licensor [***] or (c) if such increased withholding tax would not have been imposed but for [***] under this Agreement, the [***] or (ii) the [***]. Licensor shall use its
commercially reasonable efforts to obtain a refund or exemption of such withheld amounts or offset such withheld amounts against other tax liabilities to the extent practicable under Applicable Law. 

7.10 Indirect Taxes. All payments due under this Agreement are exclusive of value added taxes, sales taxes,
consumption taxes and other similar taxes (the “Indirect Taxes”). If any Indirect Taxes are chargeable in respect of any payments, the paying Party shall pay such Indirect Taxes at the applicable rate in respect of such payments
following receipt, where applicable, of an Indirect Taxes invoice in the appropriate form issued by the receiving Party in respect of those payments. The Parties shall issue invoices for all amounts payable under this Agreement consistent with
Indirect Tax requirements and irrespective of whether the sums may be netted for settlement purposes. If the Indirect Taxes originally paid or otherwise borne by the paying Party are in whole or in part subsequently determined not to have been
chargeable, all reasonably necessary steps will be taken by the receiving Party to receive a refund of these undue Indirect Taxes from the applicable governmental authority or other fiscal authority and any amount of undue Indirect Taxes repaid by
such authority to the receiving Party will be transferred to the paying Party within [***] of receipt. 

  
 - 35 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 7.11 Interest on Late Payments. If any payment due to either
Party under this Agreement is not paid when due, then such paying Party shall pay interest thereon (before and after any judgment) at [***], such interest to run from the date on which payment of such sum became due until payment thereof in full
together with such interest. 
 7.12 Audit. AbbVie shall, shall cause its Affiliates to, and shall use
commercially reasonable efforts to cause its Sublicensees to keep complete and accurate books and records pertaining to Net Sales of Licensed Products in sufficient detail to calculate all amounts payable hereunder. At the request of Licensor,
AbbVie shall permit an independent public accounting firm of nationally recognized standing designated by Licensor and reasonably acceptable to AbbVie, at reasonable times during normal business hours and upon reasonable notice, to audit the books
and records maintained pursuant to this Section 7.12 to ensure the accuracy of all reports and payments made hereunder. Such examinations may not (a) be conducted for any Calendar Quarter [***], (b) be conducted more
than once in any [***] period or (c) be [***]. The accounting firm shall disclose to Licensor only whether the reports are correct or not, and the specific details concerning any discrepancies. No other information shall be shared. Except as
provided below, the cost of this audit shall be borne by Licensor, unless the audit reveals a variance of [***] from the reported amounts or [***], in which case AbbVie shall bear the cost of the audit. 

7.13 Audit Dispute. In the event of a dispute with respect to any audit under
Section 7.12, Licensor and AbbVie shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***], the dispute shall be submitted
for resolution to a certified public accounting firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Audit Arbitrator”). The decision of the Audit
Arbitrator shall be final and the costs of such arbitration as well as the initial audit shall be borne between the Parties in such manner as the Audit Arbitrator shall determine. Not later than [***] after such decision and in accordance with such
decision, AbbVie shall pay the additional amounts or Licensor shall reimburse the excess payments, as applicable. 

7.14 Confidentiality. The receiving Party shall treat all information subject to review under this ARTICLE
7 in accordance with the confidentiality provisions of ARTICLE 10 and the Parties shall cause the Audit Arbitrator to enter into a reasonably acceptable confidentiality agreement with AbbVie obligating such firm to retain all such
financial information in confidence pursuant to such confidentiality agreement. 

  
 - 36 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 7.15 [***]. The development milestone payments, regulatory milestone
payments, commercialization milestone payments, sales-based milestone payments and royalties in Sections 7.2, 7.3, 7.4, 7.5 and 7.6 shall not apply to Development and Commercialization of Discovery T-Cell Receptor Constructs or Licensed Products [***] a Discovery T-Cell Receptor Construct or Licensed Product or [***] a Discovery
T-Cell Receptor Construct or Licensed Product. In the event that a Discovery T-Cell Receptor Construct or Licensed Product is Developed for any such purposes, [***] for
the sale of such Licensed Product that [***] such Licensed Product and [***], as applicable, provided that, for clarity, any such [***] under this Agreement with respect to Discovery T-Cell Receptor Constructs
or Licensed Products that are [***]. 
 7.16 No Other Compensation. Each Party hereby agrees that the terms of
this Agreement fully define all consideration, compensation and benefits, monetary or otherwise, to be paid, granted or delivered by one (1) Party to the other Party in connection with the transactions contemplated herein. Neither Party
previously has paid or entered into any other commitment to pay, whether orally or in writing, any of the other Party’s employees, directly or indirectly, any consideration, compensation or benefits, monetary or otherwise, in connection with
the transaction contemplated herein. 
 ARTICLE 8 

INTELLECTUAL PROPERTY 

8.1 Ownership of Intellectual Property. 

8.1.1 Licensor Ownership. As between the Parties, Licensor shall own all right, title and interest in and to any and all
Licensor Background Patents, Licensor Background Know-How, Licensor Program Patents and Licensor Program Know-How. 

8.1.2 AbbVie Ownership. As between the Parties, AbbVie or an Affiliate designated by AbbVie shall own and retain all right,
title, and interest in and to any and all AbbVie Background Patents, AbbVie Background Know-How, AbbVie Program Patents, AbbVie Program Know-How, Product-Specific Know-How and Product-Specific Patents. 
 8.1.3 Ownership of Joint Program Patents and Joint
Program Know-How. Subject to Section 4.7.1(b), as between the Parties, each Party shall own an equal, undivided interest in any and all Joint Program Patents and Joint Program Know-How. Subject to the licenses and rights of reference granted under Sections 6.1 and 6.2 and Licensor’s exclusivity obligations hereunder, each Party shall have the right to Exploit the Joint
Intellectual Property Rights without a duty of seeking consent from or accounting to the other Party. 
 8.1.4 United States
Law. The determination of whether Information and inventions are conceived, discovered, developed, or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights)
therein, shall, for purposes of this Agreement, be made in accordance with Applicable Law in the United States. 

  
 - 37 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 8.1.5 Assignment Obligation. 

(a) Each Party shall cause all Persons who perform activities for such Party under this Agreement to be under an obligation to assign (or, if
such Party is unable to cause such Person to agree to such assignment obligation despite such Party’s using commercially reasonable efforts to negotiate such assignment obligation, provide a license under) their rights in any Information and
inventions resulting therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental, not-for-profit and public
institutions which have standard policies against such an assignment (in which case a suitable license, or right to obtain such a license, shall be obtained). 

(b) AbbVie will promptly disclose to Licensor in writing, the conception, discovery, development or making of any Licensor Program Know-How, Licensor Program Patents, Product-Specific Know-How and Product-Specific Patents by Persons who perform activities for AbbVie under this Agreement. AbbVie, for
itself and on behalf of its Affiliates, hereby assigns (and to the extent such assignment can only be made in the future hereby agrees to assign), to Licensor all its right, title and interest in and to any Licensor Program Know-How and Licensor Program Patents. AbbVie will execute and record assignments and other necessary documents consistent with such ownership promptly upon request. 

(c) Licensor will promptly disclose to AbbVie in writing, the conception, discovery, development or making of any AbbVie Program Know-How, AbbVie Program Patents, Product-Specific Know-How and Product-Specific Patents by Persons who perform activities for Licensor under this Agreement. Licensor, for
itself and on behalf of its Affiliates, hereby assigns (and to the extent such assignment can only be made in the future hereby agrees to assign), to AbbVie all its right, title and interest in and to any AbbVie Program Know-How, AbbVie Program Patents, Product-Specific Know-How and Product-Specific Patents. Licensor will execute and record assignments and other necessary documents consistent
with such ownership promptly upon request. 
 (d) Each Party will promptly disclose to the other Party in writing, the conception,
discovery, development or making of any Joint Program Know-How or Joint Program Patents by Persons who perform activities for it under this Agreement. Each Party will execute and record assignments and other
necessary documents consistent with such ownership promptly upon request. 
 8.2 Maintenance and Prosecution of
Patents. 
 8.2.1 Patent Prosecution and Maintenance of Licensor Background Patents. Licensor shall have the sole right,
but not the obligation, through the use of internal or outside counsel, to prepare, file, prosecute, and maintain the Licensor Background Patents worldwide, at Licensor’s sole cost and expense. Licensor shall keep AbbVie informed regarding each
Licensor Background Patent relating to use of the Licensor Platform incorporating a T-Cell Receptor that Licensor is prosecuting, and shall provide copies to AbbVie of all material communications sent to such
patent offices by or on behalf of Licensor. 

  
 - 38 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 8.2.2 Patent Prosecution and Maintenance of Licensor Program Patents. In
consultation with AbbVie, Licensor shall have the right, but not the obligation, through the use of internal or outside counsel reasonably acceptable to AbbVie, to prepare, file, prosecute, and maintain the Licensor Program Patents worldwide, at
Licensor’s sole cost and expense. Licensor shall [***] with regard to the preparation, filing, prosecution, and maintenance of Licensor Program Patents, including by providing AbbVie with a copy of material communications to and from any patent
authority in the Territory regarding such Licensor Program Patents, and by providing AbbVie drafts of any material filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings or
responses so as to allow for a reasonable opportunity for AbbVie to review and comment thereon. Licensor shall consider in good faith the requests and suggestions of AbbVie with respect to such Licensor drafts and with respect to strategies for
filing and prosecuting the Licensor Program Patents in the Territory. Notwithstanding the foregoing, Licensor shall promptly inform AbbVie of any adversarial patent office proceeding or sua sponte filing, including a request for, or filing of
or declaration of, any interference, opposition, Third Party observation, derivation proceeding, post grant review, supplementary examination, reissue or inter parte or ex parte reexamination relating to a Licensor Program Patent in the Territory.
The Parties shall thereafter consult and cooperate to determine a course of action with respect to any such proceeding in the Territory and Licensor shall consider in good faith all comments, requests and suggestions provided by AbbVie. [***] 

8.2.3 Patent Prosecution and Maintenance of AbbVie Background Patents, AbbVie Program Patents and Joint Program Patents. AbbVie
shall have the right, but not the obligation, to prepare, file, prosecute, and maintain the AbbVie Background Patents and AbbVie Program Patents worldwide, at AbbVie’s sole cost and expense. AbbVie shall have the first right, but not the
obligation, to prepare, file, prosecute, and maintain the Joint Program Patents worldwide, at AbbVie’s sole cost and expense. AbbVie shall keep Licensor fully informed of all material steps with regard to the preparation, filing, prosecution,
and maintenance of AbbVie Program Patents and Joint Program Patents, including by providing Licensor with a copy of material communications to and from any patent authority in the Territory regarding such AbbVie Program Patents and Joint Program
Patents, and by providing Licensor drafts of any material filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for
Licensor to review and comment thereon. AbbVie shall consider in good faith the requests and suggestions of Licensor with respect to such AbbVie drafts and with respect to strategies for filing and prosecuting the AbbVie Program Patents and Joint
Program Patents in the Territory. In the event that AbbVie decides not to prepare, file, prosecute, or maintain a Joint Program Patent in a country or other jurisdiction in the Territory, AbbVie shall provide reasonable prior written notice to
Licensor of such intention (which notice shall, in any event, be given no later than [***] prior to the next deadline for any action that may be taken with respect to such Joint Program Patent in such country or other jurisdiction), and Licensor
shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of such Joint Program Patent at its sole cost and expense in such country or other jurisdiction.
Upon Licensor’s written acceptance of such option, Licensor shall assume the responsibility and control for the preparation, filing, prosecution, and maintenance of such specific Joint Program Patent. In such event, AbbVie shall reasonably
cooperate with Licensor in such country or other jurisdiction as provided under Section 8.2.5. 

  
 - 39 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 8.2.4 Patent Prosecution and Maintenance of Product-Specific Patents. AbbVie
shall have the first right, but not the obligation, to prepare, file, prosecute, and maintain the Product-Specific Patents worldwide, at AbbVie’s sole cost and expense. AbbVie shall keep Licensor fully informed of all material steps with regard
to the preparation, filing, prosecution, and maintenance of Product-Specific Patents, including by providing Licensor with a copy of material communications to and from any patent authority in the Territory regarding such Product-Specific Patents,
and by providing Licensor drafts of any material filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for Licensor to
review and comment thereon, which in any event shall be at least [***] prior to any such submission. AbbVie shall consider in good faith the requests and suggestions of Licensor with respect to such AbbVie drafts and with respect to strategies for
filing and prosecuting the Product-Specific Patents in the Territory. In the event that AbbVie decides not to prepare, file, prosecute, or maintain a Product-Specific Patent in a country or other jurisdiction in the Territory, AbbVie shall provide
reasonable prior written notice to Licensor of such intention (which notice shall, in any event, be given no later than [***] prior to the next deadline for any action that may be taken with respect to such Product-Specific Patent in such country or
other jurisdiction), and Licensor shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of such Product-Specific Patent at its sole cost and expense in
such country or other jurisdiction. Upon Licensor’s written acceptance of such option, Licensor shall assume the responsibility and control for the preparation, filing, prosecution, and maintenance of such specific Product-Specific Patent. In
such event, AbbVie shall reasonably cooperate with Licensor in such country or other jurisdiction as provided under Section 8.2.5. Notwithstanding anything to the contrary in this Agreement, each Party agrees that [***].
Subject to Section 13.6.2, if this Agreement is terminated (in its entirety or otherwise), with respect to an Accepted Target, the applicable Product-Specific Patents claiming Discovery
T-Cell Receptor Constructs or Licensed Products directed to such Accepted Target shall be [***]. 

8.2.5 Cooperation. The Parties agree to cooperate fully in the preparation, filing, prosecution, and maintenance of the
Licensor Program Patents, AbbVie Program Patents, Product-Specific Patents and Joint Program Patents in the Territory under this Agreement. Cooperation shall include: 

(a) without limiting any other rights and obligations of the Parties under this Agreement, cooperating with respect to the timing, scope and
filing of such Patents to preserve and enhance the patent protection for Discovery T-Cell Receptor Constructs and Licensed Products, including the manufacture and use thereof. 

(b) executing all papers and instruments, or requiring its employees or contractors to execute such papers and instruments, so as to
(i) effectuate the ownership of intellectual property set forth in Section 8.1.1, 8.1.2 and 8.1.3; (ii) enable the other Party to apply for and to prosecute Patent applications in the Territory; and
(iii) obtain and maintain any Patent extensions, supplementary protection certificates, and the like with respect to the Licensor Program Patents, AbbVie Program Patents, Product-Specific Patents and Joint Program Patents in the Territory, in
each case ((i), (ii), and (iii)) to the extent provided for in this Agreement; 

  
 - 40 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 (c) consistent with this Agreement, assisting in any license registration processes with
applicable governmental authorities that may be available in the Territory for the protection of a Party’s interests in this Agreement; and 

(d) promptly informing the other Party of any matters coming to such Party’s attention that may materially affect the preparation,
filing, prosecution, or maintenance of any such Patents in the Territory. 
 8.2.6 Patent Term Extension and Supplementary
Protection Certificate. AbbVie shall be responsible for making decisions regarding patent term extensions, including supplementary protection certificates and any other extensions that are now or become available in the future, wherever
applicable, for AbbVie Background Patents, AbbVie Program Patents, Product-Specific Patents and Joint Program Patents in any country or other jurisdiction and for applying for any extension or supplementary protection certificate with respect to
such Patents in the Territory. Licensor shall provide prompt and reasonable assistance, as requested by AbbVie, including by taking such action as patent holder as is required under any Applicable Law to obtain such patent extension or supplementary
protection certificate. AbbVie shall pay all expenses in regard to obtaining the extension or supplementary protection certificate in the Territory. In case that AbbVie determines that patent term extension should be applied for a Licensor Program
Patent or a Licensor Background Patent, Licensor and AbbVie should discuss in good faith with respect to such patent term extension. 

8.2.7 European Patents. AbbVie shall have the sole right to decide whether a European Patent within Joint Program Patents
should be validated or maintained as a Unitary Patent, whether and when such European Patent should be opted out of or opted in to the jurisdiction of the Unified Patent Court (UPC) (including withdrawal of an
opt-out), as well as any other issues concerning the jurisdiction of the UPC in connection with Joint Program Patents. Licensor shall, at AbbVie’s cost and expense, cooperate with AbbVie and provide to
AbbVie and submit to authorities all necessary documents to effect such decision. 
 8.2.8 Patent Listings. AbbVie will have
the sole right to make all filings with Regulatory Authorities in the Territory with respect to AbbVie Background Patents, AbbVie Program Patents, Product-Specific Patents and Joint Program Patents, including as required or allowed under Applicable
Law, provided that with respect to Joint Program Patents, such right shall be solely with respect to Licensed Products. AbbVie shall notify Licensor in writing of any Licensor Background Patents or Licensor Program Patents that it intends to list
with Regulatory Authorities related to the Licensed Products and, prior to filing any such listing, consult with and consider in good faith the requests and suggestions of Licensor regarding the same. 

  
 - 41 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 8.3 Enforcement of Patents. 

8.3.1 Enforcement of Licensor Background Patents and Licensor Program Patents. 

(a) Each Party shall promptly notify the other Party in writing of any alleged or threatened infringement of the Licensor Background Patents
or Licensor Program Patents by a Third Party in the Territory of which such Party becomes aware based on the development, commercialization, or an application to market a product containing a Discovery T-Cell
Receptor Construct or any Licensed Product in the Territory (the “Product Infringement”). 
 (b) Licensor shall have the
sole right, but not the obligation, to prosecute any Product Infringement involving any claims of Licensor Background Patents and Licensor Program Patents at its sole expense and Licensor shall retain control of the prosecution of such claim, suit
or proceeding. 
 8.3.2 Enforcement of AbbVie Background Patents, AbbVie Program Patents, Product-Specific Patents and Joint Program
Patents. 
 (a) Each Party shall promptly notify the other Party in writing of any alleged or threatened infringement of the AbbVie
Background Patents, AbbVie Program Patents, Product-Specific Patents or Joint Program Patents by a Third Party in the Territory of which such Party becomes aware (including alleged or threatened infringement based on the development,
commercialization, or an application to market a product containing a Discovery T-Cell Receptor Construct or any Licensed Product in the Territory). 

(b) AbbVie shall have the sole right, but not the obligation, to prosecute any such infringement of AbbVie Background Patents, AbbVie Program
Patents and Product-Specific Patents in the Territory at its sole expense and AbbVie shall retain control of the prosecution of such claim, suit or proceeding. 

(c) AbbVie shall have the first right, but not the obligation, to prosecute any such infringement of Joint Program Patents in the Territory
at its sole expense and AbbVie shall retain control of the prosecution of such claim, suit or proceeding. In the event AbbVie prosecutes any such infringement, Licensor shall have the right to join as a party to such claim, suit or proceeding in the
Territory and participate with its own counsel at its own expense; provided that AbbVie shall retain control of the prosecution of such claim, suit or proceeding. If AbbVie does not take commercially reasonable steps to prosecute the alleged or
threatened infringement in the Territory with respect to such Joint Program Patents (i) within [***] following the first notice provided above with respect to such alleged infringement, or (ii) provided such date occurs after the first
such notice of infringement is provided, [***] before the time limit, if any, set forth in appropriate laws and regulations for filing of such actions, whichever comes first, then Licensor may prosecute the alleged or threatened infringement in the
Territory at its own expense. 

  
 - 42 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 8.3.3 Patent Exclusivity Listings. If either Party receives a copy of an
application submitted to the FDA under subsection (k) of Section 351 of the PHSA (a “Biosimilar Application”) naming a Licensed Product as a reference product or otherwise becomes aware that such a Biosimilar Application
has been filed (such as in an instance described in Section 351(l)(9)(C) of the PHSA), such Party shall, within [***], notify the other Party so that the other Party may seek permission to view the application and related confidential
information from the filer of the Biosimilar Application under Section 351(l)(1)(B)(iii) of the PHSA. If either Party receives any equivalent or similar certification or notice in any other jurisdiction in the Territory, either Party shall,
within [***], notify and provide the other Party with copies of such communication. Regardless of the Party that is the “reference product sponsor” for purposes of such Biosimilar Application, (a) [***]; (b) AbbVie shall have the right to
list any AbbVie Background Patents, AbbVie Program Patents, Product-Specific Patents, Joint Program Patents, and, upon the written consent of Licensor, such consent not to be unreasonably withheld, conditioned or delayed (taking into account,
without limitation, the potential impact of such consent on other products undergoing development or commercialization by Licensor or its Third Party licensees and covered by such Licensor Program Patents), Licensor Program Patents, and upon the
written consent of Licensor, Licensor Background Patents, insofar as they cover the applicable Licensed Product as required pursuant to Section 351(l)(3)(A), Section 351(l)(5)(b)(i)(II), or Section 351(l)(7) of the PHSA, to respond to
any communications with respect to such lists from the filer of the Biosimilar Application, and to negotiate with the filer of the Biosimilar Application as to whether to utilize a different mechanism for information exchange than that specified in
Section 351(l) of the PHSA; and (c) [***] shall have the sole right to identify such Patents or respond to communications under any equivalent or similar listing in any other jurisdiction in the Territory. If required pursuant to Applicable
Law, [***] shall prepare such lists and make such responses [***]. If Licensor has provided written consent as contemplated by this Section 8.3.3, Licensor shall cooperate with AbbVie’s reasonable requests in
connection therewith, including meeting any submission deadlines, in each case, to the extent required or permitted by Applicable Law. AbbVie shall (A) reasonably consult with Licensor prior to [***] to a Third Party as contemplated by this
Section 8.3.3 and shall consider in good faith Licensor’s advice, requests and suggestions with respect thereto, and (B) notify Licensor of any such lists or communications promptly after they are made. 

8.3.4 Conduct of Patent Litigation Under the Biologics Price Competition and Innovation Act. Notwithstanding anything to the
contrary in this Section 8.3, AbbVie shall have the first right to bring an action for infringement of the AbbVie Background Patents, AbbVie Program Patents, Product-Specific Patents, Joint Program Patents and, upon the
written consent of Licensor, such consent not to be unreasonably withheld, conditioned or delayed (taking into account, without limitation, the potential impact of such consent on other products undergoing development or commercialization by
Licensor or its Third Party licensees and covered by such Licensor Program Patents), Licensor Program Patents, and upon the written consent of Licensor, Licensor Background Patents, as required under Section 351(l)(6) of the PHSA following the
agreement on a list of patents for litigation under Section 351(l)(4) or exchange of Patent lists pursuant to Section 351(l)(5)(B) of such act, or as required following any equivalent or similar certification or notice in any other
jurisdiction. The Parties’ rights and obligations with respect to the foregoing legal actions shall be as set forth in Sections 8.3.1 through 8.3.5; provided, that within [***] of reaching agreement on a list of Patents for
litigation under Section 351(l)(4) or exchange of Patent lists pursuant to Section 351(l)(5)(B), AbbVie 

  
 - 43 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
shall notify Licensor as to whether or not it elects to prosecute such infringement. Either Party shall, within [***], notify and provide the other Party with copies of any notice of commercial
marketing provided by the filer of a Biosimilar Application pursuant to Section 351(l)(8)(A) of the PHSA, or any equivalent or similar certification or notice in any other jurisdiction. Thereafter, the Party controlling any Patent infringement
litigation pursuant to this Section 8.3.4 shall have the first right to seek an injunction against such commercial marketing as permitted pursuant to Section 351(l)(8)(B) of the PHSA. If no such litigation is ongoing
at the time of such notice, then [***] shall have the first right to seek such an injunction. 
 8.3.5 Cooperation. The
Parties agree to cooperate fully in any infringement action pursuant to this Section 8.3. Where a Party brings such an action, the other Party shall, where necessary, furnish a power of attorney solely for such purpose or
shall join in, or be named as a necessary party to, such action. Unless otherwise set forth herein, the Party entitled to bring any patent infringement litigation in accordance with this Section 8.3 shall have the right to
settle such claim; provided that neither Party shall have the right to settle any patent infringement litigation under this Section 8.3 in a manner that materially diminishes or has a material adverse effect on the rights
or interest of the other Party, or in a manner that imposes any costs or liability on, or involves any admission by, the other Party, without the express written consent of such other Party. The Party commencing the litigation shall provide the
other Party with copies of all pleadings and other documents filed with the court and shall consider reasonable input from the other Party during the course of the proceedings. 

8.3.6 Recovery. Any recovery realized as a result of such litigation described in Sections 8.3.1, 8.3.2, or
8.3.4 (whether by way of settlement or otherwise) shall be first allocated to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such
expenses). [***]. 
 8.4 Infringement Claims by Third Parties. If the manufacture, sale, or use of a Discovery
T-Cell Receptor Construct or Licensed Product in the Territory pursuant to this Agreement results in, or may result in, any claim, suit, or proceeding by a Third Party alleging patent infringement by AbbVie
(or its Affiliates or Sublicensees), AbbVie shall promptly notify Licensor thereof in writing. AbbVie shall have the first right, but not the obligation, to defend and control the defense of any such claim, suit, or proceeding at its own expense,
using counsel of its own choice. Licensor may participate in any such claim, suit, or proceeding with counsel of its choice at its own expense. Without limitation of the foregoing, if AbbVie finds it necessary or desirable to join Licensor as a
party to any such action, Licensor shall, at AbbVie’s expense, execute all papers and perform such acts as shall be reasonably required. If AbbVie elects (in a written communication submitted to Licensor within a reasonable amount of time after
notice of the alleged patent infringement) not to defend or control the defense of, or otherwise fails to initiate and maintain the defense of, any such claim, suit, or proceeding, within such time periods so that Licensor is not prejudiced by any
delays, Licensor may conduct and control the defense of any such claim, suit, or proceeding at its own expense. Each Party shall keep the other Party reasonably informed of all material developments in connection with any such claim, suit, or
proceeding. [***] under this Section 8.4 shall be [***] 

  
 - 44 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 8.5 Invalidity or Unenforceability Defenses or Actions. 

8.5.1 Notice. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity
or unenforceability of any of the Licensor Background Patents, Licensor Program Patents, AbbVie Background Patents, AbbVie Program Patents, Product-Specific Patents or Joint Program Patents by a Third Party, in each case in the Territory and of
which such Party becomes aware. 
 8.5.2 Licensor Background Patents. Licensor shall have the sole right, but not the
obligation, to defend and control the defense of the validity and enforceability of the Licensor Background Patents at its own expense in the Territory. 

8.5.3 Licensor Program Patents. Licensor shall have the first right, but not the obligation, to defend and control the defense
of the validity and enforceability of the Licensor Program Patents at its own expense in the Territory. AbbVie may participate in any such claim, suit, or proceeding in the Territory with counsel of its choice at its own expense; provided that
Licensor shall retain control of the defense in such claim, suit, or proceeding. If Licensor elects not to defend or control the defense of such Licensor Program Patents in a suit brought in the Territory, or otherwise fails to initiate and maintain
the defense of any such claim, suit, or proceeding, then AbbVie may conduct and control the defense of any such claim, suit, or proceeding at its own expense; provided, that AbbVie shall obtain the written consent of Licensor prior to settling or
compromising such defense. 
 8.5.4 AbbVie Background Patents, AbbVie Program Patents, Product-Specific Patents and Joint Program
Patents. 
 (a) AbbVie shall have the sole right, but not the obligation, to defend and control the defense of the validity and
enforceability of the AbbVie Background Patents, AbbVie Program Patents and Product-Specific Patents at its own expense in the Territory. 

(b) AbbVie shall have the first right, but not the obligation, to defend and control the defense of the validity and enforceability of the
Joint Program Patents at its own expense in the Territory. Licensor may participate in any such claim, suit, or proceeding in the Territory related to the Joint Program Patents with counsel of its choice at its own expense; provided that AbbVie
shall retain control of the defense in such claim, suit, or proceeding. If AbbVie elects not to defend or control the defense of the Joint Program Patents in a suit brought in the Territory, or otherwise fails to initiate and maintain the defense of
any such claim, suit, or proceeding, then Licensor may conduct and control the defense of any such claim, suit, or proceeding, at its own expense; provided, that Licensor shall obtain the written consent of AbbVie prior to settling or compromising
such defense. 

  
 - 45 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 8.5.5 Cooperation. Each Party shall assist and cooperate with the other Party
as such other Party may reasonably request from time to time in connection with its activities set forth in this Section 8.5, including by being joined as a party plaintiff in such action or proceeding, providing access to
relevant documents and other evidence, and making its employees available at reasonable business hours. In connection with any such defense or claim or counterclaim, the controlling Party shall consider in good faith any comments from the other
Party and shall keep the other Party reasonably informed of any steps taken, and shall provide copies of all documents filed, in connection with such defense, claim, or counterclaim. In connection with the activities set forth in this
Section 8.5, each Party shall consult with the other as to the strategy for the defense of the Licensor Program Patents, AbbVie Program Patents, Product-Specific Patents and Joint Program Patents. 

8.6 Third Party Licenses. If [***], the Development, Manufacture, or Commercialization of any Discovery T-Cell Receptor Construct or Licensed Product by AbbVie, any of its Affiliates, or any of its or their Sublicensees infringes or misappropriates any [***] of a Third Party in any country or other jurisdiction in the
Territory, such that AbbVie, any of its Affiliates or any of its or their Sublicensees cannot Develop, Manufacture, or Commercialize such Discovery T-Cell Receptor Construct or Licensed Product in such country
or other jurisdiction without infringing such [***] of such Third Party, then [***] and [***] shall promptly provide [***] with written notice of any such license, including the identity of the counter-party and a description of the [***]. 

8.7 Product Trademarks. As between the Parties, AbbVie shall own all right, title, and interest to the Product
Trademarks in the Territory, and shall be responsible for the registration, prosecution, maintenance and enforcement thereof. All costs and expenses of registering, prosecuting, maintaining and enforcing the Product Trademarks shall be borne solely
by AbbVie. Licensor shall provide all assistance and documents reasonably requested by AbbVie in support of its prosecution, registration, maintenance and enforcement of the Product Trademarks. 

8.8 Inventor’s Remuneration. Each Party shall be solely responsible for any remuneration that
may be due such Party’s inventors under any applicable inventor remuneration laws. 
 8.9 Common
Interest. All information exchanged between the Parties regarding the prosecution, maintenance, enforcement and defense of Patents under this ARTICLE 8 will be deemed to be Confidential Information of the disclosing Party. In addition,
the Parties acknowledge and agree that, with regard to such prosecution, maintenance, enforcement and defense, the interests of the Parties as collaborators and licensor and licensee are to, for their mutual benefit, obtain patent protection and
plan patent defense against potential infringement activities by Third Parties, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any
legal privilege concerning Patents under this ARTICLE 8, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary in this Agreement, to the extent a Party has a good
faith belief that any 

  
 - 46 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
information required to be disclosed by such Party to the other Party under this ARTICLE 8 is protected by attorney-client privilege or any other applicable legal privilege or immunity,
such Party shall not be required to disclose such information and the Parties shall in good faith cooperate to agree upon a procedure (which may include entering into a specific common interest agreement, disclosing such information on a “for
counsel eyes only” basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity. 

ARTICLE 9 

PHARMACOVIGILANCE AND SAFETY 

9.1 Pharmacovigilance. On an Accepted
Target-by-Accepted Target basis, no later than [***] for a Discovery T-Cell Receptor Construct or Licensed Product, the Parties
shall enter into an agreement to initiate a process for the exchange of safety data (including post-marketing spontaneous reports received by each Party and its Affiliates) in a mutually agreed format in order to monitor the safety of the Discovery T-Cell Receptor Constructs or Licensed Products and to meet reporting requirements with any applicable Regulatory Authority. 

9.2 Global Safety Database. On an Accepted
Target-by-Accepted Target basis, no later than [***] for a Discovery T-Cell Receptor Construct or Licensed Product, AbbVie shall
set up, hold, and maintain (at AbbVie’s sole cost and expense) the global safety database for Discovery T-Cell Receptor Constructs or Licensed Products. Licensor shall provide AbbVie with all information
necessary or desirable for AbbVie to comply with its pharmacovigilance responsibilities in the Territory, including, as applicable, any adverse drug experiences, from pre-clinical or clinical laboratory,
animal toxicology and pharmacology studies, Clinical Studies, and commercial experiences with a Discovery T-Cell Receptor Construct or Licensed Product, in each case in any form agreed upon between AbbVie and
Licensor at the time of the request. 
 ARTICLE 10 

CONFIDENTIALITY AND NON-DISCLOSURE 

10.1 Product Information. Licensor recognizes that by reason of AbbVie’s status as an exclusive licensee
pursuant to the grants under Section 6.1, AbbVie has an interest in Licensor maintaining the confidentiality of certain information of Licensor. Accordingly, on an Accepted Target-by-Accepted Target basis, from the applicable Target Acceptance Date and for the remainder of the Term, Licensor shall, and shall cause its Affiliates and its and their respective officers, directors,
employees, and agents to, keep confidential, and not publish or otherwise disclose, and not use directly or indirectly for any purpose other than to fulfill Licensor’s obligations hereunder any Information owned or otherwise Controlled by
Licensor or any of its Affiliates specifically relating to any Discovery T-Cell Receptor Construct or Licensed Product, or the Exploitation of any of the foregoing (the “Product Information”);

  
 - 47 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
except to the extent (a) the Product Information is in the public domain through no fault of Licensor, its Affiliates or any of its or their respective officers, directors, employees, or
agents; (b) such disclosure or use is expressly permitted under Section 10.3, or (c) such disclosure or use is otherwise expressly permitted by the terms of this Agreement. For purposes of
Section 10.3, AbbVie shall be deemed to be the disclosing Party with respect to Product Information under Section 10.3 and Licensor shall be deemed to be the receiving Party with respect thereto.
For further clarification, (i) without limiting this Section 10.1, to the extent Product Information is disclosed by Licensor to AbbVie pursuant to this Agreement, such information shall, subject to the other terms and
conditions of this ARTICLE 10, also constitute Confidential Information of Licensor with respect to the use and disclosure of such Information by AbbVie, but (ii) the disclosure by Licensor to AbbVie of Product Information shall not
cause such information to cease to be subject to the provisions of this Section 10.1 with respect to the use and disclosure of such Confidential Information by Licensor. In the event this Agreement is terminated in its
entirety or with respect to the Terminated Territory or Terminated Target, this Section 10.1 shall have no continuing force or effect with respect to the use or disclosure of such information solely in connection with the
Exploitation of the Discovery T-Cell Receptor Construct or Licensed Product for the benefit of the Terminated Territory or Terminated Target, as applicable, but the Product Information, to the extent disclosed
by AbbVie to Licensor hereunder, shall continue to be Confidential Information of AbbVie, subject to the terms of Sections 10.2, 10.3, and 10.6 for purposes of the surviving provisions of this Agreement. 

10.2 Confidentiality Obligations. At all times during the Term and for a period of [***] following termination
or expiration hereof in its entirety, each Party shall, and shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any purpose,
any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement or is reasonably necessary or useful
for the performance of, or the exercise of such Party’s rights under, this Agreement. Notwithstanding the foregoing, to the extent the receiving Party can demonstrate by documentation or other competent proof, the confidentiality and non-use obligations under this Section 10.2 with respect to any Confidential Information shall not include any information that: 

10.2.1 has been published by a Third Party or otherwise is or hereafter becomes part of the public domain by public use, publication,
general knowledge or the like through no wrongful act, fault or negligence on the part of the receiving Party; 
 10.2.2 has been in
the receiving Party’s possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such information; provided that the foregoing exception shall not apply with respect to Regulatory
Documentation (excluding clinical protocols) or Joint Program Know-How; 

  
 - 48 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 10.2.3 is subsequently received by the receiving Party from a Third Party without
restriction and without breach of any agreement between such Third Party and the disclosing Party; 
 10.2.4 is generally made
available to Third Parties by the disclosing Party without restriction on disclosure; 
 10.2.5 has been independently developed by
or for the receiving Party without reference to, or use or disclosure of, the disclosing Party’s Confidential Information; provided that the foregoing exception shall not apply with respect to Regulatory Documentation (excluding clinical
protocols) or Joint Program Know-How; or 
 10.2.6 in the case of [***], has been [***]
concerning such [***]. 
 Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of
the receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the receiving Party. Further, any combination of Confidential Information shall not be considered in
the public domain or in the possession of the receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the receiving Party unless the combination and its principles are in
the public domain or in the possession of the receiving Party. 
 10.3 Permitted Disclosures. Each Party may
disclose Confidential Information to the extent that such disclosure is: 
 10.3.1 in the reasonable opinion of the receiving
Party’s legal counsel, required to be disclosed pursuant to law, regulation or a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial or local governmental body of competent
jurisdiction (including by reason of filing with securities regulators, but subject to Section 10.5); provided, that the receiving Party shall first have given prompt written notice (and to the extent possible, at least
[***] notice) to the disclosing Party and given the disclosing Party a reasonable opportunity to take whatever action it deems necessary to protect its Confidential Information. In the event that no protective order or other remedy is obtained, or
the disclosing Party waives compliance with the terms of this Agreement, the receiving Party shall furnish only that portion of Confidential Information which the receiving Party is advised by counsel is legally required to be disclosed; 

10.3.2 made by or on behalf of the receiving Party to the Regulatory Authorities as required in connection with any filing,
application or request for Regulatory Approval of a Licensed Product in accordance with the terms of this Agreement; provided, that reasonable measures shall be taken to assure confidential treatment of such Confidential Information to the extent
practicable and consistent with Applicable Law; 

  
 - 49 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 10.3.3 made by or on behalf of the receiving Party to a patent authority as may be
reasonably necessary or useful for purposes of obtaining, defending or enforcing a Patent in accordance with the terms of this Agreement; provided, that reasonable measures shall be taken to assure confidential treatment of such Confidential
Information, to the extent such protection is available; 
 10.3.4 made to its or its Affiliates’ financial and legal advisors
who have a need to know such disclosing Party’s Confidential Information and are either under professional codes of conduct giving rise to expectations of confidentiality and non-use or under written
agreements of confidentiality and non-use, in each case, at least as restrictive as those set forth in this Agreement; provided that the receiving Party shall remain responsible for any failure by such
financial and legal advisors, to treat such Confidential Information as required under this Article; 
 10.3.5 made by the receiving
Party or its Affiliates to potential or actual investors or acquirers as may be necessary in connection with their evaluation of such potential or actual investment or acquisition; provided, that such Persons shall be subject to obligations of
confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use of the receiving Party
pursuant to this ARTICLE 10; 
 10.3.6 made by AbbVie or its Affiliates or Sublicensees to its or their advisors,
consultants, clinicians, vendors, service providers, contractors, existing or prospective collaboration partners, licensees, sublicensees, or other Third Parties as may be necessary or useful in connection with the Exploitation of the Discovery T-Cell Receptor Construct, the Licensed Products, or otherwise in connection with the performance of its obligations or exercise of its rights as contemplated by this Agreement; provided, that such Persons shall be
subject to obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and
non-use of AbbVie pursuant to this ARTICLE 10; or 
 10.3.7 made by Licensor or its
Affiliates after receiving advanced approval from AbbVie, to its or their advisors, consultants, clinicians, vendors, service providers, contractors, or other Third Parties as may be necessary or useful in connection with the performance of their
obligations or exercise of their rights as contemplated by this Agreement; provided, that such Persons shall be subject to obligations of confidentiality and non-use with respect to such Confidential
Information of AbbVie substantially similar to the obligations of confidentiality and non-use of Licensor pursuant to this ARTICLE 10; provided, further, that the advanced approval requirement set forth
in this Section 10.3.7 shall not apply to Third Party Providers approved by AbbVie pursuant to Section 4.6. 

10.4 Use of Name. Except as expressly provided herein, neither Party shall mention or otherwise use the name,
logo, or Trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material, or other form of publicity without the prior written approval of such
other Party in each instance. The restrictions imposed by this Section 10.4 shall not prohibit either Party from making any disclosure identifying the other 

  
 - 50 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
Party that, in the opinion of the disclosing Party’s counsel, is required by Applicable Law; provided, that such Party shall submit the proposed disclosure identifying the other Party in
writing to the other Party as far in advance as reasonably practicable (and in no event less than [***] prior to the anticipated date of disclosure) so as to provide a reasonable opportunity to comment thereon. 

10.5 Public Announcements. Neither Party shall issue any public announcement, press release, or other public
disclosure regarding this Agreement or its subject matter without the other Party’s prior written consent, except (i) for a mutually agreed press release to be issued promptly following the Effective Date, or (ii) for any such
disclosure that is, in the opinion of the disclosing Party’s counsel, required by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been
submitted). In the event a Party is, in the opinion of its counsel, required by Applicable Law or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public
disclosure, such Party shall submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable (and in no event less than [***] prior to the anticipated date of disclosure) so as to provide a reasonable
opportunity to comment thereon. Notwithstanding the foregoing, AbbVie, its Sublicensees and its and their respective Affiliates shall have the right to publicly disclose research, development and commercial information (including with respect to
regulatory matters) regarding the Discovery T-Cell Receptor Construct and Licensed Products, provided that any such disclosure does not contain any Confidential Information of Licensor. 

10.6 Publications. The Parties acknowledge that scientific publications must be strictly monitored to prevent
any adverse effect from premature publication of results of the activities contemplated hereunder. Accordingly, Licensor shall not publish, present, or otherwise disclose, and shall cause its Affiliates and Third Party Providers and its and their
employees and agents not to disclose any material related specifically to the Exploitation of the Discovery T-Cell Receptor Constructs or Licensed Products without the prior written consent of AbbVie, except
as required by Applicable Law. 
 10.7 Return of Confidential Information. Upon the effective date of the
termination of this Agreement for any reason, either Party may request in writing, and the other Party shall either, with respect to Confidential Information (in the event of termination of this Agreement with respect to one (1) or more
Terminated Territories or Terminated Targets but not in its entirety, solely to the extent relating specifically and exclusively to such Terminated Territories or Terminated Targets, as applicable) to which such other Party does not retain rights
under the surviving provisions of this Agreement: (a) as soon as reasonably practicable, destroy all copies of such Confidential Information in the possession of the other Party and confirm such destruction in writing to the requesting Party;
or (b) as soon as reasonably practicable, deliver to the requesting Party, at such other Party’s expense, all copies of such Confidential Information in the possession of such other Party; provided, that such other

  
 - 51 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
Party shall be permitted to retain one (1) copy of such Confidential Information for the sole purpose of performing any continuing obligations hereunder, as required by Applicable Law, or
for archival purposes. Notwithstanding the foregoing, such other Party also shall be permitted to retain such additional copies of or any computer records or files containing such Confidential Information that have been created solely by such
Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such other Party’s standard archiving and
back-up procedures, but not for any other use or purpose. 
 10.8
Survival. All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section 10.2. 

ARTICLE 11 

REPRESENTATIONS AND WARRANTIES 

11.1 Mutual Representations and Warranties. Licensor and AbbVie each represents and warrants to the other, as of
the Effective Date, as follows: 
 11.1.1 Organization. It is a corporation duly incorporated, validly existing, and in good
standing under the laws of the jurisdiction of its incorporation, and has all requisite corporate power and authority, to execute, deliver, and perform this Agreement. 

11.1.2 Authorization. The execution and delivery of this Agreement and the performance by it of the transactions contemplated
hereby have been duly authorized by all necessary corporate action, and do not violate (a) such Party’s charter documents, bylaws, or other organizational documents, (b) in any material respect, any agreement, instrument, or
contractual obligation to which such Party is bound, (c) any requirement of any Applicable Law, or (d) any order, writ, judgment, injunction, decree, determination, or award of any court or governmental agency presently in effect
applicable to such Party. 
 11.1.3 Binding Agreement. This Agreement is a legal, valid, and binding obligation of such Party
enforceable against it in accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability
of specific performance, and general principles of equity (whether enforceability is considered a proceeding at law or equity). 

11.1.4 No Inconsistent Obligation. It is not under any obligation, contractual or otherwise, to any Person that conflicts with
or is inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder. 

11.1.5 No Misstatements or Omissions. The representations and warranties of such Party in this Agreement, and the Information,
documents and materials furnished to the other Party in response to such Party’s written requests for due diligence information prior to the Effective Date, do not, taken as a whole, (a) contain any untrue statement of a material fact, or
(b) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading. 

  
 - 52 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 11.2 Additional Representations and Warranties of Licensor.
Licensor further represents and warrants to AbbVie, as of the Effective Date, as follows: 
 11.2.1 All Licensor Background Patents
existing as of the Effective Date are listed on Schedule 11.2.1 (the “Existing Patents”). To Licensor’s Knowledge, all Existing Patents existing as of the Effective Date are subsisting and, to Licensor’s Knowledge,
are not invalid or unenforceable, in whole or in part, are being diligently prosecuted in the applicable patent offices in the Territory in accordance with Applicable Law, and have been filed and maintained properly and correctly and all applicable
fees have been paid on or before the due date for payment. 
 11.2.2 There are no judgments, or settlements against, or amounts with
respect thereto, owed by Licensor or any of its Affiliates relating to the Existing Patents, or the Licensor Background Know-How. No claim or litigation has been brought or threatened in writing or any other
form by any Person alleging, and Licensor has no Knowledge of any claim, whether or not asserted, that (a) the Existing Patents are invalid or unenforceable, or (b) the Development or Commercialization of the Discovery T-Cell Receptor Constructs or Licensed Products as contemplated herein [***], does or will violate, infringe, misappropriate or otherwise conflict or interfere with, any Patent or other intellectual property or
proprietary right of any Third Party. To Licensor’s Knowledge, no Person is infringing or threatening to infringe or misappropriating or threatening to misappropriate the Existing Patents or the Licensor Background Know-How. 
 11.2.3 Licensor is (a) the sole and exclusive owner of the entire right, title
and interest in the Existing Patents listed on Schedule 11.2.1, Part A (the “Owned Patents”) and the Licensor Background Know-How and (b) the sole and exclusive licensee of the
Existing Patents listed on Schedule 11.2.1, Part B (the “In-Licensed Patents”) subject to valid and enforceable in-license agreements (each, a
“Licensor In-License Agreement”), in each case ((a) and (b)) free of any encumbrance, lien, or claim of ownership by any Third Party. Licensor is entitled to grant the licenses specified
herein. The Owned Patents and In-Licensed Patents represent all of the Existing Patents. The Existing Patents represent all Patents within Licensor’s or its Affiliates’ ownership or Control relating
to the Licensor Platform, or the Exploitation thereof, as of the Effective Date. To Licensor’s Knowledge, there is no [***]. 

11.2.4 To Licensor’s Knowledge, Licensor has the right to use all Information and Patents necessary to Develop, Manufacture and
Commercialize the Discovery T-Cell Receptor Constructs and the Licensed Products as contemplated herein [***] and such are not subject to any license or agreement to which Licensor or any of its Affiliates is
a party other than a Licensor In-License Agreement. 
 11.2.5 As of the Effective Date, none
of Licensor or its Affiliates and, to Licensor’s Knowledge, any Third Party is in breach of any Licensor In-License Agreement. 

  
 - 53 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 11.2.6 True, complete, and correct copies of: (a) the file wrapper and other
documents and materials relating to the prosecution, defense, maintenance, validity, and enforceability of the Existing Patents; (b) all existing Licensor In-License Agreements; and (c) all material
adverse information with respect to the safety and efficacy of the Discovery T-Cell Receptor Constructs known to Licensor, in each case ((a) through (c)) have been provided or made available to AbbVie prior to
the Effective Date. 
 11.2.7 Licensor and its Affiliates have generated, prepared, maintained, and retained all Regulatory
Documentation that is required to be maintained or retained pursuant to and in accordance with Applicable Law, and all such information is true, complete and correct and what it purports to be. 

11.2.8 Each Person who has or has had any rights in or to any Owned Patents or any Licensor Background
Know-How, has assigned and has executed an agreement assigning its entire right, title, and interest in and to such Owned Patents and Licensor Background Know-How to
Licensor. To Licensor’s Knowledge, no current officer, employee, agent, or consultant of Licensor or any of its Affiliates is in violation of any term of any assignment or other agreement regarding the protection of Patents or other
intellectual property or proprietary information of Licensor related to the Licensor Background Patents. 
 11.2.9 All rights in all
inventions and discoveries, made, developed, or conceived by any employee or independent contractor of Licensor or any of its Affiliates during the course of their employment (or other retention) by Licensor or such Affiliate, and included in
Licensor Background Know-How or that are the subject of one (1) or more Existing Patents have been or will be assigned in writing to Licensor or such Affiliate. 

11.2.10 Licensor has obtained the right (including under any Patents and other intellectual property rights) to use all Information
and all other materials (including any formulations and manufacturing processes and procedures) developed or delivered by any Third Party under any agreements between Licensor and any such Third Party that is reasonably necessary or useful for the
Development or Commercialization of Discovery T-Cell Receptor Constructs, and Licensor has the rights under each such agreement to transfer such Information or other materials to AbbVie and its designees and
to grant AbbVie the right to use such Information or other materials in the Development or Commercialization of the Discovery T-Cell Receptor Constructs or the Licensed Products as set forth in this Agreement.

 11.2.11 Licensor has made (and will make) available to AbbVie, as set forth in Section 4.4(a), all
Regulatory Documentation and Licensor Background Know-How and all such Regulatory Documentation and Licensor Background Know-How are (and, if made available after the
Effective Date, will be), to Licensor’s Knowledge, true, complete, and correct. Neither Licensor nor any of its Affiliates has any Knowledge of [***] that has not been disclosed to AbbVie as of the Effective Date. [***] of a Licensed Product.

 11.2.12 Neither Licensor nor any of its Affiliates, nor any of its or their respective officers, employees, or agents has made an
untrue statement of material fact or fraudulent statement to the FDA or any other Regulatory Authority with respect to the Development of the Discovery T-Cell Receptor Constructs or the Licensed Products,
failed to 

  
 - 54 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority with respect to the Development of the Discovery T-Cell
Receptor Constructs or the Licensed Products, or committed an act, made a statement, or failed to make a statement with respect to the Development of the Discovery T-Cell Receptor Constructs or the Licensed
Products that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”, set forth in 56 Fed. Reg. 46191 (September 10, 1991)
and any amendments thereto or any analogous laws or policies in the Territory. 
 11.2.13 There are no amounts that will be required
to be paid to a Third Party as a result of the Development or Commercialization of Discovery T-Cell Receptor Construct or the Licensed Products that arise out of any agreement to which Licensor or any of its
Affiliates is a party, [***]. 
 11.2.14 Neither Licensor nor any of its employees nor, to Licensor’s Knowledge, agents
performing hereunder, have ever been, are currently, or are the subject of a proceeding that could lead to it or such employees or agents becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or
a Convicted Entity or Convicted Individual or added to the FDA’s Disqualified/Restricted List. If, during the Term, Licensor, or any of its employees or agents performing hereunder, become or are the subject of a proceeding that could lead to a
Person becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual or added to the FDA’s Disqualified/Restricted List, Licensor shall immediately
notify AbbVie, and AbbVie shall have the right, exercisable upon written notice given by AbbVie to terminate this Agreement. This provision shall survive termination or expiration of this Agreement. For purposes of this Agreement, the following
definitions shall apply: 
 (a) A “Debarred Individual” is an individual who has been debarred by the FDA pursuant to 21
U.S.C. §335a (a) or (b) from providing services in any capacity to a person that has an approved or pending drug or biological product application. 

(b) A “Debarred Entity” is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C.
§335a (a) or (b) from submitting or assisting in the submission of any Drug Approval Application, or a subsidiary or affiliate of a Debarred Entity. 

(c) An “Excluded Individual” or “Excluded Entity” is (i) an individual or entity, as applicable, who
has been excluded, debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or
(ii) is an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those
produced by the U.S. General Services Administration (GSA). 

  
 - 55 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 (d) A “Convicted Individual” or “Convicted Entity” is an
individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 21 U.S.C. §335a (a) or 42 U.S.C. §1320a—7(a), but has not yet been excluded, debarred, suspended or otherwise
declared ineligible. 
 (e) “FDA’s Disqualified/Restricted List” is the list of clinical investigators restricted
from receiving investigational drugs, biologics, or devices if the FDA has determined that the investigators have repeatedly or deliberately failed to comply with regulatory requirements for studies or have submitted false Information to the study
sponsor or the FDA. 
 11.2.15 The inventions claimed or covered by the Existing Patents (a) were not conceived, discovered,
developed, or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof, and (b) are not a “subject invention” as that term is described
in 35 U.S.C. Section 201(f). 
 11.2.16 The representations and warranties of Licensor in this Agreement, [***], or (b) [***].

 11.3 Additional Representations and Warranties of AbbVie. AbbVie further represents and warrants to
Licensor, as of the Target Acceptance Date with respect to an Accepted Target, as follows: 
 11.3.1 To AbbVie’s Knowledge,
AbbVie has the right to use all Information and Patents necessary to Develop, Manufacture and Commercialize the Discovery T-Cell Receptors that Bind to such Accepted Target and AbbVie is entitled to grant
Licensor the licenses specified in Section 6.2. 
 11.3.2 All rights in all inventions and discoveries, made, developed, or
conceived by any employee or independent contractor of AbbVie or any of its Affiliates during the course of their employment (or other retention) by AbbVie or such Affiliate, and included in AbbVie Background
Know-How or that are the subject of one (1) or more AbbVie Background Patents existing as of the Effective Date that claim or cover Discovery T-Cell Receptors that
Bind to such Accepted Target (the “Existing AbbVie TCR Patents”) have been or will be assigned in writing to AbbVie or such Affiliate. 

11.3.3 AbbVie has obtained the right (including under any Patents and other intellectual property rights) to use all Information and
all other materials developed or delivered by any Third Party under any agreements between AbbVie and any such Third Party that is necessary for the Development or Commercialization of Discovery T-Cell
Receptors that Bind to such Accepted Target, and AbbVie has the rights under each such agreement to transfer such Information or other materials to Licensor and its designees and to grant Licensor the right to use such Information or other materials
in the Development of the Discovery T-Cell Receptor Constructs or the Licensed Products as set forth in this Agreement. 

  
 - 56 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 11.3.4 Neither AbbVie nor any of its employees nor, to AbbVie’s Knowledge,
agents performing hereunder, have ever been, are currently, or are the subject of a proceeding that could lead to it or such employees or agents becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded
Individual or a Convicted Entity or Convicted Individual or added to the FDA’s Disqualified/Restricted List. If, during the Term, AbbVie, or any of its employees or agents performing hereunder, become or are the subject of a proceeding that
could lead to a Person becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual or added to the FDA’s Disqualified/Restricted List, AbbVie shall
immediately notify Licensor. This provision shall survive termination or expiration of this Agreement. 
 11.4
Covenants of Licensor. Licensor covenants to AbbVie as follows: 
 11.4.1 During the Term, neither Licensor nor any of its
Affiliates shall encumber or diminish the rights granted to AbbVie hereunder with respect to the Licensor Background Patents or Licensor Program Patents, including by not (a) committing any acts or permitting the occurrence of any omissions
that would cause the breach or termination of any Licensor In-License Agreement, or (b) amending or otherwise modifying or permitting to be amended or modified, any Licensor
In-License Agreement, where such amendment or modification would adversely affect the rights granted to AbbVie hereunder. Licensor shall promptly provide AbbVie with notice of any alleged, threatened, or
actual breach of any Licensor In-License Agreement. 
 11.4.2 Licensor and its Affiliates
will employ Persons with appropriate education, knowledge and experience to conduct and to oversee the Discovery Research Activities. 

11.4.3 Licensor shall have obtained from each of its Affiliates, sublicensees, employees and agents who are participating in the
Exploitation of the Discovery T-Cell Receptor Constructs or Licensed Products or who otherwise have access to any AbbVie Information or other Confidential Information of AbbVie, rights to any and all
Information that is reasonably necessary or useful for the Development or Commercialization of Discovery T-Cell Receptor Constructs or Licensed Products, in each case prior to the performance of or
participation in such activities, such that AbbVie shall, by virtue of this Agreement, receive from Licensor, without payments beyond those required by ARTICLE 7, the licenses and other rights granted to AbbVie hereunder. 

11.5 Covenants of AbbVie. AbbVie covenants to Licensor as follows: 

11.5.1 AbbVie shall have obtained from each of its Affiliates, Sublicensees, employees and agents who are participating in the
Exploitation of the Discovery T-Cell Receptor Constructs or Licensed Products or who otherwise have access to any Licensor Information or other Confidential Information of Licensor, rights to any and all
Information that is reasonably necessary or useful for the Development or Commercialization of Discovery T-Cell Receptor Constructs or Licensed Products, in each case prior to the performance of or
participation in such activities, such that Licensor shall, by virtue of this Agreement, receive from AbbVie, without additional consideration, the licenses specified in Section 6.2. 

  
 - 57 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 11.6 DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS
WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER
WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT
OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 ARTICLE 12 

INDEMNITY 

12.1 Indemnification of Licensor. AbbVie shall indemnify Licensor, its Affiliates and its and their respective
directors, officers, employees, and agents (the “Licensor Indemnitees”) and defend and save each of them harmless, from and against any and all losses, damages, liabilities, penalties, costs, and expenses (including reasonable
attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims, or demands of Third Parties (collectively, “Third Party Claims”) incurred by or rendered
against the Licensor Indemnitees arising from or occurring as a result of: [***] 
 12.2 Indemnification of
AbbVie. Licensor shall indemnify AbbVie, its Affiliates and their respective directors, officers, employees, and agents (the “AbbVie Indemnitees”), and defend and save each of them harmless, from and against any and all Losses
in connection with any and all Third Party Claims incurred by or rendered against the AbbVie Indemnitees arising from or occurring as a result of: [***]. 

12.3 Notice of Claim. All indemnification claims in respect of a Party, its Affiliates, or their respective
directors, officers, employees and agents shall be made solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party prompt written notice (an “Indemnification
Claim Notice”) of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under this ARTICLE 12, but in no event shall the indemnifying Party be liable for any Losses that
result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The
Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. 

  
 - 58 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 12.4 Control of Defense. 

12.4.1 In General. Subject to the provisions of Sections 8.4, 8.5 and 8.7, at its option, the indemnifying
Party may assume the defense of any Third Party Claim by giving written notice to the Indemnified Party within [***] after the indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim
by the indemnifying Party shall not be construed as an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the indemnifying Party of any
defenses it may assert against the Indemnified Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel
selected by the indemnifying Party which shall be reasonably acceptable to the Indemnified Party. In the event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall promptly deliver to the indemnifying Party
all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the indemnifying Party assume the defense of a Third Party Claim, except as provided in
Section 12.4.2, the indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third
Party Claim unless specifically requested in writing by the indemnifying Party. In the event that it is ultimately determined that the indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party from and against
the Third Party Claim, the Indemnified Party shall reimburse the indemnifying Party for any Losses incurred by the indemnifying Party in its defense of the Third Party Claim. 

12.4.2 Right to Participate in Defense. Without limiting Section 12.4.1, any Indemnified Party shall
be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, that such employment shall be at the Indemnified Party’s own expense unless (a) the
employment thereof, and the assumption by the indemnifying Party of such expense, has been specifically authorized by the indemnifying Party in writing, (b) the indemnifying Party has failed to assume the defense and employ counsel in
accordance with Section 12.4.1 (in which case the Indemnified Party shall control the defense), or (c) the interests of the Indemnified Party and the indemnifying Party with respect to such Third Party Claim are
sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles. 

12.4.3 Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party
Claim and that shall not result in the Indemnified Party’s becoming subject to injunctive or other relief, and as to which the indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder,
the indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate. With
respect to all other Losses in connection with Third Party Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 12.4.1, the indemnifying Party shall have authority
to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided, that it obtains the prior written consent 

  
 - 59 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). If the indemnifying Party does not assume and conduct the defense of a Third Party Claim as
provided above, the Indemnified Party may defend against such Third Party Claim. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnified Party shall admit any liability with respect to, or
settle, compromise or dispose of, any Third Party Claim without the prior written consent of the indemnifying Party. The indemnifying Party shall not be liable for any settlement, compromise or other disposition of a Loss by an Indemnified Party
that is reached without the written consent of the indemnifying Party. 
 12.4.4 Cooperation. Regardless of whether the
indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall, and shall cause each indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony,
provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the
indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnified Parties and other employees and agents available on a mutually
convenient basis to provide additional information and explanation of any material provided hereunder, and the indemnifying Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith. 
 12.4.5 Expenses. Except as
provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim shall be reimbursed on a Calendar Quarter basis in arrears by
the indemnifying Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to
indemnify the Indemnified Party. 
 12.5 Special, Indirect, and Other Losses. EXCEPT (A) FOR WILLFUL
MISCONDUCT OR GROSS NEGLIGENCE, (B) FOR A PARTY’S BREACH OF ITS OBLIGATIONS UNDER [***], (C) AS PROVIDED UNDER [***], AND (D) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY
PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 12, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF PROFITS OR BUSINESS INTERRUPTION,
HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE IN CONNECTION WITH OR ARISING IN ANY WAY OUT OF THE TERMS OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE
USE OF THE DISCOVERY T-CELL RECEPTOR CONSTRUCTS OR LICENSED PRODUCTS, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 - 60 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 12.6 Insurance. Each Party shall obtain and carry in full force
and effect the minimum insurance requirements set forth herein. Such insurance (a) shall be primary insurance with respect to each Party’s own participation under this Agreement, (b) shall be issued by a recognized insurer rated by
[***] (or its equivalent) or better, or an insurer pre-approved in writing by the other Party, (c) shall list the other Party as an additional named insured thereunder, and (d) shall require [***] written notice to be given to the other
Party prior to any cancellation, non-renewal or material change thereof. 
 12.6.1 Types
and Minimum Limits. The types of insurance, and minimum limits shall be: 
 Worker’s Compensation with statutory limits in
compliance with the Worker’s Compensation laws of the state or states in which the Party has employees in the United States (excluding Puerto Rico). 

Employer’s Liability coverage with a minimum limit of [***]; provided, that a Party has employees in the United States (excluding Puerto
Rico). 
 General Liability Insurance with a minimum limit of [***] and [***]. General Liability Insurance, which, in the case of AbbVie
only, shall include, at a minimum, Professional Liability, Clinical Trial Insurance and, beginning at least [***] prior to First Commercial Sale of a Licensed Product, product liability insurance. 

12.6.2 Certificates of Insurance. Upon request by a Party, the other Party shall provide Certificates of Insurance evidencing
compliance with this Section (including evidence of permitted self-insurance, as applicable). The insurance policies shall be under an occurrence form, but if only a claims-made form is available to a Party, then such Party shall continue to
maintain such insurance after the expiration or termination of this Agreement for the longer of (a) a period of [***] following termination or expiration of this Agreement in its entirety, or (b) with respect to a particular Party, [***]
by a Party. 
 12.6.3 Self-Insurance. Notwithstanding the foregoing, a Party may self-insure, in whole or in part, the
insurance requirements described above, provided that such Party (on a consolidated basis with its Affiliates) has [***], and, if such Party is not publicly traded on a recognized securities exchange, upon request of the other Party, provides
reasonable evidence thereof to such other Party. 
 ARTICLE 13 

TERM AND TERMINATION 

13.1 Term. 

13.1.1 Term. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall continue
in force and effect until the date of expiration of the last Royalty Term for the last Licensed Product (such period, the “Term”). 

  
 - 61 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 13.1.2 Effect of Expiration of the Term. Following the expiration of the Term, the
grants in Section 6.1 shall become non-exclusive, fully-paid, royalty-free and irrevocable. 

13.2 Termination for Material Breach. 

13.2.1 Material Breach. If either Party (the “Non-Breaching Party”) believes
that the other Party (the “Breaching Party”) has materially breached one (1) or more of its material obligations under this Agreement, then the Non-Breaching Party may deliver notice of
such material breach to the Breaching Party (a “Default Notice”). If the Breaching Party does not dispute that it has committed a material breach of one (1) or more of its material obligations under this Agreement, then if the
Breaching Party fails to cure such breach within ninety (90) days after receipt of the Default Notice, or if such compliance cannot be fully achieved within such ninety (90) day period and the Breaching Party has failed to commence
compliance or has failed to use diligent efforts to achieve full compliance as soon thereafter as is reasonably possible, the Non-Breaching Party may terminate this Agreement upon written notice to the
Breaching Party. If the Breaching Party disputes that it has materially breached one (1) of its material obligations under this Agreement, the dispute shall be resolved pursuant to Section 14.7. If, as a result of the
application of such dispute resolution procedures, the Breaching Party is determined to be in material breach of one (1) or more of its material obligations under this Agreement (an “Adverse Ruling”), then if the Breaching
Party fails to complete the actions specified by the Adverse Ruling to cure such material breach within ninety (90) days after such ruling, or if such compliance cannot be fully achieved within such ninety (90) day period and the Breaching
Party has failed to commence diligent efforts to achieve full compliance as soon thereafter as is reasonably possible, then the Non-Breaching Party may terminate this Agreement upon written notice to the
Breaching Party. 
 13.2.2 Material Breach Related to Diligence in a Major Market. Notwithstanding
Section 13.2.1, if the material breach and failure to cure contemplated by Section 13.2.1 is with respect to AbbVie’s Commercialization diligence obligations under
Section 5.2 with respect to any Major Market, Licensor shall not have the right to terminate this Agreement in its entirety, but shall have the right to terminate this Agreement solely with respect to such Major Market.

 13.2.3 Material Breach Related to an Accepted Target. Notwithstanding Section 13.2.1, if the
material breach and failure to cure contemplated by Section 13.2.1 is with respect to AbbVie’s obligations under this Agreement with respect to any particular Accepted Target, Licensor shall not have the right to
terminate this Agreement in its entirety, but shall have the right to terminate this Agreement solely with respect to such Accepted Target. 

  
 - 62 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 13.2.4 Invocation of Material Breach. Notwithstanding the foregoing, the
Parties agree that termination pursuant to this Section 13.2 is a remedy to be invoked only if the breach is not (a) cured in accordance with Section 13.2.1 (including the timeframes set forth
therein), (b) remedied through the payment of money damages determined in accordance with Section 14.7 or (c) adequately remedied through a combination of (a) and (b). 

13.3 Additional Termination Rights by AbbVie. 

13.3.1 For Cause. AbbVie may terminate this Agreement in its entirety or on an Accepted Target-by-Accepted Target basis effective immediately upon written notice to Licensor in the event that (a) a Discovery T-Cell Receptor Construct Failure occurs,
or (b) AbbVie in good faith believes that it is not advisable for AbbVie to continue to Develop or Commercialize the Discovery T-Cell Receptor Constructs or Licensed Products as a result of a serious
safety issue regarding the use of any Licensed Product. 
 13.3.2 Termination For Convenience by AbbVie. AbbVie may terminate
this Agreement in its entirety, or on a country-by-country or other jurisdiction basis, or on an Accepted
Target-by-Accepted Target basis, for any or no reason, upon thirty (30) days’ prior written notice to Licensor. 

13.4 Termination for Insolvency. In the event that either Party (a) files for protection under bankruptcy
or insolvency laws, (b) makes an assignment for the benefit of creditors, (c) appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not discharged within ninety (90) days after such
filing, (d) is a party to any dissolution or liquidation, (f) files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is not discharged within ninety (90) days of the filing thereof, or
(g) admits in writing its inability generally to meet its obligations as they fall due in the general course, then the other Party may terminate this Agreement in its entirety effective immediately upon written notice to such Party. 

13.5 Rights in Bankruptcy. 

13.5.1 Applicability of 11 U.S.C. § 365(n). All rights and licenses (collectively, the “Intellectual
Property”) granted under or pursuant to this Agreement, including all rights and licenses to use improvements or enhancements developed during the Term, are intended to be, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the United States Bankruptcy Code (the “Bankruptcy Code”) or any analogous provisions in any other country or jurisdiction, licenses of rights to “intellectual property” as defined under
Section 101(35A) of the Bankruptcy Code. The Parties agree that the licensee of such Intellectual Property under this Agreement shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, including
Section 365(n) of the Bankruptcy Code, or any analogous provisions in any other country or jurisdiction. All of the rights granted to either Party under this Agreement shall be deemed to exist immediately before the occurrence of any bankruptcy
case in which the other Party is the debtor. 

  
 - 63 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 13.5.2 Rights of non-Debtor Party in
Bankruptcy. If a bankruptcy proceeding is commenced by or against either Party under the Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the non-debtor Party shall be
entitled to a complete duplicate of (or complete access to, as appropriate) any Intellectual Property and all embodiments of such Intellectual Property, which, if not already in the non-debtor Party’s
possession, shall be delivered to the non-debtor Party within [***] of such request; provided, that the debtor Party is excused from its obligation to deliver the Intellectual Property to the extent the debtor
Party continues to perform all of its obligations under this Agreement and the Agreement has not been rejected pursuant to the Bankruptcy Code or any analogous provision in any other country or jurisdiction. 

13.6 Termination in Entirety. 

13.6.1 In the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 13.3.2
or by Licensor pursuant to Section 13.2.1 or 13.4: 
 (a) all rights and licenses granted by Licensor
hereunder shall immediately terminate; 
 (b) all rights and licenses granted by AbbVie hereunder shall immediately terminate, other than
any Unblocking License granted pursuant to Section 2.4; 
 (c) AbbVie shall grant Licensor an Unblocking License
for each Accepted Target, subject to the good faith negotiation of mutually agreeable terms and conditions for such Unblocking License; and 

(d) solely in the case of termination pursuant to Section 13.3.2, upon the effective date of AbbVie’s notice
of termination (i) AbbVie will have no further diligence obligations under this Agreement and (ii) AbbVie will not be required to make any milestone payments to Licensor under this Agreement for milestones achieved during the period
between the notice of termination by AbbVie under Section 13.3.2 and the effective date of termination or thereafter. 

13.6.2 In the event of a termination of this Agreement in its entirety by AbbVie pursuant to Sections 13.2.1 or 13.4:

 (a) all rights and licenses granted by AbbVie hereunder shall immediately terminate; 

(b) Licensor will have no further obligations under this Agreement with respect to the Development of Discovery T-Cell Receptor Constructs and Licensed Products, including any obligations under ARTICLE 4; and 

(c) all rights and licenses granted to AbbVie hereunder shall become [***], irrevocable, unrestricted, and perpetual rights and licenses and
the Parties shall [***], taking into consideration: (i) [***] or Licensed Product due to termination; (ii) [***] Licensed Product; and (iii) [***]. If, despite good faith discussions, the Parties are unable to agree on the consideration, then the
dispute shall be resolved pursuant to Section 14.7. 

  
 - 64 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 13.7 Termination of Terminated Territory. In the event of a
termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 13.3.2 or with respect to a Terminated Territory by Licensor pursuant to Section 13.2.2
(but not in the case of any termination of this Agreement in its entirety), the term “Territory” shall be automatically amended to exclude the Terminated Territory and all rights and licenses granted by Licensor hereunder
(a) shall automatically be deemed to be amended to exclude, if applicable, the right to market, promote, detail, distribute, import, sell, offer for sale, file any Drug Approval Application for, or seek any Regulatory Approval for Discovery T-Cell Receptor Construct or Licensed Products in such Terminated Territory, and (b) shall otherwise survive and continue in effect in such Terminated Territory solely for the purpose of furthering any
Commercialization of the Discovery T-Cell Receptor Constructs or Licensed Products in the Territory other than the Terminated Territory or any Development or Manufacturing in support thereof. 

13.8 Termination of Accepted Target. In the event of a termination of this Agreement with respect to one
Accepted Target (the “Terminated Target”) pursuant to Sections 13.2.3 or 13.3.2 (but not in the case of any termination of this Agreement in its entirety) then: 

13.8.1 the Terminated Target shall cease to be an Accepted Target; 

13.8.2 all rights and licenses granted by Licensor hereunder shall automatically be deemed to be amended to exclude the Terminated
Target but shall otherwise survive and continue in effect for the remaining Accepted Target(s); 
 13.8.3 all rights and licenses
granted by AbbVie hereunder shall automatically be deemed to be amended to exclude the Terminated Target but shall otherwise survive and continue in effect for the remaining Accepted Target(s); 

13.8.4 AbbVie shall grant Licensor an Unblocking License for the Terminated Target, subject to the good faith negotiation of mutually
agreeable terms and conditions for such Unblocking License; 
 13.8.5 Licensor will have no further obligations under this Agreement
with respect to the Development of Discovery T-Cell Receptor Constructs and Licensed Products that are directed to the Terminated Target, including any obligation under ARTICLE 4 with respect to
the Terminated Target; and 
 13.8.6 solely in the case of termination pursuant to Section 13.3.2, upon
the effective date of AbbVie’s notice of termination (i) AbbVie will have no further diligence obligations under this Agreement with respect to the Terminated Target and (ii) AbbVie will not be required to make any milestone payments
to Licensor under this Agreement for milestones achieved with respect to the Terminated Target during the period between the notice of termination by AbbVie under Section 13.3.2 and the effective date of termination or
thereafter. 

  
 - 65 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 13.9 Remedies. Except as otherwise expressly provided herein,
termination of this Agreement (either in its entirety or with respect to one (1) or more country(ies) or other jurisdiction(s) or with respect to a Terminated Target) in accordance with the provisions hereof shall not limit remedies that may
otherwise be available in law or equity. 
 13.10 Accrued Rights; Surviving Obligations. 

13.10.1 Termination or expiration of this Agreement (either in its entirety or with respect to one (1) or more country(ies) or
other jurisdiction(s) or with respect to a Terminated Target) for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not
relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement. Without limiting the foregoing, ARTICLE 1 (Definitions), ARTICLE 12 (Indemnification), Sections 4.7.1(b)
(Regulatory Activities), 4.7.4 (Records), 5.4 (Product Trademarks), 7.11 (Interest on Late Payments), 7.12 (Audit), 7.13 (Audit Dispute), 7.14 (Confidentiality), 7.16 (No Other Compensation),
8.1.1 (Licensor Ownership), 8.1.2 (AbbVie Ownership), 8.2.4 (Patent Prosecution and Maintenance of Product-Specific Patents), 10.2 (Confidentiality Obligations), 10.3 (Permitted Disclosures), 10.4 (Use of
Name), 10.5 (Public Announcements), 10.7 (Return of Confidential Information), 10.8 (Survival), 13.6 (Termination in Entirety), 13.9 (Remedies), 13.10 (Accrued Rights; Surviving Obligations), 14.4
(Assignment), 14.5 (Severability), 14.6 (Governing Law, Jurisdiction and Service), 14.7 (Dispute Resolution), 14.8 (Notices), 14.9 (Entire Agreement; Amendments), 14.10 (English Language), 14.11
(Equitable Relief), 14.12 (Waiver and Non-Exclusion of Remedies), 14.13 (No Benefit to Third Parties), 14.14 (Further Assurance), 14.15 (Relationship of the Parties), 14.16
(Performance by Affiliates), 14.17 (Counterparts; Facsimile Execution), 14.18 (References), 14.19 (Schedules), 14.20 (Construction) and, solely with respect to Joint Program Patents, Sections 8.1.3 (Ownership of
Joint Program Patents and Joint Program Know-How), 8.2.3 (Patent Prosecution and Maintenance of AbbVie Background Patents, AbbVie Program Patents and Joint Program Patents), 8.2.5 (Cooperation),
8.3.2 (Enforcement of AbbVie Background Patents, AbbVie Program Patents, Product-Specific Patents and Joint Program Patents), 8.3.5 (Cooperation), 8.3.6 (Recovery), 8.5.4 (AbbVie Background Patents, AbbVie Program
Patents, Product-Specific Patents and Joint Program Patents) and 8.5.5 (Cooperation) of this Agreement shall survive the termination or expiration of this Agreement for any reason. If this Agreement is terminated with respect to a Terminated
Territory or a Terminated Target but not in its entirety, then following such termination the foregoing provisions of this Agreement shall remain in effect with respect to the Terminated Territory or Terminated Target, as applicable (to the extent
they would survive and apply in the event the Agreement expires or is terminated in its entirety), and all provisions not surviving in accordance with the foregoing shall terminate upon termination of this Agreement with respect to the Terminated
Territory or Terminated Target, as applicable and be of no further force and effect (and, for purposes of clarity, all provisions of this Agreement shall remain in effect with respect to all countries in the Territory other than the Terminated
Territory or with respect to the Accepted Target other than the Terminated Target). 

  
 - 66 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 13.10.2 Notwithstanding the termination of AbbVie’s licenses and other rights
under this Agreement or with respect to a particular Major Market or country or other jurisdiction or with respect to a Terminated Target, as the case may be, AbbVie shall have the right [***] the effective date of such termination with respect to
each Major Market or country or other jurisdiction or Terminated Target with respect to which such termination applies to sell or otherwise dispose of all Discovery T-Cell Receptor Construct or Licensed
Product then in its inventory and any in-progress inventory, in each case that is intended for sale or disposition in such Major Market or country or other jurisdiction or, in the case of a Terminated Target,
in the Territory, as though this Agreement had not terminated with respect to such Major Market or country or other jurisdiction or Terminated Target, as applicable, and such sale or disposition shall not constitute infringement of Licensor’s
or its Affiliates’ Patent or other intellectual property or other proprietary rights. For purposes of clarity, AbbVie shall continue to make payments thereon as provided in ARTICLE 7 (as if this Agreement had not terminated with
respect to such Major Market or country or other jurisdiction or Terminated Target, as applicable). 
 ARTICLE 14 

MISCELLANEOUS 

14.1 Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have
defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from events beyond the reasonable control of the
non-performing Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots,
civil commotion, strikes, lockouts, or other labor disturbances (whether involving the workforce of the non-performing Party or of any other Person), acts of God or acts, omissions or delays in acting by any
governmental authority (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates of any term or condition of this Agreement). The non-performing Party shall notify the other Party of such force majeure within [***] after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration, and
any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use commercially
reasonable efforts to remedy its inability to perform. 
 14.2 Change in Control of Licensor. 

14.2.1 Licensor (or its successor) shall provide AbbVie with written notice of any Change in Control of Licensor or Acquisition by
Licensor within [***] 

  
 - 67 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 14.2.2 In the event of [***] 

14.3 Export Control. This Agreement is made subject to any restrictions concerning the export of products or
technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under
this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the
appropriate agency or other governmental entity in accordance with Applicable Law. 
 14.4 Assignment. 

14.4.1 Without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed,
neither Party shall sell, transfer, assign, delegate, pledge, or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided, that either Party may
make such an assignment without the other Party’s consent to its Affiliate or to a successor, whether in a merger, sale of stock, sale of assets or any other transaction, of the business to which this Agreement relates. With respect to an
assignment to an Affiliate, the assigning Party shall remain responsible for the performance by such Affiliate of the rights and obligations hereunder. Any attempted assignment or delegation in violation of this
Section 14.4 shall be void and of no effect. All validly assigned and delegated rights and obligations of the Parties hereunder shall be binding upon and inure to the benefit of and be enforceable by and against the
successors and permitted assigns of Licensor or AbbVie, as the case may be. The permitted assignee or transferee shall assume all obligations of its assignor or transferor under this Agreement. Without limiting the foregoing, the grant of rights set
forth in this Agreement shall be binding upon any successor or permitted assignee of Licensor, and the obligations of AbbVie, including the payment obligations, shall run in favor of any such successor or permitted assignee of Licensor’s
benefits under this Agreement. 
 14.4.2 [***] 

14.5 Severability. If any provision of this Agreement is held to be illegal, invalid, or unenforceable under any
present or future law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and
enforced as if such illegal, invalid, or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid, or
unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid, or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid, and enforceable provision as similar in
terms to such illegal, invalid, or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision
hereof illegal, invalid, or unenforceable in any respect. 

  
 - 68 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 14.6 Governing Law, Jurisdiction and Service. 

14.6.1 Governing Law. This Agreement or the performance, enforcement, breach or termination hereof shall be interpreted,
governed by and construed in accordance with the laws of the State of Delaware, United States, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive
law of another jurisdiction; provided, that all questions concerning (a) inventorship of Patents under this Agreement shall be determined in accordance with Section 8.1.4 and (b) the construction or effect of
Patents shall be determined in accordance with the laws of the country or other jurisdiction in which the particular Patent has been filed or granted, as the case may be. The Parties agree to exclude the application to this Agreement of the United
Nations Convention on Contracts for the International Sale of Goods. 
 14.6.2 Service. Each Party further agrees that
service of any process, summons, notice or document by registered mail to its address set forth in Section 14.8.2 shall be effective service of process for any action, suit, or proceeding brought against it under this
Agreement in any such court. 
 14.7 Dispute Resolution. Except for disputes resolved by the procedures set
forth in Section 3.2.3 or 7.13, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a “Dispute”),
it shall be resolved pursuant to this Section 14.7. 
 14.7.1 General. Any Dispute shall first be
referred to the Senior Officers of the Parties, who shall confer in good faith on the resolution of the issue. Any final decision mutually agreed to by the Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are
not able to agree on the resolution of any such issue within [***] (or such other period of time as mutually agreed by the Senior Officers) after such issue was first referred to them, then, except as otherwise set forth in
Section 14.7.2, either Party may, by written notice to the other Party, elect to initiate an alternative dispute resolution (“ADR”) proceeding pursuant to the procedures set forth in
Section 14.7.3 for purposes of having the matter settled. 
 14.7.2 Intellectual Property Disputes.
In the event that a Dispute arises with respect to the validity, scope, enforceability, inventorship or ownership of any Patent, Trademark or other intellectual property rights, and such Dispute cannot be resolved in accordance with
Section 14.7.1, unless otherwise agreed by the Parties in writing, such Dispute shall not be submitted to an ADR proceeding in accordance with Section 14.7.3 and instead, either Party may initiate
litigation in a court of competent jurisdiction, notwithstanding Section 14.6, in any country or other jurisdiction in which such rights apply. 

14.7.3 ADR. Any ADR proceeding under this Agreement shall take place pursuant to the procedures set forth in Schedule
14.7.3. 

  
 - 69 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 14.7.4 Adverse Ruling. Any determination pursuant to this
Section 14.7 that a Party is in material breach of its material obligations hereunder shall specify a (nonexclusive) set of actions to be taken to cure such material breach, if feasible. 

14.7.5 Interim Relief. Notwithstanding anything herein to the contrary, nothing in this Section 14.7
shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction or other interim equitable relief concerning a Dispute, if necessary to protect the interests of such Party. This
Section shall be specifically enforceable. 
 14.8 Notices. 

14.8.1 Notice Requirements. Any notice, request, demand, waiver, consent, approval, or other communication permitted or
required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if (a) delivered by hand, (b) sent by facsimile transmission (with transmission confirmed), or (c) by
internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 14.8.2 or to such other address as the Party to whom
notice is to be given may have provided to the other Party in accordance with this Section 14.8.1. Such notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with
transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as
practicable thereafter. This Section 14.8.1 is not intended to govern the day-to-day business communications necessary between the Parties in
performing their obligations under the terms of this Agreement. 
 14.8.2 Address for Notice. 

If to AbbVie, to: 
 AbbVie
Biotechnology LTD 
 c/o Conyers, Dill & Pearman, 

Clarendon House, 
 2 Church
Street, 
 Hamilton HM 11 Bermuda 

with a copy (which shall not constitute notice) to: 

AbbVie Inc. 
 1 N. Waukegan
Road 
 North Chicago, IL 60064-6011 USA 

Attention: [***] 
 Facsimile:
[***] 

  
 - 70 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 If to Licensor, to: 

Harpoon Therapeutics, Inc. 

4000 Shoreline Court, Suite 250 

South San Francisco, CA 94080 

Attention: [***] 
 with a copy
(which shall not constitute notice) to: 
 Wilson Sonsini Goodrich & Rosati 

650 Page Mill Road 
 Palo Alto,
CA 94304 
 Attention: [***] 

Facsimile: [***] 

14.9 Entire Agreement; Amendments. This Agreement, together with the Schedules attached hereto, sets forth and
constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises, and representations, whether written or oral, with respect thereto are superseded
hereby (including the Prior NDA). The foregoing shall not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party (or its Affiliates) of its obligations under
the Prior NDA. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification, release, or discharge with respect to this Agreement
shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties. 

14.10 English Language. This Agreement shall be written and executed in, and all other communications under or
in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the English version and such
translation, the English version shall control. 
 14.11 Equitable Relief. Each Party acknowledges and agrees
that the restrictions set forth in Section 6.8 and ARTICLE 8 and ARTICLE 10 are reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not
have entered into this Agreement in the absence of such restrictions, and that any breach or threatened breach of any provision of such Section or Articles may result in irreparable injury to such other Party for which there will be no adequate
remedy at law. In the event of a breach or threatened breach of any provision of such Section or Articles, the non-breaching Party shall be authorized and entitled to seek from any court of competent
jurisdiction injunctive relief, whether preliminary or permanent, specific performance, and an equitable accounting of all earnings, profits, and other benefits arising from such breach, which rights shall be cumulative and in

  
 - 71 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 
addition to any other rights or remedies to which such non-breaching Party may be entitled in law or equity. Both Parties agree to waive any requirement
that the other (a) post a bond or other security as a condition for obtaining any such relief, and (b) show irreparable harm, balancing of harms, consideration of the public interest, or inadequacy of monetary damages as a remedy. Nothing
in this Section 14.11 is intended, or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any other provision of this Agreement. 

14.12 Waiver and Non-Exclusion of Remedies. Any term or condition of
this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition.
The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a
similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein. 

14.13 No Benefit to Third Parties. Except as provided in ARTICLE 11, covenants and agreements set
forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other Persons. 

14.14 Further Assurance. Each Party shall duly execute and deliver, or cause to be duly executed and delivered,
such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with
this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

14.15 Relationship of the Parties. It is expressly agreed that Licensor, on the one hand, and AbbVie, on the
other hand, shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture, or agency including for all tax purposes. Neither Licensor, on the one hand, nor AbbVie, on the other hand,
shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the other, without the prior written consent of the other Party to do so. All persons employed by a Party
shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party. 

  
 - 72 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 14.16 Performance by Affiliates. AbbVie may use one (1) or
more of its Affiliates to perform its obligations and duties hereunder and such AbbVie Affiliates are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding obligations of AbbVie and, subject
to an assignment to such Affiliate pursuant to Section 14.4, AbbVie shall remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder. 

14.17 Counterparts; Facsimile Execution. This Agreement may be executed in two (2) counterparts, each of
which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. This Agreement may be executed by facsimile or electronically transmitted signatures and such signatures shall be deemed to bind each
Party hereto as if they were original signatures. 
 14.18 References. Unless otherwise specified,
(a) references in this Agreement to any Article, Section or Schedule shall mean references to such Article, Section or Schedule of this Agreement, (b) references in any Section to any clause are references to such clause of such Section,
and (c) references to any agreement, instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so
amended, replaced, or supplemented and in effect at the relevant time of reference thereto. 
 14.19
Schedules. In the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control. 

14.20 Construction. Except where the context otherwise requires, wherever used, the singular shall include the
plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such
number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement.
The term “including,” “include,” or “includes” as used herein shall mean “including, but not limited to,” and shall not limit the generality of any description preceding such term. The language of this
Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. Each Party represents that it has been represented by legal counsel in connection with this
Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and
provisions. 

  
 - 73 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 [SIGNATURE PAGE FOLLOWS.] 

 

  
 - 74 - 

[  ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant
to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the Effective Date. 

 

							
	HARPOON THERAPEUTICS, INC.	    	 ABBVIE BIOTECHNOLOGY LTD.

				
	 By:
	 	/s/ Gerald McMahon	    	 By:
	 	/s/ William J. Chase
				
	 Name:
	 	Gerald McMahon	    	 Name:
	 	William J. Chase
				
	 Title:
	 	President & CEO	    	 Title:
	 	Director

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 Schedule 1.45 

Discovery Research Plan 
  

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	 	  	 	  	[***]	  	[***]	  	[***]

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	 	  	 	  	[***]	  	[***]	  	 [***]
 [***]

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	 [***]
 [***]
	  	[***]	  	 [***]
 [***]
	  	[***]	  	[***]
					
	 	  	[***]	  	 [***]
 [***]
	  	[***]	  	[***]
					
	 	  	[***]	  	[***]	  	[***]	  	[***]

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	 	  	[***]	  	 [***]
  

• [***]
 • [***]

• [***]
  

[***]
	  	[***]	  	[***]
					
	 [***]
  

[***]
	  	[***]	  	 [***]
  

[***]
	  	[***]	  	[***]

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	 [***]
  

[***]
	  	[***]	  	 [***]
  

[***]
	  	[***]	  	[***]
					
	 	  	[***]	  	 [***]
  

[***]
	  	[***]	  	[***]

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	 	  	[***]	  	 [***]
  

[***]
  

[***]
	  	[***]	  	[***]
					
	 	  	[***]	  	[***]	  	[***]	  	[***]

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	 [***]
  

[***]
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 	  	[***]	  	[***]	  	[***]	  	[***]

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 Schedule 1.50 

Discovery T-Cell Receptor Construct Success Criteria 

 

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 Schedule 2.1.2 

Unavailable Targets as of the Effective Date 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 Schedule 4.6 

Pre-Approved Third Party Providers 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 Schedule 11.2.1 

Existing Patents 
 Part A (Owned
Patents) 
  

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 Part B (In-Licensed Patents) 

[***] 

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

 Schedule 14.7.3 

ADR Procedures 
 [***] 

 

	1.	 [***] 

  

	2.	 [***] 

  

	3.	 [***] 

  

	4.	 [***] 

  

	 	(a)	 [***] 

  

	 	(b)	 [***] 

  

	 	(c)	 [***] 

  

	 	(d)	 [***] 

[***] 
  

	5.	 [***] 

  

	 	(a)	 [***] 

  

	 	(b)	 [***] 

  

	 	(c)	 [***] 

  

	 	(d)	 [***] 

  

	 	(e)	 [***] 

  

	6.	 [***] 

  

	7.	 [***] 

  

	8.	 [***] 

  

	 	(a)	 [***] 

  

	 	(b)	 [***] 

  

	9.	 [***] 

  

	10.	 [***] 

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXECUTION VERSION 

 
  

	11.	 [***] 

  

	12.	 [***] 

  
 [  ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.12

 Exhibit 10.12 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to
Rule 406 of the Securities Act of 1933, as amended. 
 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is made and is effective this _21_th day of June, 2017 (the “Effective
Date”) between TCR2 Therapeutics, Inc., a Delaware corporation (“TCR2”) and having an address at 450 Kendall St, Cambridge, MA 02142, and Harpoon Therapeutics, Inc., a
Delaware corporation (“HARPOON”) and having an address at Suite 250, 4000 Shoreline Ct., South San Francisco, CA 94080. TCR2 and HARPOON are each referred to as a “Party” and collectively referred to as the
“Parties.” 
 Recitals 

WHEREAS, TCR2 and HARPOON are engaged in the research and development of therapeutics for the treatment of diseases; 

WHEREAS, each Party possesses certain technology and related intellectual property rights useful for the research, development, and
commercialization of therapeutics for the treatment of diseases; 
 WHEREAS, TCR2 granted to HARPOON certain rights under the
Material Transfer Agreement dated August 7, 2016 (the “BCMA MTA”); 
 WHEREAS, HARPOON granted to TCR2 certain rights
under the Material Transfer Agreement dated October 28, 2016 (the “Mesothelin MTA”); 
 WHEREAS, TCR2 wishes to grant
to HARPOON, a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid up license under the Licensed TCR2 Patent Rights (as defined below) to develop, make, have made, use, import, export,
offer for sale or sell or otherwise commercialize Products (as defined below) with the right to sublicense, in all cases subject to the terms and conditions of this Agreement; 

WHEREAS, HARPOON wishes to grant to TCR2, a perpetual, irrevocable, non-exclusive, worldwide,
royalty-free, fully paid up license under the Licensed HARPOON Patent Rights (as defined below) to develop, make, have made, use, import, export, offer for sale or sell or otherwise commercialize Products (as defined below) with the right to
sublicense, in all cases subject to the terms and conditions of this Agreement; 
 NOW THEREFORE, TCR2 and HARPOON, intending to be
legally bound, agree as follows: 
 ARTICLE 1 

Definitions 
 1.1
“Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is under common control with such Party. For purposes of this Section 1.1, “control” shall refer to (i) in
the case of a Person that is a corporate entity, direct or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors of such Person and (ii) in the case of a Person that is
not a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise. 

  
 1 

 1.2 “Base BCMA Binder” means the BCMA antibody sequence set forth on
Exhibit A. 
 1.3 “Base MSLN Binders” means the MSLN antibody sequences set forth on Exhibit B. 

1.4 “Base Binders” means either Base BCMA Binder or Base MSLN Binders. 

1.5 “Confidential Information” means any confidential or proprietary information furnished by one Party to the other Party in
connection with this Agreement, provided that such information is (i) specifically designated as confidential or (ii) reasonably identifiable by an individual familiar with the industry as confidential or proprietary.
Confidential Information includes: 
 (a) non-public information disclosed by either Party to the
other Party in the initial and any subsequent Regulatory Base Binder Reports pursuant to Section 3.3; 
 (b) the know how set
forth on Exhibit E that is disclosed or made available by HARPOON to TCR2 pursuant to the grant of a know how license under Section 2.1(iii); and 

(c) information of one Party received by the other Party prior to the Effective Date pursuant to the Confidentiality Agreement between the
Parties, dated as of September 1, 2015, the BCMA MTA and the Mesothelin MTA. 
 1.6 “Controlled” means, with respect
to Patent Rights, that a Party owns or has a license or sublicense to such Patent Rights and has the ability to grant a license or sublicense to such Patent Rights as provided for in this Agreement, or has the ability to assign its right, title and
interest in and to such Patent Rights, without violating the terms of any agreement or other arrangement with any Third Party. 
 1.7
“Cover,” “Covering” or “Covered” means, with respect to a product, technology, process or method, that in the absence of ownership of or a license granted under Licensed Patent Rights, the
manufacture, use, offer for sale, sale, exportation or importation of such product or the practice of such technology, process or method would infringe such Licensed Patent Rights. 

1.8 “HARPOON Improved BCMA Binders” means the BCMA antibody sequences derived from, or improvements to, the Base BCMA Binder
that may have been generated, developed or invented by or on behalf of HARPOON prior to the Effective Date, or are generated, developed or invented by or on behalf of HARPOON on and after the Effective Date pursuant to Section 3.2. Such
derivations and improvements may include, but are not limited to, humanization, affinity enhancement, and cross reactivity optimization. 

  
 -2- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 1.9 “Improved Binders” means any and all of HARPOON Improved BCMA Binders,
and TCR2 Improved MSLN Binders (as defined below). 
 1.10 “IND” means an investigational new drug application filed by
either Party with the FDA, or the equivalent application in any foreign jurisdiction filed with another Regulatory Authority. 
 1.11
“Intellectual Property” means ideas, concepts, discoveries, inventions, developments, know-how, trade secrets, techniques, methodologies, modifications, processes, innovations, improvements,
writings, documentation, electronic code, data and rights (whether or not protectable under state, federal or foreign patent, trademark, copyright or similar laws) or the like, whether or not written or otherwise fixed in any form or medium,
regardless of the media on which contained and whether or not patentable or copyrightable. 
 1.12 “Law” means all federal,
state, provincial, local, supranational, national and regional laws, statutes, rules, codes, regulations, orders, judgments, ordinances, guidelines, directives and regulatory requirements applicable to a Party, this Agreement or the activities
contemplated hereunder. 
 1.13 “Licensed HARPOON Patent Rights” means any patents or patent applications and any and all
related Patent Rights (a) listed on Exhibit D, but only to the extent such patents or patent applications and any and all related Patent Rights Cover the Base MSLN Binders, or (b) to the extent Covering the Base MSLN Binders.
HARPOON shall endeavor to amend and update Exhibit D to incorporate the details of any additional Licensed HARPOON Patent Rights during the Term. 

1.14 “Licensed Patent Rights” means either Licensed TCR2 Patent Rights (as defined below) or Licensed HARPOON Patent Rights.

 1.15 “Licensed TCR2 Patent Rights” means any patents or patent applications and any and all related Patent
Rights (a) listed on Exhibit C, but only to the extent such patents or patent applications and any and all related Patent Rights Cover the Base BCMA Binders, or (b) Covering the Base BCMA Binder. TCR2 shall endeavor to amend
and update Exhibit C to incorporate the details of any additional Licensed TCR2 Patent Rights during the Term. 
 1.16
“Patent Rights” means with respect to any patents or patent applications, any and all (a) patents issuing from such patent applications, (b) substitutions, divisionals, renewals, continuations or continuations-in-part (only to the extent of claims that are entitled to the priority date of the parent application); (c) patents of addition, restorations,
extensions, supplementary protection certificates, registration or confirmation patents, patents resulting from post-grant proceedings, re-issues and re-examinations; (d) other patents or patent applications claiming and entitled to
claim priority to (i) such patents and patent applications and any patent or patent application specified in (a), (b) or (c), or (ii) any patent or patent application from which such patents and patent applications or a
patent or patent application specified in (a), (b) or (c) claims and is entitled to claim priority; (d) all rights of priority attendant to such patents and patent applications and any of the patents and patent applications
listed in (a) through (c); and (e) in each case of such patents and patent applications and of the patents and patent applications described in (a) through (d), including all counterparts and foreign equivalents thereof
filed in any country, territory or jurisdiction in the world. 

  
 -3- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 1.17 “Person” means any natural person or any corporation, company,
partnership, joint venture, firm or other entity, including a Party, or any government or agency or political subdivision thereof. 
 1.18
“Product” means, on a country-by-country basis, any product or part of a product containing either a Base Binder or Improved Binder, the making, using,
selling, offering for sale, importing or exporting of which in such country would, but for the licenses granted herein, infringe any of the Licensed Patent Rights in such country. 

1.19 “Prosecution and Maintenance” or “Prosecute and Maintain” means, with respect to the applicable Patent
Rights, the preparation, filing, prosecution and maintenance of such Patent Rights, as well as re-examinations, reissues, appeals, and requests for patent term adjustments and patent term extensions with
respect to such Patent Rights, together with the initiation or defense of interferences, the initiation or defense of oppositions, post grant review, and other similar proceedings with respect to the particular Patent Rights, and any appeals
therefrom. For clarification, “Prosecution and Maintenance” or “Prosecute and Maintain” shall not include any other enforcement actions taken with respect to Patent Rights. 

1.20 “Regulatory Approval” means, with respect to a country or territory, the approvals (including any applicable
governmental price and reimbursement approvals), licenses, registrations or authorizations of Regulatory Authorities necessary for the commercialization of a pharmaceutical product in such country or territory, including, as applicable, approval of
a BLA or comparable filing in the United States or approval of a comparable filing in any other country or jurisdiction, including a marketing authorization approval by the EMA. 

1.21 “Regulatory Authority” means a federal, national, multinational, state, provincial or local regulatory agency,
department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, export, promotion, marketing or sale of a product in the applicable country. 

1.22 “Regulatory Base Binder Information” means any information related to a Base Binder that a comparable Third Party in the
same industry would reasonably be expected to provide to the Regulatory Authority in order to file an IND and/or seek Regulatory Approval for the Product containing such Base Binder. 

1.23 “Sublicensee” shall have the meaning set forth in Section 2.2(a). 

1.24 “TCR2 Improved MSLN Binders” means the MSLN antibody sequences derived from, or improvements to, the Base MSLN Binders
that may have been generated, developed or invented by or on behalf of TCR2 prior to the Effective Date, or are generated, developed or invented by or on behalf of TCR2 on and after the Effective Date pursuant to Section 3.2. Such
derivations and improvements may include, but are not limited to, humanization, affinity enhancement, and cross reactivity optimization. 

  
 -4- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 1.25 “Term” means the term of this Agreement as provided in
Section 9.1. 
 1.26 “Third Party” means any Person other than a Party or any of its Affiliates. 

1.27 Additional Definitions. Each of the following definitions is set forth in the section of this Agreement indicated below: 

 

			
	 Definition
	  	Section
	AAA	  	10.11(b)(i)
		
	Bankruptcy Code	  	2.5(a)
		
	HARPOON Intellectual Property	  	5.1
		
	Prosecuting Party	  	5.2(b)
		
	TCR2 Intellectual Property	  	5.1

 ARTICLE 2 

Grant of License 
 2.1
License Grant. 
 Subject to the terms and conditions of this Agreement, without additional consideration, (i) TCR2 hereby
grants to HARPOON a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid up license under the Licensed TCR2 Patent Rights, with the right to grant sublicenses as set forth in
Section 2.2, to research, develop, make, have made, use, sell, have sold, offer to sell, import, export, commercialize or otherwise exploit Products containing the Base BCMA Binder, itself and through its Affiliates and Third Parties;
(ii) HARPOON hereby grants to TCR2 a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid up license under the Licensed HARPOON Patent Rights, with the right to grant
sublicenses as set forth in Section 2.2, to research, develop, make, have made, use, sell, have sold, offer to sell, import, export, commercialize or otherwise exploit Products containing Base MSLN Binders, itself and through its
Affiliates and Third Parties; and (iii) HARPOON hereby grants to TCR2 a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid up, non-exclusive license, with the right to grant
sublicenses as set forth in Section 2.2, to use the know-how that is set forth on Exhibit E hereto. For the avoidance of doubt, HARPOON does not grant to TCR2 any rights or licenses whatsoever with
respect to any HARPOON Improved BCMA Binders or Products containing the Base BCMA Binder or any HARPOON Improved BCMA Binders, and HARPOON shall not update Exhibit E (such that the know how that is being licensed by HARPOON to TCR2 hereunder, is
limited to the know how that is set forth on Exhibit E as of the Effective Date). It is understood and agreed that TCR2 shall not use the know-how that is licensed hereunder in any way that would preclude or prevent HARPOON from being able to use
any of the licensed know how without restriction, or that would otherwise impair HARPOON’s ability to use any of the licensed know-how without restriction. 

  
 -5- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 2.2 Sublicensing. 

(a) Each Party shall have the right to grant sublicenses under the license granted to it under Section 2.1 hereof (a
“Sublicensee”); provided that each such sublicense shall be subject to all relevant provisions, restrictions and limitations set forth in this Agreement. Each Party shall be responsible for each of its Sublicensee’s
complying with all obligations of such Party under this Agreement that are applicable to sublicenses. 
 (b) If this Agreement is terminated
for any reason, then, at the option of any Sublicensee not in default of the applicable sublicense (or any provision of this Agreement applicable to such Sublicensee), it shall become a direct licensee under, and subject to the terms and conditions
of, this Agreement, subject only to modifications with respect to territory, field and exclusivity (as applicable) so as to accommodate all such Sublicensees. 

2.3 Affiliates and Sublicensees. Each Party may exercise or perform, or have exercised or performed on its behalf, some or all of its
rights or obligations under this Agreement by one or more of such Party’s Affiliates or Sublicensees. Each Party shall be responsible for each of its Affiliates’ and Sublicensees’ compliance with all obligations of such Party under
this Agreement. 
 2.4 Subcontractors. Each Party may exercise or perform some or all of its rights or obligations under this
Agreement by subcontracting the exercise or performance of all or any portion of such rights and obligations on the Party’s behalf, provided that the Party shall be responsible for each of its subcontractors complying with all obligations of
the Party under this Agreement. 
 2.5 Section 365(n) of the Bankruptcy Code. 

(a) All rights and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of
Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended or any comparable Law outside the United States (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined
in Section 101(35A) of the Bankruptcy Code. Each Party agrees that each Party, as a party to this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of Law
outside the United States that provide similar protection for “intellectual property.” Any agreement supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n)
of the Bankruptcy Code. 
 (b) In the event that either Party is unable to obtain or retain the licenses set forth in
Section 2.1 of this Agreement as a result of a bankruptcy proceeding by or against the other Party under provisions of applicable Law analogous to Section 365(n) of the Bankruptcy Code, such Party shall have a right to
purchase such other Party’s right, title and interest in and to Licensed Patent Rights of such other Party at fair market value, provided that such Party gives such other Party written notice of such intention no later than four
(4) weeks after such Party becomes aware of the commencement of such bankruptcy proceeding. The fair market value of the Licensed Patent Rights shall be determined by an assessment made by a mutually agreed upon third party, or, if the
Parties do not agree within thirty (30) days of such Party’s written notice, a third party reasonably selected by such Party with a background in conducting such assessments. The costs of any such assessment shall be borne equally by the
Parties. 

  
 -6- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 ARTICLE 3 

Development and Commercialization 

3.1 Compliance. Each Party shall, and shall ensure that its Affiliates and Sublicensees, and its and their subcontractors, conduct all
research and development, manufacture and commercialization of Base Binders, Improved Binders, and Products Covered under Licensed Patent Rights in compliance with all Laws. 

3.2 Research and Development Activities. TCR2 may at its sole discretion and expense, and without restriction, carry out research and
development activities on Base MSLN Binders and Improved MSLN Binders during the Term and thereafter. HARPOON may at its sole discretion and expense, and without restriction, carry out research and development activities on the Base BCMA Binder and
Improved BCMA Binders during the Term and thereafter. For the avoidance of doubt, any and all Intellectual Property (and all associated Patent Rights) arising from, made or developed solely by or on behalf of the Party carrying out such research and
development activities (“Developed IP” ) shall also be solely owned by such Party. 
 3.3 Regulatory Base Binder
Information. Each Party shall provide, within twenty (20) days of receipt of written request from the other Party made anytime during the Term, a written report of Regulatory Base Binder Information on the Base Binder(s) Covered under
the Licensed Patent Rights of such Party. 
 ARTICLE 4 

Consideration 
 The Parties jointly and
severally represent, warrant and covenant that each has received full and sufficient consideration for all grants made and obligations undertaken under this Agreement. 

ARTICLE 5 
 Intellectual
Property Protection and Related Matters 
 5.1 Ownership. 

5.1.1 As between the Parties, other than as provided for in this Section 5.1, each Party shall solely own all
Intellectual Property, including Patent Rights related thereto, made, conceived, reduced to practice, or otherwise discovered, whether prior to, on or after the Effective Date, solely by employees, agents, contractors or consultants of such Party or
its Affiliates. For purposes of determining ownership under this Section 5.1, inventorship shall be determined in accordance with the Laws of the United States. 

  
 -7- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 5.1.2 Notwithstanding the foregoing or anything to the contrary herein, the Parties agree
that all Intellectual Property, including Patent Rights related thereto, made, conceived, reduced to practice, or otherwise discovered, whether prior to, on or after the Effective Date, by or on behalf of a Party or its Affiliates, alone or with
others, pertaining to: 
 (i) any and all Base MSLN Binders (either isolated or as incorporated into a composition), 

(ii) any and all HARPOON Improved BCMA Binders, 

(iii) any and all products containing HARPOON Improved BCMA Binders or the Base BCMA Binder, which products are covered by any
claims in [***], and 
 (iv) any and all Products containing HARPOON Improved BCMA Binders or the Base BCMA Binder, which
Products are developed and/or commercialized by or on behalf of HARPOON or its Affiliates or Sublicensees, 
 in each case, shall be solely owned by HARPOON
(“HARPOON Intellectual Property”). 
 5.1.3 Notwithstanding the foregoing or anything to the contrary herein, the Parties agree
that all Intellectual Property, including Patent Rights related thereto, made, conceived, reduced to practice, or otherwise discovered, whether prior to, on or after the Effective Date, by or on behalf of a Party or its Affiliates, alone or with
others, pertaining to: 
 (i) any and all Base BCMA Binders (either isolated or as incorporated into a composition), 

(ii) any and all TCR2 Improved MSLN Binders, 

(iii) any and all products containing TCR2 Improved MSLN binders or Base MSLN Binders, which products are covered by any claims
in [***], and 
 (iv) any and all Products containing TCR2 Improved MSLN Binders or Base MSLN Binders, which Products are
developed and/or commercialized by or on behalf of TCR2 or its Affiliates or Sublicensees. 
 in each case, shall be solely owned by TCR2 (“TCR2
Intellectual Property”). 
 5.1.4 Accordingly and without additional consideration, (i) TCR2 hereby assigns and agrees to assign
to Harpoon, all HARPOON Intellectual Property, including Patent Rights related thereto and enforcement rights, made, conceived, reduced to practice, or otherwise discovered, whether prior to, on or after the Effective Date, and TCR2 shall cause its
employees, agents, contractors and Affiliates to do the same; and (ii) HARPOON hereby assigns and agrees to assign to TCR2, all TCR2 Intellectual Property, including Patent Rights related thereto and enforcement rights, made, conceived, reduced
to practice, or otherwise discovered, whether prior to, on or after the Effective Date, and HARPOON shall cause its employees, agents, contractors and Affiliates to do the same. For the avoidance of any doubt, under no circumstances and in no event,
under this Agreement or otherwise, shall TCR2 acquire any ownership rights in any Base MSLN Binder, nor shall HARPOON acquire any ownership rights in the Base BCMA Binder. 

  
 -8- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 5.2 Prosecution and Maintenance of Licensed Patent Rights. 

(a) During the Term and thereafter, HARPOON shall remain solely responsible for the Prosecution and Maintenance of all HARPOON Intellectual
Property worldwide and TCR2 shall remain solely responsible for the Prosecution and Maintenance of all TCR2 Intellectual Property worldwide. 

(b) The Party controlling the Prosecution and Maintenance of the applicable Licensed Patent Rights in accordance with
Section 5.2(a) is referred to as the “Prosecuting Party”. The Prosecuting Party shall be responsible for all fees and costs charged by patent counsel with respect to the Prosecution and Maintenance of the applicable
Licensed Patent Rights and all other out-of-pocket costs and expenses incurred by the Prosecuting Party in connection with such Prosecution and Maintenance of the applicable Licensed Patent Rights during the
Term. For clarity, such expenses shall not include any actions undertaken by the other Party other than at the Prosecuting Party’s request. 

5.3 Third Party Infringement. 

Each Party shall notify the other Party promptly of any knowledge it acquires of any actual or potential infringements of the Licensed Patent
Rights with respect to any activities of a Third Party in any country in the world and shall provide the other Party with all available evidence regarding such known or suspected infringement or unauthorized use. 

ARTICLE 6 

Confidentiality 
 6.1
Confidential Obligations. Each Party shall (a) maintain in strict confidence the Confidential Information of the other Party to the same extent such Party maintains its own confidential information, but in no event less than a
reasonable degree of care, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the other Party (except as permitted pursuant to Section 6.3 below), and (c) not use such
Confidential Information for any purpose except those expressly permitted by this Agreement. The obligations of confidentiality, non-disclosure and non-use under this
Section 6.1 shall be in full force during the Term and for a period of ten (10) years thereafter. Each Party, upon the request of the other Party, will return all copies of or destroy (and certify such destruction in writing) the
Confidential Information disclosed or transferred to it by the other Party pursuant to this Agreement, within sixty (60) days of such request or, if earlier, the termination or expiration of this Agreement; provided however that a Party
may retain (i) Confidential Information of the other Party which expressly survives such termination pursuant to this Agreement, and (ii) one (1) copy of all other Confidential Information in archives solely for the purpose of
establishing the contents thereof; provided, further, that a Party is not required to return or destroy Confidential Information contained in electronic back-ups unless and until such Confidential Information
is accessed. 

  
 -9- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 6.2 Exceptions to Confidentiality. Notwithstanding the foregoing, the obligations of
confidentiality set forth in Section 6.1 shall not apply to information that, in each case as demonstrated by competent written documentation: 

(a) is publicly disclosed or made generally available to the public by the disclosing Party, either before or after it becomes known to the
receiving Party; 
 (b) was known to the receiving Party, without any obligation to keep it confidential, prior to the date of first
disclosure by the disclosing Party to the receiving Party, as shown by the receiving Party’s files and records; 
 (c) is subsequently
disclosed to the receiving Party by a Third Party lawfully in possession thereof without obligation to keep it confidential and without a breach of such Third Party’s obligations of confidentiality; 

(d) has been publicly disclosed or made generally available to the public other than through any act or omission of the receiving Party or its
Affiliates or Sublicensees in breach of this Agreement; or 
 (e) has been independently developed by the receiving Party without the aid,
application or use of or reliance on or reference to the disclosing Party’s Confidential Information (the competent written proof of which must be contemporaneous with such independent development). 

6.3 Authorized Disclosure. Notwithstanding Section 6.1, a Party may disclose Confidential Information of the other
Party to the extent such disclosure is reasonably necessary in the following instances: 
 (a) complying with applicable Laws or submitting
information to governmental authorities; provided that if a Party is required by Law or governmental authority to make any public disclosure of Confidential Information of the other Party, to the extent it may legally do so, it will give
reasonable advance written notice to the other Party of such disclosure and will use its reasonable efforts to challenge or limit such required disclosure or secure confidential treatment of such Confidential Information prior to its disclosure
(whether through protective orders or otherwise); 
 (b) to obtain and maintain Regulatory Approval of Products or to research, develop,
make, have made, use, have used, offer to sell, sell, import, export, commercialize or otherwise exploit Products subject to and in accordance with this Agreement; 

(c) to its Affiliates, its and their directors, and to prospective and actual acquirers, lenders, licensees, investors and sublicensees, and
to each of their employees, consultants, contractors, agents, accountants, lawyers, advisors, investors and underwriters, on a need to know basis, each of whom, in the case of Third Parties, prior to disclosure must be bound by written or
professional ethical obligations of confidentiality and non-use equivalent in scope to those set forth in this Article 6; or 

(d) to the extent mutually agreed to in writing by the Parties. 

  
 -10- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 ARTICLE 7 

Representations and Lack of Warranties 

7.1 Representations of Authority. Each Party represents and warrants to the other that as of the Effective Date it has full right,
power and authority to enter into this Agreement and to perform its respective obligations under this Agreement. 
 7.2 Consents.
Each Party represents and warrants that as of the Effective Date all necessary consents, approvals and authorizations of all government authorities and other Persons required to be obtained by such Party in connection with execution, delivery and
performance of this Agreement have been obtained. 
 7.3 No Conflict. Each Party represents and warrants that, as of the Effective
Date, the execution and delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable Laws and (b) do not conflict with, violate or breach
or constitute a default of, or require any consent under, any contractual obligations of such Party, except such consents as have been obtained as of the Effective Date. 

7.4 Employee, Consultant and Advisor Obligations. Each Party represents and warrants that, as of the Effective Date, each of its and
its Affiliates’ employees, consultants and advisors has executed an agreement or has an existing obligation under law obligating such employee, consultant or advisor to maintain the confidentiality of Confidential Information to the extent
required under Article 6. 
 7.5 No Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THERE ARE NO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR
NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY. EACH PARTY MAKES NO WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE PATENTABILITY, VALIDITY OR
ENFORCEABILITY OF ANY LICENSED PATENT RIGHTS. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 

ARTICLE 8 

Indemnification; Limitation on Damages 

8.1 By HARPOON. HARPOON agrees to defend TCR2, its Affiliates and their respective directors, officers, employees, consultants and
agents at HARPOON’s cost and expense, and shall indemnify and hold harmless TCR2 and its Affiliates and their respective 

  
 -11- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 
directors, officers, employees, consultants and agents from and against any liabilities, losses, costs, damages, fees or expenses (including without limitation, attorney fees and the costs of
litigation, investigation and settlement regardless of outcome) arising out of any Third Party claim, suit, action or demand to the extent resulting from (i) any breach by HARPOON of any of its representations, warranties or obligations
pursuant to this Agreement, (ii) the alleged or actual infringement or misappropriation of any Third Party Intellectual Property by the manufacture, use or sale of the Base BCMA Binder, any HARPOON Improved BCMA Binder, or Product
containing the Base BCMA Binder or HARPOON Improved BCMA Binder, in each case by or on behalf of HARPOON or its Affiliates or Sublicensees, (iii) personal or bodily injury, illness or death, property damage or other loss or damage
resulting from the research, development, making, having made, using, offering for sale, selling, having sold, importing, exporting, commercialization or other exploitation of Products containing the Base BCMA Binder or any HARPOON Improved BCMA
Binder, in each case by or on behalf of HARPOON or its Affiliates or Sublicensees. 
 8.2 By TCR2. TCR2 agrees to defend HARPOON, its
Affiliates and their respective directors, officers, employees, consultants and agents at TCR2’s cost and expense, and shall indemnify and hold harmless HARPOON and its Affiliates and their respective directors, officers, employees, consultants
and agents from and against any liabilities, losses, costs, damages, fees or expenses (including without limitation, attorney fees and the costs of litigation, investigation and settlement regardless of outcome) arising out of any Third Party claim,
suit, action or demand to the extent resulting from (i) any breach by TCR2 of any of its representations, warranties or obligations pursuant to this Agreement, (ii) the alleged or actual infringement or misappropriation of any Third Party
Intellectual Property by the manufacture, use or sale of any Base MSLN Binder, TCR2 Improved MSLN Binder, or Product containing a Base MSLN Binder or TCR2 Improved MSLN Binder, in each case by or on behalf of TCR2 or its Affiliates or Sublicensees,
(iii) personal or bodily injury, illness or death, property damage or other loss or damage resulting from the research, development, making, having made, using, offering for sale, selling, having sold, importing, exporting, commercialization or
other exploitation of Products containing Base MSLN Binders or TCR2 Improved MSLN Binders, in each case by or on behalf of TCR2 or its Affiliates or Sublicensees. 

8.3 Procedures. A Person entitled to indemnification under this Article 8 (an “Indemnified Party”) shall
give prompt written notification to the Party from whom indemnification is sought (the “Indemnifying Party”) of any claim, suit, action or demand for which indemnification is sought under this Agreement; provided, however, that no
delay or failure on the part of an Indemnified Party in so notifying the Indemnifying Party shall relieve the Indemnifying Party of any liability or obligation hereunder except to the extent of any damage or liability caused by or arising out of
such delay or failure. Within thirty (30) days after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense and settlement of such claim, suit, action or
demand with counsel reasonably satisfactory to the Indemnified Party. If the Indemnifying Party does not assume control of such defense, the Indemnified Party shall control such defense. The Party not controlling such defense may participate therein
with counsel of its own choosing at its own expense; provided that, the Indemnified Party shall have the right to retain its own counsel, at the expense of the Indemnifying Party, if representation of such Indemnified Party by the

  
 -12- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 
counsel retained by the Indemnifying Party would be inappropriate because of actual or potential differences in the interests of such Indemnified Party and any other party represented by such
counsel. The Indemnified Party shall cooperate with the Indemnifying Party in its defense and settlement of any claim, suit, action or demand for which indemnification is sought under this Agreement, and the Indemnified Party shall not agree to any
disposition, compromise or settlement of such action, suit, proceeding or claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. 

8.4 NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST
PROFITS OR LOSS OF USE, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH LOSSES OR DAMAGES OR IF A PARTY KNEW OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES. THIS EXCLUSION OF LOSSES AND DAMAGES SHALL
NOT APPLY WITH RESPECT TO A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTIONS 8.1 AND 8.2. 
 ARTICLE 9 

Term and Termination 
 9.1
Term. This Agreement shall become effective as of the Effective Date and unless earlier terminated as set forth in this Article 9, shall otherwise remain in effect on a Product-by- Product basis until it expires (the “Term”) in its entirety upon the expiration of all Licensed Patent Rights. 

9.2 Termination for Material Breach. Upon any material breach of this Agreement by either Party, the other Party may terminate this
Agreement by providing sixty (60) days’ prior written notice to the breaching Party, specifying the material breach. The termination shall become effective at the end of the sixty (60) day period unless the breaching Party cures such
breach during such sixty (60) day period. 
 9.3 Termination for Bankruptcy. To the extent allowed under applicable Law, either Party
shall have the right to terminate this Agreement in the event of the commencement of any proceeding in or for bankruptcy, insolvency, dissolution or winding up by or against the other Party (other than pursuant to a corporate restructuring) that is
not dismissed or otherwise disposed of within sixty (60) days thereafter and/or the administrator of the bankruptcy estate or the Party under in-court restructuring has not, within five (5) days
after the receipt of an inquiry from the other Party, confirmed that the bankruptcy estate or the Party under in-court restructuring will adopt this Agreement. 

9.4 Effects of Termination. 

(a) Generally. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such
expiration or termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination. Termination of this
Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of
whether or not such breach was the reason for the termination. 

  
 -13- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 (b) Rights and Licenses. In the event of any termination of this Agreement by a Party
pursuant to Section 9.2 or 9.3, notwithstanding anything contained in this Agreement to the contrary, upon the effective date of such termination: (i) all rights and licenses granted herein to the terminated Party
shall automatically terminate and all such rights and licenses granted by the terminating Party to the terminated Party shall revert in their entirety to the terminating Party; and (ii) the terminated Party shall return or destroy all
Confidential Information of the terminating Party. 
 9.5 Survival. The following provisions shall survive the expiration or
termination of this Agreement: Article 1 (Definitions) (to the extent necessary to give effect to other surviving provisions), Article 5 (Intellectual Property), Article 6 (Confidentiality), Article 8
(Indemnification; Limitation on Damages) and Article 10 (Miscellaneous Provisions), and Sections 2.2 (Sublicensing) (and such other provisions of this Agreement as are necessary to give effect to the continuing licenses
contemplated under Section 2.2), 9.4 (Effects of Termination) and this Section 9.5 (Survival). 
 ARTICLE
10 
 Miscellaneous Provisions 

10.1 Governing Law; Language. This Agreement and all disputes arising out of or related to this Agreement shall be construed and the
respective rights of the Parties determined in accordance with the laws of the State of New York, U.S.A., excluding application of any conflict of laws principles that would require application of the laws of a jurisdiction outside of New York, and
will be subject to the exclusive jurisdiction of the courts of competent jurisdiction located in New York, New York. The Parties hereby expressly consent to the jurisdiction of such courts and irrevocably waive any objection to jurisdiction or
venue. This Agreement and all communications related to it, or to any dispute or controversy arising out of it, shall be conducted in English. 

10.2 Notice. Any notices required or permitted by this Agreement shall be in writing, shall specifically refer to this Agreement, and
shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic mail or registered or certified mail, postage prepaid, return receipt requested, to the following address or facsimile number of the
Parties: 
 If to HARPOON: 
 Harpoon
Therapeutics, Inc. 
 Suite 250 

4000 Shoreline Ct., 
 South San
Francisco, CA 94080 
 Attention: Chief Executive Officer 

  
 -14- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 If to TCR2: 

TCR2 Therapeutics, Inc. 

450 Kendall St 
 Cambridge, MA
02142 
 Attention: Chief Executive Officer 

All notices under this Agreement shall be deemed effective upon receipt. A party may change its contact information immediately upon written
notice to the other party in the manner provided in this Section 10.2. 
 10.3 Assignment. Either Party may assign this
Agreement, in its entirety, without the consent of the other Party, (a) in connection with a sale or transfer of all or substantially all of the business and assets of the assigning Party to which this Agreement relates, including by way
of merger, consolidation, transfer, or sale of assets related to this Agreement or (b) to an Affiliate. Any assignment in circumvention of the foregoing shall be void. Subject to the foregoing, this Agreement shall be binding upon and
inure to the benefit of the Parties hereto and their respective permitted successors and assigns. 
 10.4 Entire Agreement. This
Agreement constitutes the entire agreement between the Parties with respect to its subject matter and supersedes all prior agreements or understandings between the Parties relating to its subject matter including the Confidentiality Agreement, the
BCMA MTA and the Mesothelin MTA. 
 10.5 Interpretation. The captions and headings to this Agreement are for convenience only, and
are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Articles, Sections or Exhibits mean the particular Articles, Sections or Exhibits to this
Agreement and references to this Agreement include all Exhibits hereto. Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words “include” or “including” shall be construed as incorporating,
also, “but not limited to” or “without limitation;” (b) the word “day” or “year” means a calendar day or year unless otherwise specified; (c) the word “notice” shall mean notice in writing
(whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (d) the words “hereof,” “herein,” “hereby” and derivative or
similar words refer to this Agreement (including any Exhibits); (e) the word “or” shall be construed as the inclusive meaning identified with the phrase “and/or;” (f) provisions that require that a Party or the Parties
hereunder “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter or otherwise; (g) words of any gender
include the other gender; (h) words using the singular or plural number also include the plural or singular number, respectively; and (i) the word “law” (or “laws”) when used herein means any applicable, legally binding
statute, ordinance, resolution, regulation, code, guideline, rule, order, decree, judgment, 

  
 -15- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 
injunction, mandate or other legally binding requirement of a government entity, together with any then-current modification, amendment and re-enactment
thereof, and any legislative provision substituted therefor. The Parties and their respective counsel have had an opportunity to fully negotiate this Agreement. If any ambiguity or question of intent or interpretation arises, this Agreement shall be
construed as if drafted jointly by the Parties, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement. No prior draft of this Agreement shall be used in the
interpretation or construction of this Agreement. 
 10.6 Amendment and Waiver. This Agreement may be amended, supplemented, or
otherwise modified only by means of a written instrument signed by both Parties. Any waiver of any right or failure to act in a specific instance shall related only to such instance and shall not be construed as an agreement to waive any right or
fail to act in any other instance, whether or not similar. 
 10.7 Severability. In the event that any provision of this Agreement
shall be held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any other provision of this Agreement. The Parties shall consult one another and use reasonable efforts to agree upon a valid and enforceable
provision that is a reasonable substitute for the invalid or unenforceable provision. 
 10.8 Use of Name. Neither Party shall use
the other Party’s name (except in connection with disclosures permitted under Article 6) or logo without the other Party’s express prior written consent, which consent may be granted in the context of the Parties mutually
approving in writing a press release or other public disclosure related to this Agreement. 
 10.9 Counterparts. This Agreement may
be executed in counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument. 

10.10 Force Majeure. Neither Party will be responsible for delays (excluding delays in payment) resulting from causes beyond the
reasonable control of such Party, including without limitation, fire, explosion, flood, war, strike, or riot, provided that the nonperforming Party promptly notifies the other Party in writing of such causes and uses commercially reasonable
efforts for a company of its size and resources to avoid or promptly remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are removed. 

10.11 Dispute Resolution. 

(a) Escalation. If any dispute arises out of or relates to this Agreement, the Parties agree to first seek to resolve such dispute by
referring such dispute to the respective Chief Executive Officers of each Party for resolution. Such referral shall take place within thirty (30) days after a written request by either Party to the other Party that resolution by the Chief Executive
Officers be attempted. If, after an additional sixty (60) days, the Chief Executive Officers of the Parties have not succeeded in negotiating a resolution of the dispute, and a Party wishes to pursue the matter, such Party may initiate binding
arbitration in accordance with Section 10.11(b). 

  
 -16- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 (b) Alternative Dispute Resolution. Any dispute arising out of or relating to this Agreement
that has not been resolved pursuant to Section 10.11(a) shall be resolved through binding arbitration as follows: 

(i) A Party may submit such dispute to arbitration by notifying the other Party, in writing, of such dispute. Within thirty
(30) days after receipt of such notice, the Parties shall designate in writing a single arbitrator to resolve the dispute; provided, however, that if the Parties cannot agree on an arbitrator within such
30-day period, the arbitrator shall be selected by the New York, New York office of the American Arbitration Association (the “AAA”). The arbitrator shall not be an Affiliate, employee,
consultant, officer, director or stockholder of any Party. 
 (ii) Within thirty (30) days after the designation of the
arbitrator, the arbitrator and the Parties shall meet, at which time the Parties shall be required to set forth in writing all disputed issues and a proposed ruling on the merits of each such issue. 

(iii) The arbitrator shall set a date for a hearing, which shall be no later than forty-five (45) days after the
submission of written proposals pursuant to Section 10.11(b)(ii), to discuss each of the issues identified by the Parties. The Parties shall have the right to be represented by counsel. Except as provided herein, the arbitration shall be
governed by the Commercial Arbitration Rules of the AAA; provided, however, that the Federal Rules of Evidence shall apply with regard to the admissibility of evidence and the arbitration shall be conducted by a single arbitrator. 

(iv) The arbitrator shall use his or her best efforts to rule on each disputed issue within thirty (30) days after the
completion of the hearings described in Section 10.11(b)(iii). The determination of the arbitrator as to the resolution of any dispute shall be binding and conclusive upon all Parties. All rulings of the arbitrator shall be in writing and
shall be delivered to the Parties. 
 (v) The attorneys’ fees of the Parties in any arbitration, fees of the arbitrator,
and costs and expenses of the arbitration shall be borne by the Parties as determined by the arbitrator. 
 (vi) Any
arbitration pursuant to this Section 10.11 shall be conducted in New York, New York, U.S.A. and the arbitrator shall the laws of the State of New York. Any arbitration award may be entered in and enforced by any court of competent
jurisdiction. 
 (c) No Limitation. Nothing in this Section 10.11 shall be construed as limiting in any way the right of
a Party to seek an injunction or other equitable relief with respect to any actual or threatened breach of this Agreement without having to prove actual damages or post a bond, or to bring an action in aid of arbitration. Should any Party seek an
injunction or other equitable relief, or bring an action in aid of arbitration, then for purposes of determining whether to grant such injunction or other equitable relief, or whether to issue any order in aid of arbitration, the dispute underlying
the request for such injunction or other equitable relief, or action in aid of arbitration, may be heard by the court in which such action or proceeding is brought. 

  
 -17- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 10.12 No Third Party Beneficiaries. No Person other than HARPOON, TCR2 and their
respective Affiliates, successors and permitted assignees hereunder, shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement. 

10.13 Independent Contractors. It is expressly agreed that HARPOON and TCR2 shall be independent contractors and that the relationship
between HARPOON and TCR2 shall not constitute a partnership, joint venture or agency. Neither HARPOON nor TCR2 shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be
binding on the other Party, without the prior written consent of such other Party. 
 10.14 No Implied Rights or Licenses. Other than
as expressly provided for in this Agreement, there are no licenses, rights or interests in or to the Patent Rights or other Intellectual Property or Confidential Information of a Party granted or implied under this Agreement. 

[remainder of page intentionally left blank] 

  
 -18- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 [Signature page to License Agreement] 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. 

 

									
	HARPOON THERAPEUTICS, INC.	 		 	TCR2 THERAPEUTICS, INC.
					
	By:	 	/s/ William E. Picht	 		 	By:	 	/s/ Garry E. Menzel
	Name:	 	William E. Picht, Jr.	 		 	Name:	 	Garry Menzel
	Title:	 	CFO	 		 	Title:	 	CEO

  
 -19- 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 Exhibit A 

Base BCMA Binder Sequence 
 [***] 

  
 C-1 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 Exhibit B 

Base MSLN Binders Sequences 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 

  
 D-1 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 Exhibit C 

Licensed TCR2 Patent Rights 

[***] 

  
 D-1 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 Exhibit D 

Licensed HARPOON Patent Rights 

[***] 

  
 D-1 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 Exhibit E 

Licensed Know How 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

  
 D-1 

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]